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Optimal Biodegradable Scaffolds and Progenitor Cells for  
Effective Bone Regeneration 
 
Ami Rebecca Amini, PhD 
University of Connecticut, [2014] 
 
Bone tissue engineering has been proposed as a more effective and efficient 
alternative option for bone repair and regeneration. Here, we propose a two-pronged 
approach for enhance scaffold-guided bone regeneration. Second to developing optimized 
PLGA optimally-porous scaffolds, we will pre-vascularize our constructs in vitro in order 
to reduce vascularization time, and enhance bone formation in vivo. We will pre-
vascularize our constructs by seeding and culturing them with a combination of two cell 
populations required for angiogenesis and osteogenesis: peripheral blood derived -
endothelial progenitor cells (EPCs) and bone marrow derived -mesenchymal stem cells 
(MSCs). Previous studies have demonstrated EPCs and MSCs promote enhanced bone 
regeneration via the stimulation of neo-vascularization. We will systematically examine 
of the combination of these two required cell populations and the optimally-porous 
PLGA scaffolds, and the resultant effects on healing critically sized segmental bone 
defects. We hypothesize that our pre-vascularized, optimally-porous PLGA scaffolds will 
substantially improve the performance of PLGA microsphere scaffolds by promoting 
angiogenesis, and significantly enhancing bone formation in vivo.  
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1. INTRODUCTION 
 
Oral/maxillofacial and orthopaedic surgeons perform over two million bone 
replacement procedures annually, a figure lending bone as the second most transplanted 
tissue after blood (1, 2).  Bone replacements/grafts are necessitated when patients 
experience bone loss due to high-energy trauma, tumor resection, revision surgery, 
developmental deformities, infection and non-union fractures, in addition to dental bone 
loss as a result of missing teeth and periodontal disease (3, 4).  However, all currently 
available treatment options for bone repair or regeneration (i.e., autografts, allografts and 
synthetic materials) may present very serious risks.  Although autografts are considered 
the “gold standard” and represent over half of bone substitutes, they are limited by the 
amount of available patient bone volume, and are also associated with donor site 
infection and morbidity (5-7). Allografts, isolated from cadavers, involve 
immunogenicity and disease transmission risks (8, 9).  Also, synthetic materials (i.e., 
metals, plastics and ceramics) often require follow-up surgeries due to fatigue, fracture, 
and toxicity of the material (10).  Thus, there is a warranted search for superior bone 
replacement methods to overcome the drawbacks of the current treatment options.  
Bone tissue engineering (BTE) has been proposed as a more effective and 
efficient alternative option for bone repair and regeneration.  BTE involves the 
combination of biodegradable and porous scaffolds, with or without the use of bone-
forming cells and growth factors, to regenerate bone (11-14). The success of the scaffold-
based bone regeneration approach critically depends on the effectiveness of the 
biodegradable scaffold used, as it serves as a temporary, mechanically-stable matrix for 
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cells to infiltrate and proliferate. Scaffold pore structure (i.e., pore size and 
interconnectedness) is an essential consideration in the development of scaffolds to 
ensure proper cell growth, migration and nutrient flow (15).  Scaffolds currently designed 
with small pore sizes (i.e., approximately 100 µm) display in vitro and in vivo osteoblast 
survival and bone formation limited to the periphery, due decreased oxygen and nutrient 
diffusion throughout the scaffolds (16-22). On the other hand, studies have demonstrated 
scaffolds with large pore sizes (i.e., >400 µm) increase osteoblast proliferation and 
differentiation throughout the entire scaffold, due to enhanced mass transport of oxygen 
and nutrients and neo-vascularization (17, 23-26). However, scaffolds with larger pores 
are mechanically less stable than small-pored scaffolds, and are not mechanically 
compatible with human bone (27-30). Hence, sizing pores to achieve the necessary 
balance of cell growth and mechanical support is critical.  
This work focuses on poly(85 lactide-co-15 glycolide) (PLGA) microsphere 
scaffolds. PLGA has been recognized for its biocompatibility, as well as its recent 
approval by the United States Food and Drug Administration (FDA) as a biodegradable 
material for certain biomedical devices (31, 32).  For BTE applications, current PLGA 
scaffolds developed via a microsphere sintering technique have a unique advantage as 
they display mechanical properties in the range of human cancellous bone (31).  
However, the current PLGA microsphere scaffolds with small pore sizes (i.e. ~100 µm) 
fail to provide the prerequisites required for optimal bone regeneration (i.e. a stable 
oxygen and nutrient supply), limiting bone regeneration only to the scaffold surfaces (33, 
34).  We propose the generation of optimal PLGA microsphere scaffolds with optimally-
sized pores to balance the positive and negative features of the previously mentioned pore 
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size ranges, and also allow for homogenous bone regeneration and neo-vascularization, 
while still retaining human bone-mechanical compatibility.  
In addition to the fabrication of an effective BTE scaffold, establishing a 
sufficient vascular network in a timely manner is a crucial requirement for optimal bone 
tissue growth (35). This is clearly demonstrated in large BTE constructs that fail to 
support neo-vascularization throughout the construct, as seeded cells do not survive due 
to hypoxia and insufficient nutrition (36, 37). Thus, the rate and range of vascular growth 
determines the efficiency of new bone formation (38, 39).  Although the objective of 
fabricating our PLGA optimally-porous scaffolds with increased interconnectivity and 
optimal engineering pore size is to enhance bone growth by improving neo-
vascularization, this approach presents limitations. In situ neo-vascularization of tissue 
engineered bone is very slow to meet the nutritional requirements of osteoblasts, as it 
occurs over a course of several days to weeks for the center of the implanted constructs to 
become perfused (35).    
Thus, we propose a two-pronged approach for enhance scaffold-guided bone 
regeneration.  Second to developing optimized PLGA optimally-porous scaffolds, we will 
pre-vascularize our constructs in vitro in order to reduce vascularization time, and 
enhance bone formation in vivo. We will pre-vascularize our constructs by seeding and 
culturing them with a combination of two cell populations required for angiogenesis and 
osteogenesis: peripheral blood derived -endothelial progenitor cells (EPCs) and bone 
marrow derived -mesenchymal stem cells (MSCs) (40-48).  Previous studies have 
demonstrated EPCs and MSCs promote enhanced bone regeneration via the stimulation 
of neo-vascularization (47, 49, 50).  We will systematically examine of the combination 
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of these two required cell populations and the optimally-porous PLGA scaffolds, and the 
resultant effects on healing critically sized segmental bone defects. We hypothesize that 
our pre-vascularized, optimally-porous PLGA scaffolds will substantially improve the 
performance of PLGA microsphere scaffolds by promoting angiogenesis, and 
significantly enhancing bone formation in vivo.  Upon the completion of the proposed 
specific aims, we will have addressed a significant challenge in the field of scaffold-
based BTE and its clinical applicability towards bone defect repair and regeneration in 
oral/maxillofacial and orthopaedic surgery. 
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2. BACKGROUND 
 
 Bone grafts are utilized in a wide array of clinical settings to augment bone repair 
and regeneration.  Bone defect repair via tissue engineering approach is perceived as a 
better approach as the repair process may leave with the patient own tissue by the time 
the regeneration is complete (11, 51, 52). Currently, the United States, as well as other 
countries worldwide, are experiencing an exceedingly high demand for functional bone 
grafts, as the statistics have risen above half a million recipent patients and costing over 
$2.5 billion annually in the United States. This figure not only doubles on a global basis, 
but is also expected to double by 2020 due to a variety of factors, including the growing 
baby boomer population and increased life expectancy (53).  
 Extensive studies have reported on considerable shortcomings, limitations and 
complications of current clinical treatments for bone repair and regeneration, which 
include autologous and allogeneic transplantations by using autografts and allografts 
(Table 2-1) (5, 7, 53-57).  To date, autografts serve as the gold standard for bone grafts as 
they are histocompatible and non-immunogenic, and offer all the imperative properties 
required of a bone graft material.  Specifically, autografts possess the essential 
components to acheive osteoinduction (i.e., bone morphogenetic proteins (BMPs) and 
other growth factors), osteogenesis (i.e., osteoprogenitor cells) and osteoconduction (i.e., 
3D and porous matrix).  However, autografts  involve harvesting bone from the patient’s 
iliac crest, and thus, requires a second operation at the site of tissue harvest (58).  
Autologous bone transplants are very expensive procedures, and may result in significant 
donor site injury and morbidity, deformity, scarring, as well as surgical risks, including 
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bleeding, inflammation, infection and chronic pain (6, 59, 60). Autografts, further, may 
be a null treatment option in cases where the defect site requires larger volumes of bone 
than is feasible or available.  Allografts represent the second most common bone grafting 
technique and involves transplanting donor bone tissue, often from a cadaver. Allogeneic 
bone is also likely histocompatible, and is available in various forms, including 
demineralized bone matrix (DBM), morcellised and cancellous chips, cortico-cancellous 
and cortical grafts, and osteochondral and whole-bone segments, depending on the host 
site requirements.  In comparison to autografts, allografts carry risk of immunoreactions 
and transmission of infections, and reduced osteoinductive properties and no cellular 
component, since donor grafts are devitalized via irradiation or freeze-drying processing 
(8-10).  Although less than autografts, allogenic grafts come with substantial cost issues. 
Further, the bone grafting market is experiencing an obvious unmet supply and demand 
as there is currently a shortage in allograft bone graft material (61).  Other commonly 
used bone repair techniques may involve distraction osteogenesis, bone cement fillers and 
bone morphogenic proteins.   Although the previously mentioned clinical interventions 
have been shown to improve repair of bone, none possess all the ideal characteristics: 
high osteoinductive and angiogenic potentials, biological safety, low patient morbidity, 
no size restrictions, ready access to surgeons, long shelf life, and reasonable cost.  
 The field of bone tissue engineering (BTE) was initiated nearly three decades ago.  
As seen in Figure 2-1, interest and progress in the BTE field has seen tremendous growth 
over the years, with and exponentially increasing number of studies and reviews 
published on the PubMed database since the mid-1980s.  The field of BTE is aimed to 
create an alternative treatment option that would ideally eliminate the previously 
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Table 2-1. Bone graft options for bone repair. 
Bone 
Graft 
Structural 
Strength 
Osteo-
conduction 
Osteo-
induction 
Osteo-
genesis 
Disadvantages 
Autograft 
Cancellous No +++ +++ +++ - considered gold standard 
for repairs of bone defects 
- contains osteoprogenitor 
cells capable of synthesizing 
new bone, and a structural 
matrix that acts as a scaffold 
- limited supply 
- donor-site pain, infection, 
morbidity can be as high as 
25% 
- required secondary surgery 
Cortical +++ ++ ++ ++ 
Allograft 
Cancellous No ++ + No - imunogenic response by 
the host to the foreign tissue 
of the graft 
- potential for disease 
transmission 
- plentiful supply 
Cortical +++ + + No 
De-
mineralized 
Bone 
Matrix 
(DBM) 
No + + No - prepared from cadaveric 
human bone 
- contains noncollagenous 
proteins: type 1 collagen 
(provides the 
osteoconductive scaffold for 
osseous in-growth), and 
osteoinductive growth 
factors (BMPs, fibroblast 
growth factor, insulin-like 
growth factor, platelet-
derived growth factor, and 
TGF-β) 
- available in several forms, 
including freeze-dried 
powder, granules, gel, putty, 
and strips 
Bone graft substitutes 
Coralline 
HA 
+ ++ No No - FDA approved in 1992 
- produced from marine 
coral exoskeleton that have 
pore structures resembling 
cancellous bone 
- effective for managing 
metaphyseal defects 
- not highly resorbable:  
blocks of implanted coralline 
HA remain for 10 years 
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Collagen-
based 
matrices 
No + No No - approved by FDA in 1991 
- xenografts consisting of 
sponge-like strips of bovine 
collagen combined with 
hydroxyapatite 
- Collagraft (Collagen / HA / 
Tri-calcium phosphate, 
Zimmer), Healos (Collagen / 
HA, Depuy) 
Calcium 
phosphate 
+++ ++ No No -  capable of 
osteoconduction and 
osseointegration 
- injectable calcium paste 
has 4 to 10 times the 
compressive strength of 
cancellous bone 
- calcium phosphate cement 
has the highest mechanical 
compression strength of any 
of the osteoconductive bone-
graft substitutes 
- 95% of calcium phosphate 
is resorbed in 26-86 weeks 
Calcium 
sulfate 
No + + + - approved by FDA in 1996 
- calcium sulfate resorbs in 
4-12 weeks, making it the 
quickest of any of the 
osteoconductive products 
currently available 
- wound drainage 
occasionally is noted and is 
hypothesized to be the result 
of the osmotic effect of the 
calcium sulfate 
- osteoconductive void filler 
- available from numerous 
companies (Osteoset, 
Calceon 6, Bone Blast, etc.) 
Bioglass + ++ ++ ++ - mimics mineral 
composition in bone 
Biodegrada
ble 
Polymers 
(i.e., 
PLGA) 
+ ++ No + - tunable porosity and 
mechanical strength 
depending on form 
- various polymers (PLGA, 
PLLA) release acidic 
byproducts 
- abundant supply 
- no risk of disease 
transmission 
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vasculogenic growth factors (i.e., growth factor-releasing scaffold, scaffold with growth 
factor analogs, or seeded with platelet-enriched plasma), or by housing cells that are 
genetically engineered to or naturally release growth factors.  In turn, accelerated cell 
homing, vascularization and bone regeneration of the defect site results. Although much 
progress has been made, there still are many crucial hurdles yet to be cleared on the way 
to BTE becoming a true clinical reality.  The following is a review of critical 
consideration, advances and obstacles for functional BTE.  
Figure 2-2.  Schematic illustration of bone tissue engineering paradigm. Factors 
from the implanted graft at the defect site that influence the host response may 
include growth factors (or their analogs, or from platelet-enriched plasma), and 
cells (genetically- modified to release factors, or naturally produce factors). In 
response, cell homing and enhanced vascularization and bone regeneration will 
occur.  
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2.1. Fundamentals of Bone And Developmental 
Biology 
 Bone tissue engineering (BTE) is based on the understanding of bone structure, 
mechanics and tissue formation as it aims to induce new functional bone tissues.   In 
other words, in order to successfully regenerate or repair bone, knowledge of the bone 
biology and its development is quite essential. 
 Bone possesses the ability to perform a wide array functions, and respond to a 
variety of metabolic, physical and endocrine stimuli.  Bones represent (1) the foundation 
for our bodily locomotion, (2) provide load-bearing capacity to our skeleton and 
protection to our internal organs, (3) house the biological elements required for 
hematopoiesis, (4) trap for dangerous minerals (i.e., lead), as well as (5) maintain the 
homeostasis of key electrolytes via calcium and phosphate ion storage.  In addition, it is 
engaged in a constant cycle of resorption and renewal, undergoing continual chemical 
exchange and structural remodeling due to both internal mediators and external 
mechanical demands (11).   Bone has been previously, and most appropriately referred to 
as the ultimate smart material for its scar-less regenerative capacity.  Functional bone 
tissue engineering requires that the newly restored bone to be fully integrated with the 
neighboring host bone, and importantly, possess the ability to perform the previously 
mentioned functions of native bone.    
 Bone is a highly dynamic and diverse tissue both, structurally and functionally.  
Macroscopic structure and mechanical properties of the various two hundred plus bones 
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in the human skeletal system are largely influenced by distinct loading conditions.  
Skeletal structures range from being long (i.e., tibia, ulnar, etc.), short (i.e., phalanges, 
etc.), flat (i.e., skull, sternum, etc.) and irregular (i.e., pelvic, vertebrae, etc.).  Bone 
functions range from locomotion, to vital organ protection. Bone tissue may also either 
take on a compact (i.e., cortical bone) or trabecular (i.e., cancellous bone) pattern 
arrangement, ranging in mechanical strength and modulus.  Despite these complex 
features and forms, it has a relative simplicity in terms of its microscopic, hierarchical 
architecture.  Specifically, bone extracellular matrix (ECM) is comprised of both a non-
mineralized organic component (predominantly type-1 collagen) and a mineralized 
inorganic component (composed of 4 nm thick plate-like carbonated apatite mineralites).  
The nano-composite structure (tough and flexible collagen fibers reinforced by 
hydroxyapatite crystals) is integral to the requisite compressive strength and high fracture 
toughness of bone (63). 
 
2.1.1.   Bone Development 
Bone formation occurs via two very distinct pathways (intramembranous and 
endochondral). In either case, mesenchymal cellular condensation first occurs and serves 
as a template for the subsequent bone formation.   Intramembranous bone formation 
involves mesenchymal progenitor cells differentiating directly into osteoblasts, and the 
subsequent development of parts of the mandible and clavicle, and many cranial bones. 
Most bones in the body (i.e., all long bones and vertebrae), however, are formed through 
endochondral bone formation.  This process involves mesenchymal progenitor cells first 
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differentiating into chondrocytes, which are responsible for depositing a cartilaginous 
template that is later, mineralized and replaced by bone.  
Although there are distinct differences in the bone composition and structure 
formed via endochondral and intramembranous ossification, several molecular regulators 
are shared (64, 65).  For instance, several key molecules including Indian Hedgehog 
(Ihh), parathyroid hormone related peptide (PTHrP), bone morphogenetic proteins 
(BMPs), vascular endothelial growth factor (VEGF) and fibroblastic growth factors 
(FGFs) are critical regulators in both processes (66).  In endochondral ossification, BMPs 
are responsible for the initiation of mesenchymal condensations, and Ihh and PTHrP form 
a critical feedback loop that mediate the balance between chondrocyte proliferation and 
hypertrophy and regulate the thickness of the growth plate. Likewise, during 
intramembranous bone formation, these key players are required to induce uncommitted 
mesenchymal progenitor cells along the osteogenic pathway as pre-osteoblasts, which co-
express chondrocytic and osteoblastic markers simultaneously.  Furthermore, in both 
processes, bone remodeling is required for the maintenance of all normal healthy bone, 
which involves a balance between osteoclastic bone resorption and osteoblastic bone 
formation (67).  
 
2.1.2.   Bone Defect Repair  
 Interestingly, upon fracture, bone is repaired by a process that recapitulates many 
of the events of both intramembranous and endochondral bone formation, and uniquely 
heals without the formation of scar tissue (Figure 2-3) (68, 69).  Initially, hematoma 
formation is accompanied by an inflammatory response, and the recruitment of many of 
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the signaling molecules involved in the regulation of new bone formation (i.e., ILs, TNF-
α, FGFs, BMPs, PDGF, VEGF, etc.). At the cortex and periosteum, intramembranous  
Figure 2-3.   Schematic illustration of steps involved in bone defect repair. 
 
bone formation immediately occurs.  The external soft tissues stabilize the fracture by the 
formation of a callus, which subsequently undergoes chondrogenesis, and then a process 
highly similar to endochondral ossification.  More specifically, after the callus forms, 
chondrocyte proliferation decreases, as they begin to mature (i.e., hypertrophy) and 
calcify the matrix.  In-growing blood vessels carry in chondroclasts, which are 
responsible for resorbing the calcified cartilage, and osteoblastic progenitors, which begin 
the process of new bone formation.  The mechanical continuity of the cortex is achieved 
via subsequent remodeling of the newly formed bone.  
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 The question remains, what is the optimal method for bone regeneration?  Should 
BTE focus more of on bone development processes or bone defect repair?  In my 
opinion, BTE should not exclusively focus on one or the other, but instead both.  In 
situations requiring bone regeneration, the initial events always involve hematoma 
formation and an early inflammatory response, which is largely responsible for the 
recruitment of host cells and release of critical signaling molecules.  From there, 
emulation of some aspects of normal bone tissue development and remodeling may hold 
the key to the future success of BTE.  Seminal developmental biology principles that may 
help the future success of BTE include: 
(1)   the use of pluri- or multi- potent stem cells; 
(2) the identification of critical genes, growth factors, and signal 
transduction cascades that mediate bone formation; 
(3)  the physical process of bone formation; 
(4) complex interactions between epithelium and mesenchyme within the 
underlying connective tissue; 
(5)  the understanding of mesenchyme encoding tissue-specific patterns;  
(6) the understanding that normal tissue healing involves progressive 
remodeling and restructuring of pre-existing tissue structures,   
(7) the importance of the tissue microenvironment’s physical properties 
(i.e., “mechanotherapy”) and  
(8)  angiogenesis and neo-vascularization of the newly formed bone tissue. 
  
 Incorporation of developmental biology insights will critically impact future 
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tissue engineering approaches.  For instance, inclusion of appropriate extracellular matrix 
molecules or adhesive ligands that target stem cells mediating earlier stages of tissue 
remodeling and regeneration (70).  Also, for the promotion of angiogenesis, development 
of scaffolds that incorporate growth factors and possess the necessary porosity for 
vascular ingrowth (16).  Further, engineering micro- and nano- meter featured surface 
topography of these scaffolds is critical for directing cellular adhesion, spreading, and 
proliferation.   On a broader scale, for successful BTE, it is critical to develop a scaffold 
that is inspired by the natural processes of developmental biology and promotes tissue 
remodeling, and not just simply supports final tissue form and function.  
 
2.2. Recent Advances in Bone Tissue Engineering 
(BTE) 
 
Although bone is a highly vascularized tissue and has the ability to regenerate, 
beyond a critical point, clinical intervention measures are required.  It is the hope that 
bone tissue engineering will be the future treatment of choice, as it will likely eliminate 
many of the pitfalls and concerns of current treatments.  Here, I discuss the status and key 
issues for BTE components (i.e., scaffolds, cells and vascularization). 
 
2.2.1. Biodegradable Scaffolds 
 
2.2.1.1. Scaffold Mechanical Integrity 
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 A key feature of BTE scaffolds is to provide temporary mechanical integrity at 
the defect site, until the bone tissue is repaired or regenerated, and normal biomechanical 
function is restored. It is established that in order for the bone tissue engineering scaffold 
to be “functional” immediately upon implantation, its biomechanical properties must 
match the physical demand of the healthy surrounding bone (71).   In addition, 
mechanical strength of the scaffold affects the mechanotransduction of the adherent bone 
cells on the scaffold, which plays a critical role in the bone repair and remodeling 
processes.  It has been proposed that, generally, the structural biomechanics of the BTE 
scaffold is related to the osteoconductive properties of the scaffold, while 
mechanotransduction is related to its potential osteoinductive properties (72).   
Biomechanical stimuli on cells due to the scaffold deformation largely influences 
osteoinduction (i.e., bone ingrowth from the host).  Therefore, as suggested by Sikavitsas 
et al., a mechanotransduction strategy may be used to control the function of bone cells in 
vivo by designing a scaffold with mechanical properties that allow ‘osteoinductive fluid 
flow’ in the scaffold.   By combining 3D imaging and numerical simulation of scaffold 
physical properties, it was verified that a threshold permeability of ~3 x 10-11 m2 was 
necessary for inducing vascularization and mineralization in the bone graft (73, 74).  
The BTE biomechanical paradigm has been well described in a step-wise fashion, 
where each step holds the mechanical aspects of the scaffold central to insure the safety 
of the surgical procedure using a BTE scaffold (Figure 2-4) (72).  The first step, which 
involves the bone mechanical properties and loading conditions, are analogous to the 
primary fixation of the scaffold.  At this point, the BTE scaffold should not induce a 
stress-shielding effect, resulting in peri-scaffold bone resorption as seen in the metallic 
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joint implants. Also, the elastic property of the BTE scaffold should not exceed that of 
 
Figure 2-4. Illustration of a three-step biomechanical paradigm in BTE. In the first 
step, upon implantation, it is critical that the mechanical properties of the BTE 
scaffold should closely match that of the surrounding host bone tissue and loading 
conditions to reduce the stress-shielding effect. The second step involves interface 
biomechanics, and should allow for interface scaffold-bone mechanotransduction 
for enhanced osteointegration of the scaffold. Lastly, as the scaffold degrades, 
ingrowing bone tissue will begin to support the mechanical load of BTE scaffold. 
Adapted from Pioletti et al. (72). 
 
bone in order to maintain a proper mechanical stimulation on the peri-scaffold bone, 
which is driven by the loading conditions.  The second step involves interface 
biomechanics, and may be identified as the secondary fixation. Here, the mechanical 
properties of the BTE scaffold may be adapted to generate interface scaffold-bone 
mechanotransduction, which has been shown to influence tissue differentiation and 
osteointegration of the scaffold (75).  For the third step, which may be termed ‘final 
fixation,’ involves scaffold evolution, and the ingrowing bone offering support to the 
mechanical load as the BTE scaffold degrades.   Thus, each step revolves around 
mechanical aspects, which induce a biological reaction in and around the BTE scaffold 
via mechanotransduction.  It has been suggested that the separations between these steps 
may be utilized as an engineering approach in the mechanical design of bone scaffolds.   
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Ideally, if mechanical considerations can be used to confer osteoinductivity to a BTE 
scaffold, the dependency of using osteogenic factors and bioreactors may be reduced, and 
an off-the-shelf product could be obtained (76).   
Mechanical properties of human bone vary tremendously according to location 
and function (i.e., load or non-load bearing).  Again, the restorative scaffold’s mechanical 
properties should be modulated or tailored to match the demands of that at the defect site, 
in order to decrease or avoid complications, such as stress shielding, implant-related 
osteopenia and subsequent re-fracture (77).   
 
2.2.1.2. Scaffold Porosity 
 
Micro-porosity is a critical element for the scaffold’s osteoconductive properties, 
and the resultant bone tissue ingrowth and vascularization.   Scaffold pore structure (i.e., 
pore size, volume and interconnectedness) is an essential consideration to ensure proper 
cell growth, cell migration, nutrient flow, vascularization, and better spatial organization 
for cell growth and ECM production (15, 19).  Although there is still some ambiguity 
surrounding the optimal porosity and pore size for a 3D bone scaffold, studies suggest 
that scaffolds currently designed with small pore sizes (i.e., < 200 µm) display in vitro 
and in vivo osteoblast survival and bone formation limited to the periphery, due decreased 
oxygen and nutrient diffusion throughout the scaffolds (16). On the other hand, scaffolds 
with a mean pore size above 200 µm display increased osteoblast proliferation and 
differentiation throughout the entire scaffold, due to enhanced neo-vascularization and 
mass transport of oxygen and nutrients (17, 23-25). For instance, Tsuruga et al. 
demonstrated enhanced bone formation, as well as alkaline phosphase and osteocalcin 
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levels in constructs with mean pore sizes of 300 to 400 µm four weeks post-implantation 
in a rat subcutaneous mouse model (17). In addition, Klenke et al. demonstrated a 
positive relationship between the scaffold’s mean pore size and vascular invasion, 
volume of newly-formed bone, and bone volume density.  After 4 weeks, implantation of 
scaffolds with pore sizes 200-300 µm resulted in significantly enhanced vascular and 
bone formation than that with pore sizes less than 200 µm in a mouse critical-size cranial 
defect model (78).   
A combination of various factors may attribute to the observed enhanced 
performance of scaffolds with pore sizes greater than 200 µm.  Scaffolds with larger 
pores result in decreased cell aggregations developed along the scaffold’s periphery.  
Specifically, Murphy et al. observed that scaffolds with pore sizes greater than 300 µm 
demonstrate improved cell migration, which overcome the scaffold-surface cell trapping 
phenomenon in vitro (79).  Instead, scaffolds with larger pore sizes allow for 
homogenous cell proliferation through the construct, of which is not limited to the 
scaffold periphery.   Minimizing the cell sheet formation at the scaffold’s periphery may 
also allow for enhanced diffusion of oxygen and nutrient.   Hypoxia, which defines the 
lack of oxygen, is well associated with osteoblastic cell death.  Therefore, it is critical to 
fabricate scaffolds with proper pore sizes to allow for oxygen diffusion throughout the 
scaffold.   Together, these factors allow for enhanced cell survival throughout the 
scaffold, and not central necrosis that is often observed in scaffolds with small mean pore 
sizes.  
The cruciality of increasing pore size of scaffolds is well recognized, and a variety 
of scaffold fabrication techniques have been proposed to achieve scaffolds with increased 
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pore sizes.  Porogen leaching was used in combination with several traditional scaffold 
fabrication techniques, such as gas foaming (80, 81), freeze drying (82), and phase 
separation (83) to fabricate highly porous scaffolds. However, as porosity and mean pore 
sizes increase, mechanical strength is scarified; determination of a balance between 
mechanical strength and porosity is crucial.  
2.2.2. Cellular Approaches 
Though there remains an unresolved debate on the most effective cell type for 
clinical bone regeneration, it has been established that cellular-based bone regeneration 
approach is indeed effective. Cellular-based approaches in BTE primarily target the early 
stages of bone repair when the recruitment of skeletal progenitors may be impaired.   
Proposed mechanisms by which implanted cells enhance bone regeneration in BTE 
involve (1) early release of key osteogenic and vasculogenic molecules and growth 
factors, and (2) formation of a template to recruit host osteogenic and vasculogenic cells, 
and (3) actively laying down bone matrix and vascularizing the bone construct.    
The major challenge in making these cellular therapies more efficient is the 
identification of the cell sources that can be implanted to the bone defect site, and will 
differentiate into osteoblasts and form neo-vasculature (84, 85).  Thus far, studies have 
investigated several cell types including mesenchymal stem cells (MSCs), embryonic 
stem cells (ESCs), induced pluripotent stem cells (iPSCs), adipose derived stem cells 
(ADSCs) and stem cells from human exfoliated deciduous teeth (SHED) for their abilities 
to promote bone repair and regeneration.  This variety of possible candidates for cell 
transplantation can be explained by the finding that cells involved in the reconstruction of 
osseous tissue undergo a progression from undifferentiated progenitors to 
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biosynthetically mature cells; therefore therapeutic strategies can approach supporting the 
healing process at different stages of bone tissue development (86). For successful 
clinical application in the regeneration of bone, the properties of choice include isolation 
and expansion efficiency, expression and stability of osteogenic markers, “bona fide” 
bone tissue formation, and long-term safety (i.e., immunorejection, graft-versus-host 
Cell Type Source Clinical Use 
Embryonic Stem 
Cells (ESCs) 
Embryonic Bodies 
(EBs) 
N/A 
Induced 
Pluoripotent Stem 
Cells (iPSCs) 
Any cell type that 
could be induced to 
become osteoblasts 
N/A 
Adult Stem Cells - Bone marrow 
 
• Segmental defects of long bones  
• Large bone diaphysis defects  
• Maxillary sinus augmentation  
• Posterior spinal fusion  
• Bone tumor resection  
- Adipose tissue • Large calvarial defect  
• Osteonecrotic Femoral Heads  
• Hip osteonecrosis  
- Peripheral 
Blood  
N/A 
- Teeth (pulp, 
exfoliated 
teeth) 
N/A 
- Cord blood N/A 
- Amniotic 
Fluid 
N/A 
- Stem Cells 
derived from 
ESCs and 
iPSCs 
N/A 
Genetically 
Modified Cells Any cell type that 
could be genetically 
modified 
N/A 
Autologous Cells 
and Growth 
Factor Cocktail  
Platelet Rich Plasma 
Bone marrow 
Aspirate 
• Necrosis of femur head, Avascular 
necroses, Non-unions  
• Sinus graft  
Table 2-2.  Cell Choices for Bone Tissue Engineering. 
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disease, tumorigenicity).  Table 2-2 summarizes the cell types that have been utilized for 
clinical bone defect repair thus far.  Here, I focus on mesenchymal stem cells (MSCs) and 
endothelial progenitor cells (EPCs) as they have demonstrated to be highly effective in 
promoting bone and vascular regeneration at bone defects. 
 
2.2.2.1. Mesenchymal Stem Cells 
 
Mesenchymal stem cells (MSCs) have been long recognized for their potential in 
engineering bone grafts since they differentiate and form bone during the natural bone 
development process.  Their great potential in BTE has led to their characterization and 
the identification of a plethora of sources for their isolation. MSCs have been defined 
through the expression of various CD markers (i.e., negative for CD34, CD45, CD14, 
CD11a, CD19 and HLA-DR and positive for STRO-1, CD29, CD73, CD90, CD105, 
CD106, CD166, CD146 and CD44).  Also, MSCs have been isolated from a number of 
adult sources including bone marrow (87), peripheral blood (88), umbilical cord blood 
(89), synovial membrane (90), deciduous teeth (91), dental pulp (92), amniotic fluid (93), 
adipose tissue (94), brain, skin, heart, kidneys and liver (95) through a relatively simple 
protocol that primarily relies on their ability to adhere to tissue culture plastic (96). In 
addition, their high proliferative potential combined with ability to withstand the freezing 
conditions allows for their in vitro expansion in order to obtain clinically relevant cell 
numbers (87).  
In addition to adult sources, MSCs have recently been derived from embryonic 
stem cells, as well as iPS cells (97).  These embryonic- and iPSC-derived MSCs have the 
same in vitro and in vivo multi-potent characteristics as MSCs derived from other adult 
sources (i.e., bone marrow). However, unlike MSCs derived from adult sources, iPSCs-
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derived MSCs may be indefinitely expanded without senescence. Their enhanced 
survival potential, both in vitro and in vivo, may be attributed to higher telomerase 
activity (97). In any case, MSCs of embryonic and iPSC origin have to be further tested 
to rule out the possibility of teratoma formation before considering them for clinical 
applications. 
The incorporation of MSCs into bone tissue engineering biomaterials is a widely 
studied strategy for accelerated bone formation and osteointegration during bone defect 
repair and regeneration.  Mechanisms by which enhanced bone regeneration occurs 
involves directly providing mesenchymal stem cells for osteogenic differentiation and 
bone formation, as well as enhanced osteoinductivity of the biomaterial via the release of 
osteogenic growth factors and stimulation of the migration and differentiation of host 
osteoprogenitors. In addition, pre-differentiating MSCs into the osteogenic lineage before 
implantation has been shown to further accelerate defect repair and osteointegration of 
the construct in vivo via delivering a more mature osteogenic population capable of 
immediate bone formation.  Pre-clinical trials with MSC-seeded constructs have proven 
effective in accelerating bone repair in various scenarios including critical-size femoral 
defects, cranio-maxillofacial deformities, and spinal fusions (98).  
Although seemingly a great cellular option for enhanced bone tissue engineering, 
several issues with their usage have been identified.  Firstly, several studies have shown 
that a maximum of 24–40 population doublings are reached before it comes to a 
senescence-associated growth arrest.  Also, osteogenic differentiation potential in vitro 
and bone forming efficiency in vivo significantly decreases with the increasing donor age 
and systemic disease.   Additionally, the lack of knowledge about common markers for 
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MSCs isolated from different sources make it difficult to define MSCs (99, 100). These 
factors significantly limit the actual amount and the quality of MSCs obtainable for 
clinical application.  Approximately four to six weeks is required for cell expansion 
before possible patient treatment.  Furthermore, long-term culture may lead to forced 
selection under artificial culture conditions, which increases the possibility of abnormal 
karyotype development and malignant cell transformation.  Lastly, the use fetal bovine 
serum (FBS) during in vitro expansion poses a risk of transmitting zoonotic or prion-
related diseases, which may induce an immune response triggered by xenogenic proteins.  
The option of using synthetic serum with range of recombinant growth factors, or serum-
free media are being explored as alternatives (86).   
At present, a number of strategies have been reported that are capable of 
augmenting the loss of both proliferative capacity and osteogenic differentiation potential 
of MSCs after extensive population doublings ex vivo. These methods include cultivation 
of MSCs in the presence of basic fibroblastic growth factor (FGF-2), and maintenance of 
MSCs on several extracellular matrices (i.e., basement membrane-like extracellular 
matrix produced by bovine corneal endothelial cells, denatured collagen type I matrix) 
instead of conventional tissue culture plastic during progressive number of passages (98).  
The mechanism of how various ECMs may influence the retention of MSC osteogenic 
differentiation potential after ex vivo expansion is still ambiguous; however, it has been 
suggested that the physical interactions between MSCs and certain ECM motifs (i.e., 
integrins and their ligands) may play a significant role.  
The variability of colony formation and culture conditions necessary to sustain 
proliferative capacity have led to an interesting proposal of the creation of a universal 
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allogenic human MSC cell line serving as “of-the-shelf” or “ready to use” cells (15).  
Though it may not seem possible without requiring the use of immunosuppressive drugs 
to reduce associated risks of rejection, it has recently been shown that cultured MSCs 
exhibit a poorly immunogenic phenotype (i.e., evidenced by MHC class I+, MHC Class 
II-, and low level of expression of co-stimulatory molecules, CD40, CD80, and CD86).   
Also, MSCs have been shown to be immune suppressive (i.e., immune privileged).  
Specifically, MSCs do not induce the proliferation of lymphocytes, and suppress the 
proliferation of T-cells and cytokine production in response to alloantigens or 
insignificant mitogens, as well as inhibiting the function of B cells, dendritic cells and the 
natural killer cells.  This data greatly enhances the therapeutical appeal of MSCs in bone 
tissue engineering. 
2.2.2.2. Endothelial Progenitor Cells 
 
Endothelial cell-mediated vascularization is an absolute pre-requisite for bone 
tissue formation, repair, and remodeling.  Currently, endothelial progenitor cells (EPCs) 
represent an attractive, if not the most attractive endothelial cell source involved in the 
repair and angiogenesis of damaged or ischemic bone tissues.  In addition, EPCs have 
been recognized as an attractive autologous endothelial cell population that may easily 
isolated from peripheral blood or bone marrow in clinic.      
EPCs were first characterized in 1997 by Asahara et al. (48).  EPCs were defined 
as bone marrow-derived vascular endothelial cell growth factor-receptor 2 (VEGF-R2) 
positive, CD43-positive monocyte like cells with the ability to differentiate into 
endothelial cells in vitro and in vivo based on expression of CD31, eNOS, and E-selectin.  
EPCs posses a very high and long-term proliferative potential (more than 1,000 
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population doublings), and may be quickly expanded for clinical use.  EPCs display the 
typical cobblestone morphology of endothelial cells when culture in vitro, and have good 
angiogenic ability, as demonstrated by complex and intricate network when cultured on 
and within Matrigel in vitro, and angiogenic abilities in vivo.     
Numerous subsequent studies were published attempting to further elaborate on 
the molecular characterization on EPCs.  Other studies demonstrated EPCs to express 
VEGF-R2, CD133, CXCR-4 receptor, and to posses migrational ability to VEGF and 
stromal cell derived factor-1 (SDF-1) (101).  Other studies suggest that monocyte-like 
cells expressing CD14, Mac-1 and the dendritic cell marker CD11c demonstrate EPC 
activity (i.e., uptake of acetylated LDL and binding of ulex-lectin (102, 103).  Ingram et 
al. reported EPC-derived cells express KDR, CD31, and Tie-2 (angiopoietin 1 receptor) 
(104).    Thus, there is still controversy surrounding an accurate molecular definition of 
EPCs.     
The reason for such discrepancy in the molecular definition of EPCs lies in the 
fact that there is not a universal isolation method being utilized by these studies.  There 
are three common methods that exist for the isolation of EPCs (105).  In the first method, 
peripheral blood mononuclear cells are isolated and plated on fibronectin- or collagen- 
coated tissue culture plates with a variety of endothelial growth factors.  After several 
days, the non-adherent cells are removed and the adherent cell population remaining, 
which expresses the ability to ingest acetylated low density lipoprotein and to bind 
certain plant lectins, is considered to represent EPC.  The second method utilizes 
monoclonal antibodies and fluorescence activated cell sorting (FACS) analysis to 
enumerate specific cell populations. Asahara et al. reasoned that putative EPC may 
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express cell surface markers shared by hematopoietic stem cells (HSC) since endothelial 
and blood cells share a similar mesodermal origin during embryonic development. Thus, 
Asahara et al. cultured CD34+ cells (15.7% enriched) on fibronectin-coated dishes and 
observed emergence of spindle shaped cells that expressed a variety of proteins generally 
expressed by primary endothelial cells.  However, EPCs (commonly identified by three 
cell markers CD133, CD34, and the vascular endothelial growth factor receptor 2) may or 
may not express CD34, depending on their differentiation state.  Specifically, as EPCs are 
mobilized from the bone marrow into the peripheral blood they begin to lose 
CD133/CD34 and start to express CD31, vascular endothelial cadherin, and von 
Willebrand factor (vWF).  Therefore, it is critical to identify specific cell markers for 
EPCs for this method to be effective. The third method involves in vitro colony forming 
cell assays (i.e., colony forming unit-Hill (CFU-Hill) and endothelial colony forming cell 
(ECFC) assays). In the CFU-Hill assay, adult peripheral blood or cord blood gives rise to 
cells that do express many proteins similar to primary endothelial cells, but the CFU-Hill 
also express numerous myeloid progenitor cell markers and mature into macrophages.  
Furthermore, CFU-Hill and their progeny fail to spontaneously form human blood vessels 
when implanted into immunodeficient mice. In contrast, ECFC express cell surface 
antigens like primary endothelium, clonally propagate and re-plate into secondary and 
tertiary ECFC, form capillary-like structures in vitro, but most remarkably, form human 
blood vessels in vivo and inoculate with murine vasculature to become part of the murine 
systemic circulation. Thus, ECFC display all of the properties of an EPC while the CFU-
Hill assay identifies hematopoietic cells. 
Although there is still controversy surrounding an accurate molecular definition 
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and precise phenotype of EPCs, their ability to promote enhanced vascularization and 
bone formation at bone defects are certain (104).   For instance, Yu et al. demonstrated 
that pre-seeding scaffolds with EPCs effectively promoted neovascularization in grafts, 
prevented the ischemic necrosis, and improved osteogenesis in a mouse femur bone 
defect model after 6 weeks post-implantation (47).  Zhou et al. and Tan et al. also 
demonstrated EPC-mediated enhanced vascularization and bone formation in a rabbit 
bone defect models post-implantation of pre-seeded EPC constructs (45, 49).  This 
observation was also observed in various other animal models including in rats, and 
sheep (41, 42, 106).  Thus, EPCs clearly represent an attractive cell source for promoting 
bone and vascularization in bone tissue engineering. 
 
2.2.3.  Vascularization Techniques 
The importance of vascularization to the development and repair of bone tissue 
has been extensively documented in BTE investigations (107).  The greatest amount of 
newly formed bone occurs in the most vascularized areas, whereas inadequate 
vascularization at bone defect sites is associated with decreased bone tissue repair and 
regeneration, and has been identified as the major pitfall to successful BTE.   
Specifically, until the timely onset of construct vascularization, which is typically on the 
order of hours to days (i.e., less than 1 mm/day), seeded cells in an implanted BTE 
construct rely on diffusion for the uptake of nutrients (i.e., oxygen, glucose, etc.) and 
clearing of metabolic byproducts (i.e., carbon dioxde, lactic acid, etc.), a transport 
mechanism that is only efficeint over short distances (i.e., less than 200 µm) (37).   These 
diffusional constraints result in viable cells located only superficially (i.e., periphery of 
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the constructs), and thus, limiting the success of the engineering bone tissue throughout 
the entire thickness of the defect.  Although in vitro delivery of nutrients to engineered 
constructs may be alleviated via bioreactor systems, this only delays the diffusional 
constraint problem to when it is implanted in the host defect site.  There is a critical 
obstacle in maintaining the survival of large masses of cells upon transfer from the in 
vitro culture conditions into the host defect site in vivo (108).  For this, scientists have 
proposed several methods to accelerate the onset of neo-vascualization for survival and 
integration of BTE grafts with host tissue including (1) scaffold design, (2) inclusion of 
angiogenic growth factors, (3) in vitro pre-vascularization (i.e., co-culture of endothelial 
and osteogenic cells), and (4) in vivo pre-vascularization.  Although it is still unclear 
which method is the best for successful in vivo application, a combination of these 
methods may prove to be most effective.  The following is a brief review of each method 
and its challenges. 
 
2.2.3.1. Scaffold Design 
 
Scaffold design has a profound effect on the rate of vascularization after 
implantation.  Specifically, mean pore size of the scaffold is a critical determinant of 
blood vessel ingrowth. BTE studies suggest pore sizes greater than 300 µm to be required 
for vascular ingrowth (16).  Interconnectivity of pore is also critical, as it significantly 
affects cell migration, and in turn, vascularization.  Scaffold fabrication techniques 
including gas foaming, phase separation and freeze drying are employed in association 
with porogen leaching for the generation of increasingly porous scaffolds.   Recently, the 
authors developed thermal sintering and porogen leaching method and fabricated 
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scaffolds with the desired pore size and volume. These scaffolds are proven to be 
superior because they not only support vascular in growth but also meet the mechanical 
requirements for bone regeneration (109, 110). On the other hand, methods such as layer-
by-layer deposition (i.e., solid free-form fabrication) are now commonly used to actively 
design scaffold porosity and interconnectivity.   With these fabrication systems, 
production of complex scaffolds with well-defined architecture and optimized pore 
interconnectivity is possible (111).  
 
2.2.3.2. Inclusion of Angiogenic Growth Factors 
 
The local delivery of angiogenic growth factors certainly accelerates 
vascularization of an implanted graft. Angiogenic growth factors may be incorporated 
into the BTE construct design either by way of the scaffold or seeded cells.  In the first 
scenario, the growth factor may be incorporated onto the scaffold by (1) simple soaking 
for resultant fast release, (2) encapsulated in scaffolds, or (3) covalent immobilization for 
controlled and extended release.   Otherwise, growth factors may be incorporated into the 
seeded cells via genetic modification.    
Several critical considerations should be taken into account for success in this 
method.  Firstly, the choice of growth factors is crucial.  Several commonly studied 
angiogenic growth factors in BTE include vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF). 
Secondly, the proper dosage of the growth factor has been shown to affect the quality of 
the neo-vasculature.  For instance, excess amounts of VEGF have been shown to cause 
severe vascular leakage and hypotension (112).  Lastly, it should be considered that 
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multiple growth factors along spatial and temporal gradients may allow for even 
enhanced results as bone tissue development is controlled by the interaction of multiple 
growth factors. Studies have shown that the incorporation of VEGF and bFGF results in 
accelerated vascularization of engineered tissues via the mobilization and recruitment of 
endothelial progenitor cells (EPCs), though the resulting vessels are often disorganized, 
leaky and hemorrhagic (113).  For this reason, the addition of growth factors that 
stimulate the recruitment of smooth muscle cells or pericytes for the stabilization and 
maturation of the vessels may be considered, and include PDGF, transforming growth 
factor-β (TGF-β) and angiopoietin 1 (Ang1) (114, 115).   
The addition of growth factors to scaffolds is a relatively easy and widely studied 
approach.  Since this type of growth factor delivery is either driven by passive diffusion 
or coupled to the rate of biomaterial degradation, the growth factor release may be altered 
only to some extent by the amount of growth factor added or varying the degradation rate 
of the material.  The release profile for this method is, therefore, often not in tune with 
the actual healing process and cellular demands (116).    On the other hand, growth 
factors covalently linked to the scaffolds may be released according to the cellular 
demands.  It was demonstrated that the vasculature formed in this manner via controlled 
release of VEGF formed organized vasculature, in comparison to the vasculature that 
arose from an uncontrolled VEGF release (117).    
The incorporation of growth factors into the scaffolds is not an efficient process. 
Adding the high price associated with the human recombinant growth factors make the 
growth factor-loaded scaffold approach not an attractive one. On the other hand, the 
incorporation of genetically modified cells, such as VEGF releasing ADSCs, has 
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demonstrated enhanced vascular formation (118).  In addition, cells releasing the 
combination of osteogenic and angiogenic factors (i.e., BMP-4 and VEGF, respectively) 
together have been shown to increase not only vascular formation, but also the quantity 
of regenerated bone, compared to the when each factor was alternatively delivered alone 
(119). However, gene therapy in general has safety concerns, and it is not yet approved 
for clinical use. 
 
2.2.3.3. In Vitro Pre-Vascularization 
 
Current in vitro pre-vascularization strategies of BTE involve the prior seeding 
and co-culture of endothelial cells and osteogenic cells in BTE constructs in vitro.  The 
mechanism underlying this strategy depends on the direct and indirect communication of 
these two cell types, and the formation of premature vessels by the endothelial cells in 
vitro, which may later mature, and anastomose with the host vasculature upon 
implantation.  As seen in Figure 2-5, there is a definite cross-talk between endothelial and 
osteogenic cells (120).  This approach has not only demonstrated accelerated 
vascularization in vivo, but also enhanced osteogenic differentiation in vitro and bone 
formation in vivo (43, 121). With this method, anastomoses occurs more quickly in 
comparison to non pre-vascularized constructs, as host vessels only need to grow into the 
outer region of the constructs to meet the pre-vascular structures.  This method may 
decrease the time needed for vascularization from weeks to days.  
 Figure 2-5.  Diffusible factors involved in crosstalk between osteoblastic cells and 
endothelial cells. Growth factors, as well as systemic hormones, can have effects on 
endothelial functions (purple) and/or on osteoblastic functions (blue). These factors 
act through activation of specific receptors (black arrows) that in turn stimulate the 
expression of other proteins after activation of intracellular sign
(green arrows) Adapted from Grellier 
An important consideration
cells, and identifying an abundant
Although mature endothelial 
be used, they present with m
proliferative abilities (i.e., limited
cells, namely endothelial progenitor
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and constructs demonstrate enhanced levels of vascularization and bone formation.  Yu et 
al. also noted that central necrosis is avoided when scaffolds are seeded with EPCs and 
MSC-derived osteoblasts, which is not the case when only osteoblasts are seeded alone 
and implanted (47).   Perhaps the most desirable cell source is one that contains both 
osteogenic and vasculogenic progenitor cells.  For instance, mesenchymal stem cells, 
which may be isolated from bone marrow for osteoprogenitor cells, also have been shown 
to have the potential to differentiate toward endothelial lineage (123).  Another attractive 
autologous source that may be used to isolate both osteo- and endothelial- progenitors is 
the stromal vascular fraction (SVF) of adipose tissue, which abundantly available, easy to 
harvest, and associated with minimal donor site morbidity.  In addition, in comparison to 
bone marrow, it has a much higher frequency of clonogenic mesenchymal progenitors 
compared (124). 
Several issues regarding in vitro pre-vascularization still remain uncertain.  For 
instance, it is unclear whether it is better to maintain the pre-vascularization in vitro long 
term for establishment of a premature vascular network formation, or to implant the 
construct shortly after seeding the cells in order to allow the in vivo environment help in 
the establishment of a functional vasculature.  Also, even though endothelial cells have 
the potential to form new vessels within the scaffolds that may anastomose with host 
vasculature when implanted in vivo, it is important to consider the presence of other cell 
types (i.e., smooth muscle cells, pericytes) to ensure the formation of functional 
vasculature, and so a tri-culture approach should be further investigated (125).  Lastly, 
the potential benefits of this approach have been doubted since it involves cell-containing 
constructs, which like others require immediate supply with nutrients and oxygen after 
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implantation.  One approach to solve this problem may involve the engineering of 
vascular axis within the in vitro construct, which can be surgically connected to the host 
vasculature as it is when vessels are surgically implanted. 
2.2.3.4. In Vivo (Surgically Induced) Pre-
Vascularization 
 
In vivo pre-vascularization may be performed to allow for vascularization of bone 
constructs. The “flap pre-fabrication” approach utilizes an “extrinsic” mode of 
vascularization, and involves two main stages.  First, the BTE construct is implanted in 
axially vascularized tissue (i.e., in subcutaneous, intramuscular, or intraperitoneal sites), 
where microvascular network formation within the constructs occurs within several 
weeks.  The construct is then harvested, and transferred as free bone flap to the bone 
defect site, where the vascular axis is connected via microsurgical vascular- anastomosis 
techniques, resulting in instantaneous perfusion of the entire construct.  Several 
drawbacks with this technique include the obvious requirement of two required surgeries, 
cost, the formation of a random vascularization pattern, degree of vascularization is based 
on host’s tissue vascularity, as well as donor site morbidity (126).  In another method, an 
“intrinsic” mode of vascularization is used where vessels that are suitable for 
microsurgical transfer (i.e., carotid artery, jugular vein saphenous bundle, or 
arteriovenous (AV) loop) are incorporated into the construct (127).  Though this 
procedure has clear advantages over the “flap pre-fabrication” approach, including that it 
does not require two separate operations like the “flap pre-fabrication” approach, is not 
dependent upon local vascular conditions and the included vasculature is not randomly 
oriented, this method is still very challenging since most load-bearing osteogenic 
constructs are not able to be molded or shaped around the AV loops.  
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2.3. Functional Bone Tissue Engineering  
 The term, functional bone tissue engineering, was coined over a decade ago, and 
is defined as approach that allows for full functional ability of the graft immediately 
following their surgical implantation.  In this approach, the bone graft to be implanted is 
required to have carefully defined biomechanical properties to allow its immediate usage 
upon completion surgery.  However, functional bone tissue engineering entails more than 
just the ability for immediate mechanical usage.  Instead, functional bone tissue 
engineering approaches involve those that allow for the newly restored bone to be fully 
integrated with the neighboring host bone, and importantly, possess the ability to perform 
all the functions of native bone.   The quality of the new regenerated tissue should 
seamlessly match that of the host bone.  In the future, effective quality assessment tests 
should be developed to ensure truly functional engineered bone for patients.  
 
2.4. Overall Objective and Specific Aims 
Oral/maxillofacial and orthopaedic bone grafts and substitutes represent a 
combined $2.5 billion market in the United States, a rapidly rising figure due to the aging 
baby boomer population.  Yet, currently available treatment options, including autografts 
and allografts, are far from ideal. Bone tissue engineering (BTE) is considered one of the 
most promising treatments on the horizon. Successful BTE critically depends on three 
components, (i) a three-dimensional, biodegradable scaffold, (ii) an appropriate cell 
population, and (iii) an adequate vascular supply. We propose the development of an 
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optimized biodegradable scaffold, seeded with the appropriate cells to promote enhanced 
bone regeneration and vascularization. 
Poly(85 lactide-co-15 glycolide) (PLGA) microsphere scaffolds have attracted 
significant attention due to their display of better osteocompatibility and human bone - 
compatible mechanical properties, and the recent approval of PLGA by the US FDA as a 
biodegradable material for certain biomedical devices. Unfortunately, bone regeneration 
with these microsphere scaffolds (pore size ~100 µm) is limited to the scaffold surfaces, 
due to failure to support sufficient mass transport of oxygen and nutrients, osteoclast 
activity, and neo-vascularization.  Recent studies have demonstrated other scaffold types 
with higher pore sizes (i.e., > 400 µm) can ease these limitations, increase cell 
infiltration, and ultimately, allow for bone formation and vascularization throughout the 
entire scaffold.  However, as pore size increases, the scaffold’s mechanical strength, a 
critical BTE factor for load-bearing bones, is sacrificed. Thus, we propose the generation 
of optimal PLGA microsphere scaffolds with optimally-sized pores (i.e., ~300 µm) to 
balance the positive and negative features of the previously mentioned pore size ranges, 
allowing for increased bone regeneration and neo-vascularization, while still retaining 
human bone-mechanical compatibility. 
In addition to an effective biodegradable scaffold, BTE also requires a suitable 
cell population and sufficient neo-vascularization to accomplish complete bone 
regeneration.  Our proposal includes culturing our optimized scaffolds with two 
clinically-relevant cell populations for enhanced bone formation and vascularization, 
specifically peripheral blood derived - endothelial progenitor cells (EPCs) and bone 
marrow derived - mesenchymal stem cells (MSCs).   Previous studies have demonstrated 
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EPCs and MSCs promote enhanced bone regeneration via the stimulation of neo-
vascularization.   We will systematically examine the combination of these two cell types 
and our optimized PLGA scaffolds, and their resultant effects on healing bone defects.  
We hypothesize that our approach will substantially improve the performance of PLGA 
microsphere scaffolds, and may offer a practical and effective solution to important 
clinical problems facing BTE in oral/maxillofacial and orthopaedic surgery. 
 
SPECIFIC AIM 1: To design, fabricate and characterize optimally-porous, 
mechanically compatible biodegradable microsphere scaffolds. 
 
It is hypothesized that thermal sintering combined with NaCl salt-leaching will generate 
consistent and reproducible optimally-porous, human bone-mechanically compatible 
PLGA microsphere scaffolds.  In this aim, we will design optimally-porous scaffolds, 
analyze the porosity via MicroCT, and evaluate mechanical strength via Instron 5544 
testings.  
 
SPECIFIC AIM 2: To study the ability of clinically-relevant cell populations to 
support enhanced mineralization and vascularization on optimally-porous scaffolds 
in vitro and in vivo.  
It is hypothesized that cell seeded - optimally-porous scaffolds will exhibit increased cell 
survival, proliferation and differentiation of two clinically relevant cell types (i.e., rabbit 
MSCs and EPCs) as compared to control scaffolds. In this aim, we will seed and culture 
rabbit MSCs and EPCs, which have been shown to enhance bone and vascular formation, 
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on the control and optimally-porous at pre-determined ratios in vitro.  We will examine 
the cell survival via a cell viability assay, as well as cellular localization and phenotypic 
expression via immunofluorescence and confocal microscopy.   Also, we will also study 
the mineralization and vascularization potential of these constructs in mouse 
subcutaneous model 8 weeks post-implantation. 
 
SPECIFIC AIM 3: To assess the ability of optimally-porous biodegradable scaffolds to 
promote enhanced bone formation and vascularization in vivo.  
 
It is hypothesized that optimally-porous scaffolds will achieve homogeneous bone tissue 
regeneration via increased neo-vascularization.  In this aim, we will implant optimally-
porous scaffolds seeded with rabbit MSCs and EPCs in a rabbit ulnar critically-sized 
bone defect model. At week 12, we will evaluate the explanted grafts via MicroCT to 
measure bone tissue volume, and histology to assess the enhanced osteogenesis and 
angiogenesis. 
 
With these specific aims, we aim to develop pre-vascularized, optimally-porous, human 
bone-mechanically compatible biodegradable scaffolds for effective bone defect 
regeneration. 
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3. FABRICATION AND IN VITRO EVALUATION OF 
OPTIMALLY-POROUS MICROSPHERE-BASED 
SCAFFOLDS  
 
3.1. Introduction 
 
Bone tissue engineering (BTE) has been proposed as a more effective alternative 
option for bone defect repair/regeneration.  BTE involves the combination of 
biodegradable and porous scaffolds, with or without the use of bone-forming cells and 
growth factors, to regenerate bone (13, 128).  The success of the scaffold-based bone 
regeneration approach critically depends on the effectiveness of the biodegradable 
scaffold (129).  Important design considerations for BTE scaffolds include 
biocompatibility, mechanical compatibility, osteoconductivity (i.e., ability of bone cells 
to grow on scaffold surface and form bone), osteoinductivity (i.e., ability to recruit and 
stimulate differentiation of progenitor cells into osteoblasts) and osteointegration (i.e., 
ability to achieve direct bone-to-implant contact) (130).  Of these, osteoconductivity of a 
scaffold is a critical, since cell survival and proliferation in the scaffold’s interior relies 
on mass transport upon initial implantation until the onset of vascular invasion (131).   
Methods to achieve cellular conduction involve scaffold pore structure 
optimization (16, 17).  Scaffolds currently designed with decreased accessible volume 
and/or small pore sizes (i.e., < 200 µm) display osteoblast survival and bone formation 
limited to the periphery, due to decreased oxygen and nutrient diffusion throughout the 
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scaffolds (16). On the other hand, studies have demonstrated that scaffolds with increased 
accessible volume and/or large pore sizes (i.e., macro-porous, > 200 µm) display 
increased osteoblast proliferation and differentiation throughout the entire scaffold, due 
to enhanced mass transport of oxygen and nutrients, and neo-vascularization (23-25).  
There have been many efforts to improve scaffold overall osteoconductivity by 
fabricating macro-porous scaffolds that support osteoblast survival and growth 
throughout the scaffold. Various scaffolding methodologies have been utilized to 
fabricate macro-porous scaffolds, including gas foaming (28), freeze drying (29, 82), 
phase separation (30, 83) and porogen leaching (27, 132-134). However, in comparison 
to scaffolds with smaller pore sizes, these macro-porous scaffolds display a significant 
decrease in mechanical strength.  For instance, Martin et al. demonstrated poly(85 
lactide-co-15 glycolide) (PLGA) foam scaffolds to display uniform mineralization 
throughout, but have inferior mechanical strength (i.e., average compressive modulus of 
1.3 MPa) (135).  Therefore, there is a clinical need to develop biodegradable scaffolds 
with optimal pore characteristics and adequate mechanical strength required to support 
large area bone regeneration.  
PLGA microsphere scaffolds have attracted much attention for BTE, because they 
display human cancellous bone-compatible mechanical properties and have demonstrated 
bone formation in vivo (31, 32). However, the current PLGA microsphere scaffolds, like 
other scaffold types with limited accessible volume and pore sizes, fail to provide the 
prerequisites for optimal bone regeneration (i.e. a stable oxygen and nutrient supply), 
limiting bone regeneration only to the scaffold surfaces (16, 34).   Though Boschetti et al. 
has reported the fabrication of mechanically-stable macro-porous microsphere scaffolds, 
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this study included only preliminary cellular biocompatibility studies using fibroblasts 
(136). In the present study, we systematically examined a novel set of PLGA microsphere 
scaffolds using pre-osteoblastic cells, and performed comprehensive analyses on the 
effects of increased porosity and oxygen tension in respect to cell seeding, proliferation, 
survival, and mineralization. Through this study, we established optimally-porous 
biodegradable scaffolds that are load-bearing, fully osteoconductive and suitable for large 
area bone defect repair. 
 
3.2. Materials and Methods 
 
3.2.1.   Preparation of PLGA Microspheres   
 
PLGA microspheres were prepared by an oil-in-water method as reported 
previously (31). In brief, PLGA 85/15 (Lakeshore Biomaterials, Birmingham, AL) was 
dissolved in methylene chloride (L-14119, Fisher Scientific, Pittsburgh, PA) in a 1:5 
dilution ratio (i.e., 4 g PLGA: 20 milliliters of methylene chloride).  The 
PLGA/methylene chloride solution was added slowly to 1 liter of 1% polyvinyl alcohol 
(PVA, Sigma-Aldrich, St. Louis, MO) solution under a stirring speed of 250 RPM. The 
stirring continued for 24 hours to allow the methylene chloride to evaporate. The 
resultant PLGA microspheres were washed with distilled water, filtered, air-dried, sieved 
into different sizes, and stored in a desiccator until further use. 
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3.2.2.   Fabrication of Optimally-Porous Microsphere 
Scaffolds 
3.2.2.1. Paraffin-Leached PLGA Microsphere 
Scaffolds 
 
We attempted to fabricate porogen-leached PLGA microsphere scaffolds with 
paraffin microspheres as the porogen.  We created paraffin microspheres using a similar 
method as that for PLGA microspheres.  Briefly, 5 grams of paraffin was melted at 90oC, 
and then added slowly to 1 liter of 1% polyvinyl alcohol (PVA, Sigma-Aldrich, St. Louis, 
MO) solution under a stirring speed of 300 RPM.  The speed of stirring was increased to 
a stirring speed of 350 RPM, and ice was added to the mix to decrease the temperature of 
the stirring solution. The stirring continued for 24 hours. The resultant paraffin 
microspheres were washed with distilled water, filtered, air-dried, sieved into different 
sizes, and stored in a desiccator until further use.  To fabricate paraffin-microsphere 
PLGA microsphere scaffolds, we mixed PLGA microspheres (diameter 425-600 µm) and 
a porogen, paraffin (diameter 200-300 µm), were mixed at specific weight ratios (i.e., 
PLGA:paraffin ratios of 100:0, 90:10, 80:20, 70:30, 60:40 and 50:50).  The 
PLGA/paraffin mixture was then placed into a steel mold, and thermally sintered at 
100oC.  At this time, we observed collapsed scaffold forms since the paraffin melted 
during the sintering process.  We then turned to NaCl crystals for a superior porogen for 
the fabrication of PLGA microsphere scaffolds with increased porosity. 
 
3.2.2.2. Salt-Leached, Optimally-Porous PLGA 
Microsphere Scaffolds 
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A new scaffolding method of “Thermal Sintering and Porogen Leaching” 
developed in this study was used to fabricate microsphere scaffolds with increased 
porosity. A schematic illustration of this method is shown in Figure 1a. In brief, PLGA 
microspheres (diameter 425-600 µm) and a porogen, NaCl (diameter 200-300 µm), were 
mixed at specific weight ratios (i.e., PLGA:NaCl ratios of 100:0, 90:10, 80:20, 70:30, 
60:40 and 50:50).  The PLGA/NaCl mixture was then placed into a steel mold, and 
thermally sintered at 100oC.The NaCl porogen was leached out by soaking the composite 
PLGA/NaCl scaffolds in distilled water for 2 hours, resulting in scaffolds with increased 
porosity compared to control scaffolds.  The scaffolds with 0% NaCl are referred to as 
control PLGA scaffolds, while the rest as macro-porous scaffolds.  We fabricated disc-
shaped scaffolds (10 mm diameter, 2 mm height) for porosity measurements and the 
majority of cellular studies, and cylinder-shaped scaffolds (5 mm diameter, 10 mm 
height), which were utilized for mechanical testing, live/dead study, and part of 
mineralization studies.  Scaffolds were air-dried and stored in a desiccator until future 
use. Scanning electron microscopy (SEM) was used to image the morphology of the 
microsphere scaffolds and visually examine the increased number of large pore sizes after 
NaCl-leaching. 
 
3.2.3.   Morphology of Optimally-Porous PLGA 
Microsphere Scaffolds 
 
3.2.3.1. Scanning Electron Microscope Analysis 
 
Scanning Electron Microscope (SEM, FEI Strata 400s Dual Beam FIB) analysis 
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was utilized to examine the morphology of the fabricated PLGA microsphere scaffolds 
(i.e., control scaffold, composite PLGA microsphere/NaCl scaffold before and after salt 
leaching).  Samples were prepared by coating with gold/palladium and examined under 
SEM.  
 
3.2.3.2. Micro-Computed Tomography Analysis 
 
Scaffold specimens were imaged using cone beam micro-focus X-ray computed 
tomography to render three-dimensional models for direct quantitation of porosity 
(µCT40, Scanco Medical AG, Bassersdorf, Switzerland).  Serial tomographic images 
were acquired at 45 kV and 177 µA, collecting 2000 projections per rotation at 300 msec 
integration time.  Three-dimensional 16-bit grayscale images were reconstructed using 
standard convolution back-projection algorithms with Shepp and Logan filtering, and 
rendered within a 12.3 mm field of view at a discrete density of 4,629,630 voxels/mm3 
(isometric 6 µm voxels).  Segmentation of solid scaffold from open porosity was 
performed in conjunction with a constrained Gaussian filter to reduce noise, applying a 
threshold of -220 Hounsfield units (water = 0, air = -1000).  Direct measurements of 
internal porosity included volume fraction, size, connectivity, accessible internal pore 
volume, and accessible solid surface area of scaffold (as a function of pore dimension).  
The accessible volume and surface parameters provide direct measurements of the pore 
volume and surface available to cell infiltration as a function of minimum pore 
dimension, using a distance transformation algorithm similar to Moore et al. (137) 
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3.2.4.   Mechanical Evaluation of Optimally-Porous PLGA 
Scaffolds  
 
Compressive testing of cylindrical PLGA microsphere scaffolds (5 mm diameter 
x 10 mm height, n=6/group) was performed at 2 mm/min (model 5544, Instron Corp., 
Norwood, MA) following the standard protocol of ASTM 1621 (138).  Compressive 
strength was defined as the maximum stress magnitude.  Apparent modulus was 
measured as the tangential slope of the linear region of the effective stress-strain curve at 
50% of compressive strength magnitude. 
 
3.2.5.   In Vitro Evaluation of Optimally-Porous PLGA 
Scaffolds  
 
3.2.5.1. Pre-Osteoblast MC3T3-E1 Cell Culture and 
Evaluation on Optimally-Porous PLGA Scaffolds   
 
3.2.5.1.1. MC3T3-E1 Cell Seeding and Culture on Optimally-
Porous PLGA Scaffolds  
 
The pre-osteoblast immortalized cell line MC3T3-E1 (American Type Culture 
Collection, Manassas, VA) were cultured in α-minimal essential medium (α-MEM) 
containing 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C, 5% CO2 and 
95% humidified air.  Cells were maintained in sub-confluent cultures until needed for in 
vitro scaffold studies. 
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PLGA microsphere scaffolds were sterilized by immersing the scaffolds in 70% 
ethanol for twenty minutes. Scaffolds were then washed three times in sterile PBS before 
exposing them to UV radiation for one hour.  After cell trypsinization, a MC3T3 cell 
suspension containing 4 x 104 cells was uniformly seeded onto the scaffolds.  The disc-
shaped scaffolds were placed flat on the culture plate, and a 20 µl cell suspension was 
uniformly added to the top of the scaffold.  The cylinder-shaped scaffolds were placed 
along the length of the scaffold on the culture plate, and a 40 µl cell suspension was 
added to the lengthwise surface as the scaffold was slowly rotated (i.e., along the long 
axis of the scaffold) to maintain uniform cell seeding.  The cell-seeded scaffolds were 
incubated for two hours at 37oC to allow for cell adhesion onto the scaffolds. The cell-
scaffold constructs were cultured in osteogenic media (i.e., α-MEM supplemented with 
10% FBS, 1% penicillin-streptomycin, 3mM β-glycerophosphate and 50 µg/ml ascorbic 
acid), and maintained for 7, 14, 21, and 28 days in an incubator at 37°C, 5% CO2, and 
95% humidified air. 
 
3.2.5.1.2. MC3T3-E1 Cell Seeding Efficiency on Optimally-
Porous PLGA Scaffolds 
 
After 6 hours of cell seeding, scaffolds were transferred to new wells.  Cells at the 
bottom of the original wells were trypsinized, resuspended and counted with a 
hemacytometer.  Cell seeding efficiency (i.e., the number of cells that adhered to the 
scaffolds) was determined by the difference between the number of cells initially seeded 
(i.e., 4 x 104 cells) and the number of cells that were counted at the bottom of the well. 
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3.2.5.1.3. MC3T3-E1 Cell Proliferation on Optimally-Porous 
PLGA Scaffolds 
 
DNA concentration of the pre-osteoblast MC3T3 cells cultured on control PLGA 
scaffolds and PLGA scaffolds with increased porosity (n=3) was evaluated quantitatively 
using Quant-iT PicoGreen dsDNA assay (Invitrogen, Carlsbad, CA) following 
manufacturer’s instructions.  After culturing the samples (scaffold dimensions 8 mm 
diameter x 2 mm height) for 7, 14, and 21 days in osteogenic media, the cell-scaffold 
samples (n=3) for each experimental group were harvested.  Samples were washed with 
PBS, incubated in lysis buffer (i.e., 1% Triton X-100 solution), and subjected to freeze–
thaw cycles. DNA concentration from the cell lysates was determined according to the 
manufacturer’s protocol. Experimental groups included control scaffolds (i.e., 0:100 ratio 
of NaCl:PLGA), and scaffolds with increased porosity (i.e., 10:90, 20:80, 30:70, and 
40:60 ratio of NaCl:PLGA). 
 
3.2.5.1.4. MC3T3-E1 Cell Viability on Optimally-Porous 
PLGA Scaffolds 
 
The live-dead cell viability assay we used (Invitrogen, Carlsbad, CA) includes 
calcein AM and ethidium homodimer-1 probes to label live and dead cells green and red, 
respectively.  We used this live-dead assay to compare MC3T3 cell survival on the 
surface and in the interior of scaffolds. Cylindrical scaffolds (5 mm diameter, 10 mm 
height) were cultured for 4, 7, and 14 days in osteogenic media, at which point the 
scaffolds (n=3) for each experimental group were harvested. Samples were bisected 
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lengthwise from each scaffold group to allow for the examination of cell viability in the 
sample’s interior. Live-dead cell viability assay was performed according to the 
manufacturer’s protocol, using confocal microscopy to image cells at the surface and 
interior of the scaffolds. 
 
3.2.5.1.5. MC3T3-E1 Cell Localization and Expression on 
Optimally-Porous PLGA Scaffolds 
 
To visualize cellular localization and expression via histology and 
immunohistochemistry, samples were paraffin-embedded and sectioned (139).  Briefly, 
cell-scaffold constructs were washed with PBS, and then fixed in formalin overnight at 
4oC.  Samples were dehydrated sequentially using an isopropyl alcohol series (i.e., 70%, 
90% and 100%) for one hour each, at room temperature.  Samples were directly 
transferred to molten paraffin (Tissue Path Paraplast Tissue Embedding Media, Fisher 
Scientific, Pittsburgh, PA) at 55oC for 10 minutes and then embedded in fresh molten 
paraffin.  Paraffin-embedded samples were cut into serial sections (20 µm thick) using 
Cryofilm (Section-Lab Co. Ltd., Hiroshima, Japan) and a microtome sectioning machine.  
Sections were placed on glass slides for histological analysis. Sections were stained with 
Gill’s 3 hematoxylin (Sigma-Aldrich, St. Louis, MO) to visualize MC3T3 cell 
localization within the PLGA scaffolds after culturing the constructs for 28 days in 
osteogenic media. Immunostaining of two bone markers, osteopontin (OPN) and collagen 
Type I (Col I) was performed via a rabbit polyclonal anti-human osteopontin (Abcam, 
Cambridge, MA, ab8448) antibody and a rabbit polyclonal anti-human collagen type I 
antibody (Abcam, Cambridge, MA, ab292), respectively.  Briefly, sections were de-
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paraffinized in HistoClear (National Diagnostics, Atlanta, Georgia), taken through a 
descending series of ethanol concentrations, rehydrated in distilled water, and then placed 
in 3% hydrogen peroxide (Sigma-Aldrich, St. Louis, MO) in PBS to quench endogenous 
peroxidase activity. To improve antigen exposure, the sections were boiled in Target 
retrieval (Dako, Carpinteria, CA) and washed in distilled water.  Samples were incubated 
with blocking solution (i.e., 0.5% (w/v) bovine serum albumin in PBS) for one hour. 
Primary antibodies were diluted in 0.5% (w/v) bovine serum albumin in PBS at 
concentrations of 1:200 for OPN or 1:300 for Col I.  Samples were incubated with the 
primary antibody for two hours at room temperature. Sections were washed free of 
primary antibody and incubated with SignalStain® Boost IHC Detection Reagent, HRP, 
Rabbit (Cell Signaling, Boston, MA, #8114) followed by an incubation with 3,3'-
diaminobenzidine (DAB, Vector Laboratories, Burlingame, CA) for thirty seconds.  The 
slides were rinsed three times in water, and mounted using mounting media (Electron 
Microscopy Sciences, Hatfield, PA) for thirty minutes. 
 
3.2.5.1.6. MC3T3-E1 Cell Mineralization on Optimally-
Porous PLGA Scaffolds 
 
Matrix mineralization or calcium deposition was evaluated via Alizarin Red 
staining. This colorimetric analysis is based on solubility of the red matrix precipitate 
with cetylpyridinium chloride (CPC, Sigma-Aldrich, St. Louis, MO) to yield a purple 
solution.  Briefly, after 14, 21 and 28 days of culturing in osteogenic media, cell-scaffold 
constructs were washed with distilled water and fixed with 70% ethanol at 4°C for one 
hour. Ethanol was removed and samples were air-dried for ten minutes.  Samples were 
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incubated with alizarin red dye (Sigma-Aldrich, St. Louis, MO) for ten minutes at room 
temperature. Following washes to remove excess alizarin red dye, the samples were 
incubated with 10% CPC at room temperature for thirty minutes. The absorbance of the 
resulting solution, which is proportional to the amount of calcium deposited, was read on 
a TECAN plate reader at 562 nm. 
 
3.2.5.1.7. Oxygen Tension Measurements on Optimally-
Porous PLGA Scaffolds  
 
 After culturing the MC3T3-E1 cells on control and optimally-porous PLGA 
scaffolds for 21 days in osteogenic media, the cell-scaffold samples were quantitatively 
evaluated for the oxygen tension in the interior region of each sample group using needle-
type fiber optic oxygen microsensors (501656, World Precision, Saratoga, FL), as 
previously described by Volkmer et al.  () (25).  Specifically, we examined scaffold 
groups with 0%, 10%, 20%, 30%, and 40% NaCl, and cultured 100,000 cells on each 
scaffold (dimensions 5 mm diameter, 10 mm height). The oxygen sensors were mounted 
on optic fibers with a tip diameter of 50 µm. To protect these fragile sensors, they are 
fixed within a standard hollow 27 gauge needle of 0.4-mm diameter. A 25 gauge needle 
was utilized to pre-form a 2.5 mm deep channel on the side of the scaffold for which the 
probe would then be inserted (305127, Becton Dickinson). Oxygen tension measurements 
in the medium were carried out by inserting a probe in the medium next to all 
experimental scaffold groups. Prior to sample measurements, the oxygen microsensor 
was calibrated following a conventional two-point calibration protocol described by the 
manufacturer. Briefly, oxygen-free water and water-vapor saturated air were used as 
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calibration standards.   The oxygen-free water standard was prepared by dissolving one 
gram of sodium sulfite (S430, Fisher Scientific) in 100 milliliters of water in a sealed 
vessel, and the water-vapor saturated air was prepared by placing a wet piece of cotton in 
a sealed vessel.  The oxygen tension measurements were obtained by inserting the probe 
mid-length and mid-diameter (Figure 3-1).  Measurements are expressed as the mean of 
three samples per scaffold group ± standard deviation.  
 
 72
 
Figure 3-1.  A) Photograph of needle-type fiber optic oxygen / pH microsensors set-
up.  (B)  Photograph of needle-type fiber optic micro-sensors inserting into the 
interior region the cell-scaffold construct. 
 
3.2.5.2. Mesenchymal Stem Cell (MSC) Culture and 
Evaluation on Optimally-Porous PLGA Scaffolds  
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3.2.5.2.1. MSC Isolation 
 
Mesenchymal stem cells (MSCs) were isolated from the bone marrow of one New 
Zealand white rabbit (4-5 kg).  The mononuclear cell fraction was isolated via layering 
over a Percoll density gradient, and centrifuging at 600 rpm for 20 min at room 
temperature. The mononuclear cell fraction was seeded and expanded in Dulbecco's 
Modified Eagle Medium (DMEM, Invitrogen) supplemented with 10% FBS and 1% 
Penicillin/Streptomycin (P/S, Gibco) at 37oC and 5% CO2.  Passages 3-5 were used for 
experimentation. 
 
3.2.5.2.2. MSC Seeding and Culture on Optimally-Porous 
PLGA Scaffolds  
 
PLGA microsphere scaffolds (10 mm x 5 mm) were sterilized by immersing the 
scaffolds in 70% ethanol for twenty minutes. Scaffolds were then washed three times in 
sterile PBS before exposing them to UV radiation for one hour.  After cell trypsinization, 
a MSC cell suspension was uniformly seeded onto the scaffolds. The cylinder-shaped 
scaffolds were placed along the length of the scaffold on the culture plate, and a 40 µl 
cell suspension of 1 x 105 cells was added to the lengthwise surface as the scaffold was 
slowly rotated (i.e., along the long axis of the scaffold) to maintain uniform cell seeding.  
The cell-seeded scaffolds were incubated for two hours at 37oC to allow for cell adhesion 
onto the scaffolds. The cell-scaffold constructs were cultured in osteogenic media (i.e., α-
MEM supplemented with 10% FBS, 1% penicillin-streptomycin, 3mM β-
 74
glycerophosphate and 50 µg/ml ascorbic acid), and maintained for 7, and 21 days in an 
incubator at 37°C, 5% CO2, and 95% humidified air. 
 
3.2.5.2.3. MSC Cell Viability on Optimally-Porous PLGA 
Scaffolds 
 
Live-dead cell viability assay (Invitrogen, Carlsbad, CA) was used to analyze cell 
survival in the interior of cell-seed constructs.  We seeded and cultured 100,000 MSCs on 
scaffolds (0% NaCl/100% PLGA, and 20% NaCl/80% PLGA) in osteogenic media media 
(i.e., α-MEM supplemented with 10% FBS, 1% penicillin-streptomycin, 3mM β-
glycerophosphate and 50 µg/ml ascorbic acid) for 7 and 21 days 37oC and 5% CO2. 
Samples were bisected lengthwise from each scaffold group (n=3) to allow for the 
examination of cell viability in the sample’s interior. Live-dead cell viability assay was 
performed according to the manufacturer’s protocol to label live cells green with calcein 
AM, and dead cells red with ethidium homodimer-1 probes. Confocal microscopy (Zeiss 
LSM ConfoCor2, 20X magnification) was utilized to image cells interior of the scaffolds. 
 
3.2.5.2.4. Oxygen Tension Measurements on Optimally-
Porous PLGA Scaffolds  
 
Needle-type fiber optic oxygen microsensors (501656, World Precision, Saratoga, 
FL) were utilized to analyze oxygen levels in the interior of MSC-seeded control and 
macro-porous scaffolds (25).  Briefly, 100,000 MSCs were seeded on each scaffold type 
(i.e., 0% NaCl, 10% NaCl, 20% NaCl, 30% NaCl, 40% NaCl), and cultured for 21 days 
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in osteogenic media (DMEM, 10% FBS, 10 nM dexamethasone, 50 µg/ml ascorbic acid, 
5 mM β-glycerophosphate) 37oC and 5% CO2. At this point, a 25 gauge needle was 
utilized to pre-form a 2.5 mm deep channel on the side (mid-length) of the scaffold for 
which the probe would then be inserted (305127, Becton Dickinson). Prior to sample 
measurements, the oxygen microsensor was calibrated following a conventional two-
point calibration protocol described by the manufacturer. Briefly, oxygen-free water and 
water-vapor saturated air were used as calibration standards.   The oxygen-free water 
standard was prepared by dissolving one gram of sodium sulfite (S430, Fisher Scientific) 
in 100 milliliters of water in a sealed vessel, and the water-vapor saturated air was 
prepared by placing a wet piece of cotton in a sealed vessel. Oxygen tension 
measurements in the medium were carried out by inserting a probe in the medium next to 
all experimental scaffold groups. Oxygen tension measurements of the interior of the 
cell-seeded scaffolds was carried out by placing the probe tip in the center of the scaffold 
by way of the pre-formed channel made in the constructs.  Oxygen tension measurements 
are expressed as the mean of three samples per scaffold group ± standard deviation. 
 
3.2.5.2.5. pH Measurements on Optimally-Porous PLGA 
Scaffolds  
Needle-type fiber optic pH microsensors (World Precision, Saratoga, FL) were 
utilized to analyze pH levels in the interior of MSC-seeded control and macro-porous 
scaffolds (25). Cell seeding on scaffolds and culture in vitro was performed in same 
manner for the oxygen tension measurement samples.  Prior pH measurements, the pH 
microsensors were calibrated with buffer solutions of pH 5.0, 6.0, 7.0 and 8.0.  pH 
measurements in the medium were carried out by inserting a probe in the medium next to 
 all experimental scaffold groups.
scaffolds was carried out by 
the pre-formed channel made
mean of three samples per scaffold
 
3.2.6.   Statistical
For scaffold porosity
mineralization, and oxygen tension
variance (ANOVA) was preformed
analyzed at each time point.  
and significance was determined
 
3.3. Results
3.3.1. Microsphere
Figure 3-2. (A)  Schematic diagram illustrating the fabrication process of PLGA 
microsphere scaffolds with increased pore sizes.  SEM image of (B) PLGA 
microspheres after thermal sintering, (C) PLGA/NaCl composite scaffold after 
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sintering, and (D) PLGA scaffold with increased pore sizes created after thermal 
sintering and porogen leaching. 
 
 PLGA microsphere sintering often results in three-dimensional scaffolds with 
limited pore volume.  However, we developed a novel method to fabricate PLGA 
microsphere scaffolds with increased pore volume and average pore size, as shown in 
Figure 3-2.  Through mixing a porogen (i.e., NaCl crystals, 200-300 µm diameter) with 
PLGA microspheres (425-600 µm diameter), thermal sintering, followed by porogen 
leaching, we successfully created PLGA microsphere scaffolds with increased pore 
volume. Thermal sintering, and particulate leaching are well known methods for 
fabricating three-dimensional and porous scaffolds (31, 132). Here, we combined them 
into a single method “Thermal Sintering and Porogen Leaching” to design PLGA 
microsphere scaffolds with the desired pore characteristics. SEM imaging demonstrated 
that after porogen leaching (Figure 3-2D), there was visually an increase in number of 
large pore sizes compared to scaffolds fabricated with PLGA microspheres alone. (i.e., 
control PLGA scaffolds). 
 
3.3.2.   Scaffold Porosity via Micro-CT 
MicroCT imaging was used to reconstruct 3D models of scaffolds for 
nondestructive measurements of porosity.  Computational assessment of all MicroCT 
images confirmed that the internal porosity is one interconnected space comprising 
99.9% of the total pore volume.   The porosity and accessible volume of the PLGA 
microsphere scaffolds corresponded to porogen size and amount used.  PLGA 
microsphere scaffolds that were not fabricated with NaCl (i.e., control scaffolds), 
displayed a void volume of approximately 39 mm3, whereas scaffolds fabricated with 
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20% NaCl and 40% NaCl (percent by weight) displayed a void volume of 50 mm3 and 59 
mm3, respectively (Figure 3-3).  Also, by mixing 40% NaCl and 60% PLGA 
microspheres (by dry weight), percent accessible pore volume increased 337% in relation 
to control scaffolds at an average pore size of 200 µm (Figure 3-4B). Data and images 
describing scaffold pore volume are presented as a function of pore size, providing direct 
measurements of externally accessible pore space through the full range of diametral pore 
dimension (Figure 3-4A, C).  Although the range of pore size dimensions remained 
constant, the volume of porosity increased with higher concentration of porogen.  For 
example, blue areas signify the accessible volume in the scaffolds to objects with a 
diameter in the range of 100-200 µm, and red in the range of 400-500 µm.  Thus, as 
porogen concentration increased, the accessible interconnected volume also increased 
(Figure 3-4A).   In control scaffolds, a sphere with a diameter of 200 µm can access 
approximately 10% of the total pore volume, whereas the same sphere can access 
approximately 40% of the pore volume of the 40% NaCl/60% PLGA scaffold (Figure 
3-4B).   This is illustrated in Figure 3-5C, which again shows that the experimental 
scaffolds fabricated with a porogen have a higher percentage of accessible pore volume 
in the 300-500 µm range in comparison to control scaffold. Thus, we effectively 
increased the accessible volume for cell infiltration throughout the scaffold.  In addition, 
as seen in Figure 3-5, scaffolds fabricated with altleast 20% NaCl demonstrated 
significantly enhanced pore sizes in the range of 300-400 µm as compared to control 
matrixes (i.e., 0% NaCl). 
 Figure 3-3.  Increasing porosity (i.e., void volume (mm
scaffolds fabricated with a porogen (NaCl).
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3)) in PLGA microsphere 
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Figure 3-4.  Scaffold pore interconnectivity and percent accessible volume obtained 
via micro-computed tomography imaging and analysis. (A) Accessible volume space 
images generated by imposing specific pore diameter parameters (scale 100–500 
mm) on 0% NaCl/100% PLGA, 20% NaCl/80% PLGA, and 40% NaCl/60% PLGA 
scaffolds from a top-view, mid-view, and cross-sectional view. (B) Graph comparing 
the effect of increasing porogen to accessible volume in the PLGA scaffolds. Dashed 
 line illustrates percent accessible volume of PLGA/0% NaCl
scaffolds for an object with a diameter of 200 mm. (C) Increasing scaffold accessible 
volume in optimally- porous PLGA scaffolds. Interconnected volume accessible to 
spherical objects with a specific diameter range (i.e., 100
and 400–500 mm) in PLGA/0% NaCl, PLGA/ 20% NaCl, and PLGA/40% NaCl 
scaffolds. 
 
Figure 3-5.  (A) Percent accessible volume of each scaffold group in the range of 
200-400 µm.  (B) Histogram of percentage of pores in increments of 100 µm 
scaffold group.  (C) Graphs illustrating 
range.  
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3.3.3.   Scaffold Mechanical Characterization 
 
By using an increasing amount of porogen in the scaffold fabrication process, 
compressive strength and modulus of the scaffolds were sacrificed (Figure 3-6).  
Scaffolds with increased porosity (i.e., 40% NaCl/60% PLGA by dry weight) displayed 
significantly less compressive strength and modulus than control scaffolds (i.e., 0% 
NaCl/100% PLGA).  Scaffolds with optimally-sized pores (i.e., 20% NaCl/80% PLGA) 
displayed a significant decrease, 63.2%, in compressive strength, and a 29.8% decrease in 
compressive modulus in comparison to control scaffolds. 20% NaCl/80% PLGA 
displayed significantly higher compressive strength, 140%, and modulus, 240%, than 
scaffolds with the highest porosity (i.e., 40% NaCl/60% PLGA).  The compressive 
modulus and strength for the scaffolds with increased porosity (i.e., 10-40% NaCl/90-
60% PLGA), although lower than the control scaffold, are in the range of human 
trabecular bone mechanical properties (i.e., compressive modulus 50-800 MPa and 
compressive strength 1-10 MPa. Thus, we termed the 20% NaCl/80% PLGA scaffold 
group as optimally-porous scaffolds, since they display significantly higher pore volume 
than control, while retaining mechanical strength. 
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Figure 3-6.  Mechanical characterization of PLGA microsphere scaffolds with an 
increased porogen content. Analysis of (A) compressive strength and (B) 
compressive modulus. 
 
 
3.3.4.   Effect of Scaffold Accessible Pore Volume on In 
Vitro Cell Performance 
3.3.4.1. MC3T3-E1 Cell Performance on Optimally-
Porous PLGA Scaffolds  
 
3.3.4.1.1. MC3T3-E1 Cell Infiltration, Proliferation and 
Survival 
The efficiency of initial cell seeding decreased with increasing porogen used to 
fabricate the PLGA microsphere scaffolds (Figure 3-7).  Of the 4 x 104 MC3T3 cells 
initially seeded onto each scaffold, approximately 3.3 x 104 cells adhered to the control 
scaffolds, and only 2.5 x 104 cells adhered to the scaffolds with increased porosity (i.e., 
40% NaCl/60% PLGA by dry weight).  However, after 5 days of culture in osteogenic 
media, the DNA concentration, which is proportional to cell number, was not 
significantly different in control scaffolds and scaffolds with increased porosity (i.e., 20% 
NaCl/80% PLGA and 40% NaCl/ 60% PLGA by dry weight).  By 2 weeks of culture, 
cell number and proliferation in the scaffolds with increased porosity exceeded that of 
control scaffolds (Figure 3-8). The limitation of cell culture on scaffolds was seen by 3 
weeks of culture, as the capacity of the scaffolds to support cell proliferation began to 
decrease.  The effects of scaffold porosity on cell viability were examined on the surface 
of the scaffolds, as well as the interior, of the scaffolds.  At 4, 7, and 14 days of cultures, 
cell-scaffold constructs were bisected, and live/dead assays were performed.  
Representative fields from the center of the scaffold (approximately 5 mm depth) taken 
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by confocal microscopy are shown in Figure 3-9.  After 4 days of culture, there was not a 
significant difference in live : dead cell ratio between the control scaffolds and scaffolds 
with increased porosity.  By 14 days of culture, we observed a significant difference in 
live cells present in the interior region of scaffolds with increased porosity versus control 
scaffolds.  In 20% NaCl/80% PLGA and 40% NaCl/ 60% PLGA scaffolds, the cells 
displayed a robust and healthy morphology, with extended processes.  In contrast, the 
cells in the center of the control scaffolds were mostly dead by 14 days and displayed a 
round morphology appearance. 
 
Figure 3-7.  Effect of increasing porosity on cell-seeding efficiency on scaffolds (*p < 
0.05). 
 
 Figure 3-8.  Effect of increasing porosity on proliferation of murine pre
cells (MC3T3-E1) seeded on PLGA control and 
and 21 days (*p < 0.05). 
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Figure 3-9.  Effect of increasing porosity on cell viability in the interior of the 
PLGA microsphere scaffolds at 4, 7, and 14 days (scale = 200 mm). 
 
3.3.4.1.2. MC3T3-E1 Cell Localization and Expression  
Through a modified paraffin-embedding and sectioning procedure, we were able 
to study the cellular localization and expression of the MC3T3 cells cultured on our 
PLGA microsphere scaffolds.  In Figure 3-10, PLGA scaffolds with increasing porosity 
(i.e., 20% NaCl/ 80% PLGA and 40% NaCl/ 60% PLGA; images of 40% NaCl/ 60% 
PLGA scaffolds are not shown) promote cell infiltration into the interior of the scaffolds. 
After 28 days of culturing MC3T3 cells on the scaffolds, hematoxylin staining 
highlighted cells densely located on the top of control scaffolds and not in the center of 
the control scaffolds (Figure 3-10A).  On the other hand, scaffolds with increased 
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porosity displayed cell localization on the surface, as well as increased cell infiltration 
and survival in the center of the scaffold (Figure 3-10 B, C). Likewise, we found cells 
expressing osteopontin and collagen type I only on the surface of the control scaffolds 
(Figure 3-10 D, G). PLGA scaffolds with increased porosity displayed cells expressing 
osteopontin and collagen type I at the top, as well as the center of the scaffold (Figure 
3-10 E, F, H, I). 
 
Figure 3-10.  MC3T3-E1 cellular localization and expression on control and 
optimally porous PLGA scaffolds. Hematoxylin staining of control (A) and 
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optimally porous scaffolds [top (B) and center (C)], osteopontin 
immunohistochemistry of control (D) optimally porous scaffolds [top (E) and center 
(F)], and collagen type I immunohistochemistry of control (G) and optimally porous 
scaffolds [top (H) and center (I)]. Arrows indicate cell staining.  Scale on all images 
= 200 µm.  
 
3.3.4.1.3. MC3T3-E1 Cell Mineralization  
After 28 days following seeding and culturing MC3T3 cells on scaffolds, we 
performed Alizarin Red Staining to detect calcium mineralization. Scaffolds with 
increased porosity visually appeared to have higher mineralization potential than control 
scaffolds (Figure 3-11).  Control scaffolds displayed mineralization limited to the top 
surface, and not in the center and bottom.  On the other hand, scaffolds with increased 
porosity showed Alizarin red staining throughout the entire scaffold (i.e. top and bottom 
surfaces, and middle of construct). To compare and quantify the mineralization that was 
occurring throughout the scaffolds versus mineralization occurring only in the center of 
the scaffolds, we cultured MC3T3 cells on cylindrical scaffolds that were taller (scaffold 
size 10 mm height, 5 mm diameter), so that we were able to manually dissect 2 mm off 
the top and bottom scaffold surfaces (Figure 3-12).  Alizarin Red staining quantification 
confirmed the increase in mineralization in scaffolds with increasing porosity. 20% 
NaCl/80% PLGA scaffolds displayed the highest significant difference in mineralization 
compared to control.  Although mineralization in 40% NaCl/ 60% PLGA scaffolds 
displayed higher mineralization potential than control scaffolds, it was not as high as 20% 
NaCl/ 80% PLGA (Figure 3-12 A).  After manually removing the top 2 mm and bottom 2 
mm surfaces of the tall cylindrical scaffolds, we quantified the mineralization in the 
center portions of the scaffolds.  Mineralization increased significantly in the center of 
the scaffolds with increasing porosity after 28 days in culture (Figure 3-12 B). 
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Figure 3-11.  Mineralization potential of control and optimally-porous PLGA 
microsphere scaffolds. Alizarin red staining was performed 28 days after MC3T3-
E1 cells had been cultured on scaffolds. Red staining in images signifies 
mineralization or calcium deposition. Optimally porous scaffold displayed 
mineralization on throughout the scaffold (i.e., top and bottom surfaces, and cross 
section), while control scaffold mineralization is limited to only the top surface of the 
scaffold. Scale bar = 1000 µm. 
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Figure 3-12. Effects of porosity on mineralization (A) throughout the entire scaffold, 
and (B) in the center of the scaffold.  After 28 days of cell culture on scaffolds, 
Alizarin Red staining was performed on the entire cell-scaffold construct and 
quantified.  Two millimeters from the top and bottom surfaces of the scaffolds were 
manually removed as shown in (C), and Alizarin red staining was performed to 
analyze the mineralization in the center of the constructs (B) ( * signifies p < 0.05).  
Photographs of control scaffolds (0% NaCl/100% PLGA) seeded without cells and 
with MC3T3-E1 cells, and optimally-porous scaffolds (20% NaCl/80% PLGA 
scaffolds) seeded with MC3T3 cells.  Mineralization in control scaffold is limited to 
the top of the scaffold, whereas mineralization of optimally-porous scaffolds extends 
significantly lower than control scaffolds (Scale bar = 5 mm).   
 
3.3.4.1.4. Oxygen Tension Levels in Scaffold’s Interior 
Regions 
Oxygen tension measurements demonstrated a significant gradient between the 
media surrounding the cultured constructs and the interior regions of the constructs in all 
experimental groups after 3 weeks in vitro.  Oxygen tension in the peri-construct region 
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for all experimental scaffold groups was not statistically different from each other, and 
averaged 6.67% ± 1.11%.   Oxygen tension in the interior of the cell-seeded scaffolds 
was directly related to the concentration of porogen used to fabricate the scaffolds.   
Specifically, increases in the scaffold’s porosity facilitated and enhanced oxygen 
diffusion to the construct’s interior region, and thus, decreasing the oxygen tension 
gradient from the scaffold’s exterior to interior (Figure 3-13).  The peri-construct – 
interior construct oxygen gradient was most significantly seen in control scaffolds, where 
the oxygen gradient in the interior of cell-seeded control (0% NaCl/100% PLGA 
scaffolds) scaffolds conditions dropped below 1%. Optimally-porous scaffolds (20% 
NaCl/80% PLGA scaffolds) displayed similar oxygen tension gradients as compared to 
macro-porous scaffolds (40% NaCl/60% PLGA scaffolds). 
 Figure 3-13. The effect of porosity on oxygen tension gradient from the exterior to 
interior of PLGA microsphere scaffolds after 3
ambient air is 21%, and average oxygen tension of cell culture med
1.11%. 
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3-14, optimally-porous scaffolds cultured with MSCs displayed significantly more live 
cells (i.e., live cells are stained green with calcein AM, dead cells are stained red with 
ethidium bromide) in the interior of the construct, whereas control constructs displayed 
significant cell death in the interior regions of the construct after 21 days in vitro.  This 
observed increasing cell survival trend can be attributed to the increased oxygen tension 
levels, as well as more normal pH levels in the interior of the scaffolds, as compared to 
that of control scaffolds after 21 day in vitro.  
 
Figure 3-14.  MSC viability in interior of control and optimally-porous scaffolds at 7 
and 21 days in vitro. Live cells fluoresce green (i.e., calcien-AM), and dead cells 
fluoresce red (i.e., ethidium bromide).   
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3.3.4.2.2. Oxygen Tension Levels and pH in Scaffold’s 
Interior Regions 
The observed increasing cell survival trend can be attributed to the increased 
oxygen tension levels, as well as more normal pH levels in the interior of these scaffolds, 
as compared to that of control scaffolds after 21 day in vitro.   With both, oxygen tension 
and pH levels, there was a positive correlation with the percentage of porogen used 
during fabrication (i.e., porosity)  (Figure 3-15A). For instance, in respect to oxygen 
tension levels in the scaffold’s interior regions, the control scaffolds displayed the lowest 
oxygen tension levels (0.51% ± 0.47%), whereas 60% PLGA/ 40% NaCl scaffolds 
displayed the highest oxygen tension levels (4.11% ± 0.48%).  However, there was no 
statistically significant difference in oxygen tension levels in the interior regions of 
scaffolds fabricated with 20% NaCl, 30% NaCl, or 40% NaCl.    Although the oxygen 
tension levels in the interior regions of all scaffold groups (0%-40% NaCl) was 
significantly less than the oxygen tension levels in the media surrounding the scaffold 
(6.52% ± 0.61%).   
Like oxygen tension levels, there was a positive relationship between the 
percentage of porogen used during fabrication and pH levels in the interior of the 
scaffolds (Figure 3-15B).  pH levels are critical to cell survival, as too acidic or basic 
conditions is harmful to the cell.  The media surrounding the construct (i.e., peri-cellular 
region) had a pH of 7.61 % ± 0.08%.  Only scaffolds fabricated without NaCl (i.e., 
control scaffolds), and scaffolds with 10% NaCl displayed a significant difference in pH 
levels in the scaffold’s exterior regions compared to that in the exterior regions of the 
scaffold (i.e., pH gradient from scaffold’s exterior to interior regions) (i.e., 6.83%± 
0.06% and 6.99% ± 0.06%, respectively).   
  
Figure 3-15.  Comparison of oxygen tension and pH levels in interior of control and 
macro-porous PLGA microsphere scaffolds at 21 days 
 
3.4. Discussion
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Figure 3-16.  The pros and cons of scaffolds with low and high porosity, and the 
requirement to design scaffolds with optimal porosity and mechanical properties 
(i.e., optimally porous scaffolds) for homogeneous and enhanced bone regeneration. 
 
Appropriate scaffold porosity and accessible volume are critical for obtaining 
effective osteogenesis in large area bone repair.  As seen in Figure 3-16, deviations from 
the moderate porosity range display positive and negative tradeoffs.  Scaffolds with 
decreased average pore size are associated with an increase in surface area, and thus, cell 
seeding efficiency.  Such scaffolds with relatively lower porosity exhibit higher 
mechanical strength, a critical factor in clinical applications (140). However, these 
scaffolds are also associated with significant drawbacks, including decreased mass 
transport of oxygen and nutrients, and decreased vascularization, which in turn, results in 
decreased osteoblast survival and bone regeneration (16, 17, 141, 142).  On the other 
hand, scaffolds with high porosity are not as mechanically strong and display decreased 
cell seeding efficiency, but are associated with higher mass transport of oxygen and 
nutrients, facilitating enhanced bone regeneration (21).  With respect to dynamic bone 
remodeling, increased osteoclast number and size in scaffolds with high porosity may 
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result in increased bone matrix strength via increases in bone remodeling (143).  Also, 
studies have identified scaffolds with increased pore sizes to allow for the most efficient 
vascularization (78, 144).  Thus, scaffold porosity is a crucial parameter to consider when 
fabricating scaffolds. 
For bone tissue engineering applications, PLGA scaffolds developed via 
microsphere sintering techniques have a unique advantage as they display mechanical 
properties in the range of human cancellous bone (31), an essential aspect of scaffolds to 
ensure proper support at the defect site upon implantation. These cancellous bone- 
mechanically compatible scaffolds are attractive since bone has the special ability to 
undergo remodeling and optimize its mechanical function for its particular skeletal 
location, and thus, can be effectively used for regeneration in either cancellous or cortical 
bone sites (55). Our group has fabricated and extensively investigated PLGA 85/15, 
PLGA-nano hydroxyapatite composites, and PLGA-chitosan blend microsphere scaffolds 
for bone regeneration (31-33, 145).  PLGA 85/15 based microsphere scaffolds have 
supported bone forming cell proliferation, differentiation and mineralization in vitro and 
bone formation in vivo (32).  However, these PLGA microsphere scaffolds lack the 
necessary porosity for sufficient cell in-growth, and thus, result in surface-limited 
osteogenesis in vitro and in vivo (Figure 3-17). 
 
Figure 3-17.  Schematic illustration of surface-limited and large-area bone 
regeneration in a biodegradable scaffold. Scaffolds with a limited pore size and 
reduced oxygen diffusion through their pore structure result in bone cell survival 
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and growth limited to the scaffold surface, and thus surface-limited bone 
regeneration (B), while optimally porous scaffolds with increased oxygen levels in 
the scaffold interior allow for bone regeneration throughout the scaffold thickness, 
which, in turn, can support large-area bone regeneration both in vitro and in vivo 
(C). (A) is showing the cross-sectional surface of a scaffold. 
To effectively increase microsphere scaffold porosity, we have used microsphere 
sintering followed by a porogen leaching method. In this method, we combined PLGA 
microspheres with a porogen (i.e., NaCl particles), thermally sintered, and then leached 
out the porogen by soaking the constructs in water. Scaffold porosity and mechanical 
properties can be tuned according to the clinical requirement by controlling the size and 
amount of the porogen added during the fabrication process.  Through this method, we 
have improved PLGA microsphere performance and its ability to support osteoblast cell 
survival, proliferation and mineralization throughout the construct, and yet retained 
mechanical compatibility for effective bone regeneration. 
As we increase the dry weight ratio of NaCl:PLGA used during the fabrication 
process of PLGA microsphere scaffolds, the porosity and accessible volume increases 
significantly (Table 3-).  High accessible volume within scaffolds is a crucial parameter 
that influences the efficiency of nutrient, gas, and waste exchange within the scaffolds, as 
well as cell migration needed to promote tissue regeneration.  Furthermore, it facilitates 
angiogenesis allowing for blood vessel in-growth, and thus, increases supply of oxygen 
and nutrients to the center of the construct.  However, with increases in pore volume, 
mechanical integrity is sacrificed (Figure 3-6).  Scaffolds with a higher ratio of NaCl than 
that in 40% NaCl/60% PLGA scaffolds were not mechanically stable.  Scaffolds 
fabricated with an intermediate concentration of NaCl (i.e., optimally-porous scaffolds; 
20% NaCl/80% PLGA scaffolds) were significantly more mechanically robust than those 
fabricated with 40% NaCl/60% PLGA. 
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In addition to decreasing mechanical strength, scaffolds with increased porosity 
display a lower cell seeding efficiency, as these scaffolds are less efficient in retaining 
cells during the cell seeding process (Figure 3-7).  Despite the decrease in initial cell 
number seeded on the scaffolds with increased porosity, cell numbers on these scaffolds 
reached that of control scaffolds by 5 days in culture, and surpassed it by two weeks in 
culture (Figure 3-8).  We demonstrated that scaffolds with increasing accessible pore 
volume corresponding specifically to pore sizes in the range of 200 to 400 µm (i.e., the 
critical pore size range for neovascularization of engineered bone constructs), resulted in 
  Control Scaffold 
PLGA 85/15 
Optimally-Porous 
Scaffold (20% 
NaCl/80% PLGA 85/15) 
Accessible Pore Volume ~ 12 % pore volume is 
with pore sizes ≥ 200 µm 
~ 31 % pore volume is 
with pore sizes ≥ 200 µm 
Mechanical Properties 338.4 ± 114.5 MPa 237.4 ± 46.5 MPa 
•Compressive Modulus 11.4 ± 1.73 MPa 4.19 ± 0.99 MPa 
•Compressive Strength     
Cell Seeding Efficiency 81.30% 63.70% 
Cell Proliferation 1.87 fold increase from 5-14 day in vitro 
2.98 fold increase from 5-
14 day in vitro 
Cell Viability and 
phenotypic expression Periphery limited 
Homogeneous throughout 
entire scaffold 
Mineralization Surface limited 
Homogeneous throughout 
entire scaffold (i.e., top, 
center, bottom) 
•35.5% more 
mineralization in entire 
scaffold 
•79.2% more 
mineralization in 
scaffold’s interior 
Osteoconductivity Surface limited Fully osteoconductive 
Oxygen in Scaffold Interior 0.69% ± 0.60% 3.13 ± 0.91% 
 
Table 3-1.  Porosity, mechanical performance, and osteoconductivity comparison 
between control and optimally-porous PLGA microsphere scaffolds. 
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decreasing gradient of oxygen and pH from the exterior to interior regions of the MSC-
seeded constructs after 21 days in vitro.  For instance, scaffolds fabricated with 80% 
PLGA microspheres and 20% NaCl (by weight) demonstrate 30.6% of its accessible pore 
volume to pore sizes of 200 µm, 12.5% of its accessible pore volume to pore sizes of 300 
µm, and 6.0% of its accessible pore volume to pore sizes of 400 µm, in contrast to 12.3%, 
2.0% and 0.9% of that in scaffolds that did not undergo porogen leaching.  Scaffolds 
fabricated with greater than 20% NaCl porogen further demonstrated increasing 
accessible pore volume, however significantly lower mechanical strength.   Further, we 
demonstrated that increasing accessible pore volume corresponded to increasing oxygen 
tension and more normal pH levels in the interior of the scaffolds, allowing for enhanced 
MSC-derived osteoblasts survival throughout the construct after long-term 21 day 
culture.  Thus, scaffolds with larger porosity have a better potential to support cell 
proliferation in vitro, likely due to uniform oxygen tension and near-neutral pH 
throughout the entire construct.   
Increased cell survival and activity (i.e., osteopontin and Collagen Type 1 
expression) was confirmed in the interior of scaffolds with increased porosity, compared 
to that of control scaffolds over a long-term culture.  However, there appears to be an 
important relationship between mineralization potential and surface area of scaffold, 
since macro-porous scaffolds (i.e., 40% NaCl/60% PLGA scaffolds) did not display as 
high of mineralization as for optimally-porous scaffolds.  Per these attributes, optimally-
porous scaffolds display the highest performance in supporting cell infiltration, 
proliferation, and mineralization throughout the entire construct in vitro (Table 3-2). 
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Our optimally-porous scaffolds stand superior to other methods currently utilized 
to increase cell proliferation and mineralization throughout BTE constructs in vitro. For 
instance, bioreactor culture methods are popular alternative methods utilized to increase 
cell infiltration and proliferation throughout constructs (146-148).  However, unlike 
bioreactor culture methods, which are complex in nature and only effective in vitro, 
optimally-porous scaffold development is simple and effectively allows for enhanced 
oxygen tensions throughout the constructs both in vitro and in vivo. In addition, the 
increased porosity in optimally-porous scaffolds are expected to improve vascularization 
and osteoclast participation, and hence, bone remodeling by closely mimicking the native 
bone repair process (143). Lastly, studies have citied a significant enhancement in bone 
regeneration when adding growth factors (i.e. BMP-2) to BTE constructs (149-151).  
However, functional bone regeneration may only occur when the entire construct, 
including the interior, supports cell survival and proliferation (i.e., fully osteoconductive). 
The combination of growth factors with an appropriate scaffold, such as our optimally-
porous scaffold, that is fully osteoconductive and may support vascularization 
throughout, will lead to optimal bone regeneration in large area bone defects. 
In this study, by controlling scaffold pore size and pore volume, we effectively 
designed oxygen tension controlled matrices.  Increasing the amount of porogen resulted 
in a systematic increase in not only porosity, but also available oxygen tension 
throughout the matrix.  The enhanced survival, proliferation, differentiation and 
mineralization of pre-osteoblasts may be attributed to the increase in available oxygen 
tension.  However, this increased cell performance may be cell type specific, as other cell 
types, such as chrondrocytes, display enhanced performance in scaffolds with low 
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porosity (152).  Thus, the proposed optimally-porous scaffolds with improved oxygen 
availability and bone compatible mechanical properties are desirable for large area bone 
regeneration. Oxygen tension control via scaffold porosity optimization may provide 
opportunities in designing next generation scaffold systems most effective for large area/ 
critical sized bone defect repair. 
 
3.5. Conclusions 
Large area or critically sized bone defects pose a serious challenge in orthopaedic 
surgery, as all current treatment options present with shortcomings.  Bone tissue 
engineering offers a more promising alternative treatment strategy. However, this 
approach requires mechanically-stable scaffolds that support homogenous bone formation 
throughout the scaffold thickness. Despite advances in scaffold fabrication, current 
scaffold-based techniques are unable to support uniform, three-dimensional bone 
regeneration, and are limited to only the scaffold surface in vitro and in vivo. This is 
mainly due to inadequate scaffold pore sizes (<200 µm) and accessible pore volume, and 
the associated limited oxygen diffusion and vascular invasion.  In this study, we have 
adopted a method combining microsphere sintering and porogen leaching techniques to 
fabricate scaffolds with increased accessible pore volume.  Of the scaffolds developed, 
optimally-porous PLGA microsphere scaffolds were selected as most advantageous, since 
they retain mechanical strength in the range of human cancellous bone, and display 
significantly higher accessible pore volume, which is attributed to an increased 
percentage of larger pores (i.e., size range 200-600 µm). Unlike control scaffolds with 
limited pore size and accessible pore volume, optimally-porous scaffolds displayed 
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increased oxygen diffusion, pre-osteoblast cell infiltration, proliferation, and survival 
throughout the entire scaffold.  Furthermore, optimally-porous PLGA microsphere 
scaffolds displayed enhanced and homogenous mineralization in vitro.  Since these newly 
designed optimally-porous scaffolds are weight-bearing, fully osteoconductive and have 
the ability to support vascularization, they may serve as effective scaffolds for large area 
bone defect repair/regeneration.  In addition, this study demonstrates the ability to 
modulate scaffold porosity and in turn, develop oxygen tension controlled matrices that 
are effective for large area bone regeneration. 
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4. IDENTIFICATION OF EFFECTIVE AND 
CLINICALLY-RELAVENT PROGENITOR CELLS FOR 
ENHANCED VASCULAR AND BONE REGENERATION  
 
4.1. Introduction 
 
Insufficient neo-vascularization currently represents a critical roadblock to 
successfully engineering bone (35, 110, 142).  The incorporation of endothelial cells into 
engineered bone constructs has been offered as a promising and efficient approach to 
enhance vascularization and in turn, promote successful bone formation at the graft site 
(40, 41, 106, 153).  Though many previous pre-vascularization studies have used human 
umbilical vein endothelial cells (HUVECs) and mature endothelial cells obtained via 
sacrification of blood vessels, they are not clinically applicable and have demonstrated 
significant apoptosis upon transplantation (154).  Endothelial progenitor cells (EPCs), 
however, represent an exciting alternative to mature endothelial cells as they display high 
angiogenic, proliferative and survival potential in situ.  Further, EPCs have been 
successfully isolated from a number of sources (i.e., peripheral blood, bone marrow, 
umbilical cord blood), and may be expanded to achieve adequate cell numbers for tissue 
engineering applications without loosing their endothelial cell phenotype (122).  Isolation 
of EPCs from peripheral blood eliminates donor site morbidity risks, and thus, may 
represent an ideal autologous cell source for the promotion of vascularization in tissue 
engineering applications.  
In the present study, we have isolated EPCs from two clinically-relevant sources 
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for bone tissue engineering applications, peripheral blood and bone marrow (PB-EPCs 
and BM-EPCs, respectively).  In attempt to identify a superior source for EPC isolation, 
we, for the first time, investigated the differential phenotypic expression of PB-EPCs and 
BM-EPCs, and their potential for angiogenesis in vitro.  We also assessed their ability to 
enhance osteogenic differentiation of mesenchymal stem cells in vitro, and their 
enhancement of key angiogenic and osteogenic markers.  This investigation presents a 
landmark study as it identifies the ideal isolation source for EPCs, making steps closer to 
achieving clinical success in bone regeneration and repair.  
 
4.2. Materials and Methods 
 
4.2.1.   Isolation of Rabbit Mesenchymal Stem Cells 
(MSCs) 
 
Mononuclear cells were isolated via layering over a Percoll density gradient, and 
centrifuging at 600 rpm for 20 min at room temperature. The mononuclear cell fraction 
was seeded and expanded in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) 
supplemented with 10% FBS and 1% Penicillin/Streptomycin (P/S, Gibco) at 37oC and 
5% CO2.  Passages 3-5 were used for experimentation. 
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4.2.2.   Isolation of Rabbit Endothelial Progenitor Cells 
(EPCs) 
4.2.2.1. Bone Marrow-Derived Endothelial 
Progenitor Cells (BM-EPCs) 
 
Mononuclear cells from the bone marrow of New Zealand White rabbits were 
isolated via layering over a Percoll density gradient, and centrifuging at 600 rpm for 20 
min at room temperature. The mononuclear cell fraction was re-suspended in endothelial 
cell growth medium (EGM2, Lonza; composed of endothelial cell basal medium-2 
(EBM-2), 10% FBS, 1% P/S and EGM-2-SingleQuots growth factors and supplements), 
immediately seeded on dishes coated with 1 mg/cm2 of rabbit type I collagen (C5608, 
Sigma), and cultured at 37oC and 5% CO2. Non-adherent cells were removed after 4-7 
days with gentle washes of PBS. Culture medium was changed every three days.  After 3 
weeks of passaging and expanding on collagen-coated plates, approximately 30 million 
cells were achieved.  Cells were cyropreserved for subsequent experiments.  At this point, 
collagen coating was no longer required.  Cells isolated 3-4 weeks post-isolation 
(passages 5-8) were used for experiments.  
 
4.2.2.2. Peripheral Blood-Derived Endothelial 
Progenitor Cells (PB-EPCs) 
 
Peripheral blood (50 mL) was collected via cardiac bleeding protocol (approved 
by the University of Connecticut Health Center Animal Care and Use Committee) from 
New Zealand White rabbits (Figure 4-1).  Isolation of mononuclear cell fraction, and 
subsequent cell culture was performed following procedures described in Section 4.2.2.1.  
 107
Similar numbers of PB-EPCs (30 x 106 total cells) were achieved after 3 weeks of 
culture, at which point PB-EPCs obtained a cobblestone-like morphology, and collagen 
coating the cell culture plates was no longer required. Cells isolated 3-4 weeks post-
isolation (passages 5-8) were used for experiments.  
 
Figure 4-1.  (A)  Isolation of rabbit peripheral blood via cardiac exsanguination (i.e., 
terminal bleeding).  (B)  Image of Percoll solution layered on top of peripheral blood 
in 50 milliliter centrifuge tubes prior to centrifugation.  (c) Image of peripheral 
blood separated by Percoll density gradient after centrifugation.  At this stage, the 
mononuclear fraction may be easily isolated. 
 
 
4.2.3.   Isolation of Rabbit Vascular Smooth Muscle Cells 
 
Methods for the isolation of rabbit smooth muscle cells (SMCs) from the aorta 
were adapted from methods described by Sreejayan et al. (155).  Passages 2-4 were used 
for experimentation. 
 
4.2.4.   Culture of Human Umbilical Vein Endothelial Cells 
 
HUVECs (CRL-2873, ATTC) were cultured in EGM2 on 150 mm cell culture 
plates at 37°C and 5% CO2. 
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4.2.5.   Flow Cytometry 
 
Samples were incubated with the following primary antibodies anti-human CD31 
(M0823), anti-human vWF (sc-59957), anti-human CD34 (sc-7045), anti-rabbit CD44 
(MCA806G), and anti-rabbit CD45 (MCA808G), subsequently an appropriate 
fluorochrome-conjugated secondary antibody: mouse anti-goat IgG-PE (sc-3752) or goat 
anti-mouse IgG-PE (sc-3738).  Samples were analyzed using a BD Biosciences LSR II 
using FACSDiVa software.  PE was excited by the 488 nm laser and detected using a 
575/25 bandpass filter.  Live/Dead® Fixable Far Red Dead Cell Stain was excited by the 
633 nm laser and detected using a 660/20 bandpass filter.  Data was analyzed using 
FlowJo software v.8.7.3 (TreeStar). 
 
4.2.6.   Western Blot Analysis 
 
Western blot analysis was performed on cell lysates as described by Lo et al. 
using the following primary antibodies, alpha-smooth muscle actin (ab7817), transgelin 
(sc-18513), smoothelin (sc-20479) (156). 
 
4.2.7.   Matrigel 2D Assay 
 
Cell suspensions containing 150,000 cells in 150 µl of DMEM were seeded in 
triplicates on Matrigel coated glass bottom culture dishes, and plates were incubated for 6 
hours at 37°C and 5% CO2.  Samples were then incubated with calcein-AM, and imaged 
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using confocal microscopy.  For quantification, in ten random fields per sample, a pattern 
recognition values were determined following the manufacturer’s guidelines (ECM625, 
Millipore).   Number of branch points and the number of tubular structures were counted 
under a phase contrast microscope. Results are expressed as mean ± standard deviation. 
 
4.2.8.   Co-Culture of MSCs and EPCs 
 
Gene expression of osteogenic MSCs with PB-EPCs or BM-EPCs cultured 
simultaneously (i.e., co-culture) was examined.  Prior to co-culture, MSCs were cultured 
in osteogenic media (DMEM, 10% FBS, 10 nM dexamethasone, 50 µg/ml ascorbic acid, 
10 mM β-glycerophosphate) for 7 days.  Then, MSCs were co-cultured with either PB-
EPCs or BM-EPCs at various co-culture ratios in a 1-to-1 mixture of osteogenic and 
angiogenic medium on cell culture plates (not collagen coated).  The following twelve 
sample groups were studied: PB-EPCs alone; BM-EPCs alone; MSCs:PB-EPCs co-
culture ratios of 1:4, 1:2, 1:1, 2:1, and 4:1; and MSCs:BM-EPCs co-culture ratios of 1:4, 
1:2, 1:1, 2:1, and 4:1.   Specific test conditions for cellular expression studies are 
described in the following Section 2.10, 2.11 and 2.12. 
 
4.2.9.   Analysis of Co-Culture Systems 
4.2.9.1. Matrigel 3D Assay 
 
Cells were encapsulated in Matrigel (106 cells/mL Matrigel) and cultured in a 1-
to-1 mixture of osteogenic and angiogenic medium for 7 days in 48 well cell culture 
plates.  The following twelve sample groups were studied: PB-EPCs alone; BM-EPCs 
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alone; MSCs:PB-EPCs co-culture ratios of 1:4, 1:2, 1:1, 2:1, and 4:1; and MSCs:BM-
EPCs co-culture ratios of 1:4, 1:2, 1:1, 2:1, and 4:1. Three-dimensional samples (10 mm 
diameter, 2 mm height) were paraffin-embedded, sectioned and then stained with 
hematoxylin and eosin.  Four samples per group were embedded, and three sections per 
sample were stained (one from top, middle and bottom; approximately 200 µm apart from 
each other).   Stained sections were analyzed under the light microscope Olympus BX50 
with Olympus DP70 camera.  Twelve images viewed under 10X magnification, and the 
number of branches were counted for each sample. 
 
4.2.9.2. Alkaline Phosphatase Activity 
 
Alkaline Phosphatase (ALP) Substrate Kit (172-1063) was used in accordance to 
manufacturer’s instructions.   ALP levels were normalized to total protein levels as 
determined using BCA Protein Assay Kit.   
 
4.2.9.3. Gene Expression (RT-PCR) 
 
For each cell culture condition (n=3), a total of 40,000 cells were plated on a 24 
well-cell culture plate.  For co-culture samples, 1 milliliter of a 1-to-1 mix of endothelial 
and osteogenic media was added.  For single cell type cultures (i.e., EPCs or MSCs), 1 
milliliter of endothelial or osteogenic media was added, respectively.  At the appropriate 
time points, total RNA was isolated using the Qiagen RNeasy Mini Kit, and converted 
into cDNA via Clontech Sprint RT Complete cDNA synthesis kit. For quantitative real 
time PCR, BioRad iCycler Thermal Cycler Base  and BioRad iQ Supermix, BMP-2 
 111
(Oc03824113_s1), BMP4 (Oc03233792_m1), thrombomodulin (Oc03822979_s1), 
KDR/FLK (Oc03395666_m1), collagen type 1 alpha 1 (Oc03396074_g1), VEGF-
A (Oc03395999_m1), and GAPDH (Oc03823402_g1) gene probes (Applied Biosciences, 
Carlsbad, CA) were used. Threshold cycle values of target genes was standardized 
against GAPDH expression and normalized to the expression in the control culture. 
 
4.2.10. Statistical Analysis 
For Matrigel 2D and 3D Assay analysis, ALP and gene expression quantification 
a two-way analysis of variance (ANOVA) was preformed to compare data.  Error is 
reported in figures as the standard deviation (SD) and significance was determined using 
a probability value of P<0.050. 
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4.3. Results 
4.3.1.   Cell Morphology and Expression of Isolated BM-
EPCs and PB-EPCs 
 
Figure 4-2.  Endothelial cell phenotype and immunostaining of CD31 and vWF. (D, 
E)  HUVECs and PB-EPCs stained positive for CD31 and vWF.   (F)  BM-EPCs did 
not stain positive for CD31, but did stain positive for vWF.   
 
Rabbit EPCs isolated either from bone marrow (BM) or peripheral blood (PB) by 
density gradient and cultured on collagen type 1-coated cell culture plates exhibited 
distinct morphology and cellular expressions of key endothelial cell markers (Figure 4-2). 
Initially, both PB-EPCs and BM-EPCs displayed a spindle-like morphology.  However, 
after two to three weeks of culture post-isolation, PB-EPCs formed colonies that 
exhibited a pronounced endothelial “cobblestone” morphology, which was also observed 
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by human umbilical vein endothelial cells (HUVECs), a commonly studied vascular 
endothelial cell line. BM-EPCs did not form colonies of cobblestone-like cells by this 
time, and continued to have colonies composed of spindle-shaped cells.  HUVECs were 
used in these experiments to study the characteristics of a mature, homogenous vascular 
endothelial cell line. 
 
Figure 4-3.  Flow cytometry analysis of CD31, vWF, VEGF-R2, CD34, and CD45 on 
(A) HUVECs, (B) PB-EPCs, and (C) BM-EPCs; and CD44, CD34, and CD45 on (D) 
MSCs.  Blue lines indicate fluorescence signals of isotypic controls, and red lines 
indicate fluorescence signals of the specific antigens.  Plots are depicted with % of 
Maximum Counts (%Max) on y-axes, and the PE fluorescence intensity for the 
indicated markers is shown (bi-exponential scale) on x-axes. 
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Like HUVECs, PB-EPCs are strongly positive for CD31 and von Willebrand 
factor, common endothelial cell markers (Figure 4-3A, B).  BM-EPCs, however, did not 
express CD31 (Figure 4-3C). All endothelial cell types (i.e., HUVECs, PB-EPCs, BM-
EPCs) display a low signal for CD34 and CD45 (Figure 4-3). MSCs stained positive for 
CD44, and negative for CD34 and CD45 (Figure 4-3D).  Lack of CD45 signal indicates 
no/minimal hematopoietic cell contamination. 
 
Figure 4-4.  Gene expression of key bone and vascular markers (i.e., BMP-2, COL I, 
BMP-4, VEGF, VEGF–R2 and thrombomodulin) in PB-EPCs and BM-EPCs 4 
weeks post-isolation. 
 
 Furthermore, four weeks post-isolation, PB-EPCs also demonstrated markedly 
higher gene expression levels of key vascular markers important to angiogenesis and 
 osteogenesis.  The following
in comparison to that of BM
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formations (Figure 4-6 A, B), whereas a significantly lower percentage of BM-EPCs 
demonstrated network formation, and instead, the majority of BM-EPCs showed only the 
ability to stretch on Matrigel (Figure 4-6 C, D). Also, PB-EPCs formed significantly 
more branch points and higher total tube length than BM-EPCs; however, both form 
significantly less than HUVECs (Figure 4-6 G).  
 
 
Figure 4-6.  Two-dimensional angiogenesis assay showing network formation by (A) 
HUVECs, (B) PB-EPCs and (C) BM-EPCs, (D) SMCs, and (E) MSCs. Scale bar = 
500 µm. (E) Numerical pattern recognition values were assigned to each pattern, 
such that a numerical value is associated with a degree of angiogenesis progression 
(i.e., 0 = cells isolated or in a sheet-like monolayer, 1 = cells begin to migrate and 
align themselves, 2 = capillary tubes visible but no sprouting, 3 = sprouting of new 
capillary tubes visible, 4 = closed polygons form, 5 = complex mesh like structures 
develop).  Examples of branch point (white arrow), tube length (white line), and 
polygon shape (white outlined hexagon) on indicated on (B).  Comparison of 
number of (F) formed branch points, (G) average tube length and (H) total tube 
 length formed by PB-EPCs and BM
units. Significance is signified as * (p<0.01).
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Hematoxylin/eosin staining of capillary network formation of various co-culture 
ratios of MSCs and PB-EPCs (MSCs:PB-EPCs), specifically (D) 1:4, (E) 1:2, (F) 1:1, 
(G) 2:1, (H) 4:1.  (I) Scoring of the branch points formed with different MSC:EPC 
ratios in 3D culture, data presented as mean ± SD.  Scale bar = 250 µm. 
 
 
4.3.4.   ALP Activity of BM-EPCs and PB-EPCs Co-Cultured 
with MSCs 
Alkaline phosphatase (ALP) activity in co-cultures of MSCs with either PB-EPCs 
or BM-EPCs was studied as an early marker of osteogenic differentiation.  After 14 days 
of culture, PB-EPCs displayed significantly higher ALP activity than BM-EPCs, though 
both less than that of MSCs (Figure 4-8).   ALP activity levels were also enhanced in 
MSC:PB-EPC co-cultures, in comparison to MSCs or PB-EPCs cultured alone.   ALP 
activity increased as the MSC fraction of the co-culture increased, however this trend was 
not observed in MSC:BM-EPC co-cultures.   
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Figure 4-8.  Comparison of ALP activity of MSCs co-cultured with PB-EPCs or 
BM-EPCs at various ratios. ALP activity of MSCs, PB-EPCs, and BM-EPCs alone 
under the same conditions are displayed in dashed lines, whereas MSC:PB-EPC and 
MSC:BM-EPC co-cultures at different ratios are displayed as the blue and red line, 
respectively. 
 
 
4.3.5.   Effect of MSC:EPC Co-Culture Ratios on Vascular 
and Osteogenic Gene Expression 
 
Gene expression of critical angiogenic and osteogenic markers are higher in PB-
EPCs than BM-EPCs (dashed lines) after 7 days in vitro (Figure 4-9A-F).  BMP-2 and 
BMP-4 expression levels display a direct relationship with the MSC fraction in the co-
culture ratios of both MSC:PB-EPC and MSC:BM-EPC, such that BMP-2 and BMP-4 
expression significantly increased as the MSC fraction in the co-culture increased 
(Figure 4-9A, B).  For example, co-cultures with a 4:1 MSC:EPC ratio displayed the 
highest levels of BMP-2 and BMP-4.  On the other hand, COL1 expression was also only 
enhanced in MSC:PB-EPC co-cultures, in comparison to MSCs and EPCs cultured alone; 
this trend was not observed in MSC:BM-EPC co-cultures (Figure 4-9C).  Gene 
expression of vascular markers, VEGF, VEGF-R2 and thrombomodulin, decreased with 
increasing MSC fraction in both MSC:PB-EPC and MSC:BM-EPC co-culture ratios 
(Figure 4-9D-F).  
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Figure 4-9.  Comparison of (A) BMP-2, (B) COL1, (C) BMP-4, (D) VEGF, (E) 
VEGF-R2, and (F) thrombomodulin in co-cultures with MSCs and either PB-EPCs 
or BM-EPCs at different ratios.  Gene expression normalized to GAPDH levels is 
plotted on the y-axis, and various ratios of MSCs co-cultured with EPCs on the x-
axis.  Gene expression of MSCs, PB-EPCs, and BM-EPCs alone under the same 
conditions of the MSC:EPC co-cultures after 7 day in vitro are presented as mean 
and displayed in dashed lines, whereas MSC:PB-EPC co-cultures and MSC:BM-
EPC co-cultures at different ratios are displayed as the blue and red line, 
respectively.    
 
4.3.6.   Time Course of BMP-2 and VEGF Expression of 
MSC:PB-EPC Co-Cultures 
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to the cells alone.  At day 7 and 14, VEGF expression was enhanced in all co-culture 
ratios in relation to its expression in the cells alone.   
 
4.4. Discussion 
Despite the recent exponential growth of EPC literature, critical details remain 
unclear.  In this study, we determined the best clinically-relevant cell source for EPC 
isolation.  Past studies investigated whether adult peripheral blood (PB) or fetal cord 
blood (CB) offer the best source for EPC isolation.  Many reported that CB represent a 
superior EPC cell source, as CB-EPCs had greater isolation efficiency, higher ex vivo cell 
number expression, and longer stability of vascular networks in vivo, in comparison to 
PB-EPCs (104).  Though interesting, CB-ECPs are presently not clinically relevant, as 
most patients do not have access to this.  With this, we sought to explore not only more 
clinically-relevant cell sources, but also investigate more widely reported sources in bone 
tissue engineering studies.  We have isolated, characterized and compared EPCs from 
rabbit peripheral blood and bone marrow (PB-EPCs and BM-EPCs, respectively).  
Though the investigated cells were isolated from rabbits, the same cell populations may 
be isolated from humans for their potential clinical use for bone repair and regeneration 
(104, 157). PB-EPCs have proven to be a superior endothelial cell population, in contrast 
to BM-EPCs, a population in which the majority of bone tissue engineering studies 
involving EPCs have previously reported on.    
Differences in isolation and cultivation procedures of EPCs make it difficult to 
directly compare published studies on the outcomes of EPC functionality. For this reason, 
we have isolated and cultured EPCs isolated from peripheral blood and bone marrow in a 
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similar manner, and as previously described by numerous studies (158). The PB-EPC 
population that has been characterized in our studies has also been referred to as late 
EPCs, outgrowth endothelial cells (OECs) and endothelial colony–forming cells (ECFCs) 
in other published studies (158-160). BM-EPCs did not express endothelial marker 
CD31, as confirmed by flow cytometry and western blot analysis.  
Bone formation is a complex process, and one of the most important heterotypic 
cross-talks in this process is the one between endothelial cells and osteoblasts (39, 161). 
The underlying cellular regulatory mechanisms for this cross-talk have pointed to 
paracrine signaling based on angiogenic growth factors, such as VEGF and PDGF, and 
also direct cellular communication via gap junctions (162).  Therefore, we also 
investigated how the addition of isolated EPCs contributes to osteogenic differentiation 
and bone-forming capacity of rabbit mesenchymal stem cells (MSCs) for bone tissue 
engineering purposes, a popular approach actively being investigated in vivo by many 
other groups (40, 42, 47, 153).  In co-culture, rabbit MSCs and PB-EPCs display 
significantly enhanced expression of key vascular and osteogenic markers.  The 
expression of the key markers were also significantly higher in MSC/PB-EPC co-culture 
than that in co-cultures of MSCs and BM-EPCs.  As early as 1 week in co-culture, 
expression of bone markers COL1, BMP-2, and BMP-4, and angiogenic markers VEGF, 
VEGF-R2, and thrombomodulin were enhanced beyond expression levels of MSCs and 
PB-EPCs cultured alone.  
 Figure 4-11.  Schematic illustrati
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endothelial cell markers, and begin to lose their stem cell-like properties and become less 
plastic.  Thus, the transition from the bone marrow to the peripheral blood marks a 
certain degree of maturation or committed-ness of EPCs to the endothelial cell lineage. 
EPCs and SMPCs have previously been shown to have the ability to trans-differentiate 
from one lineage to the other via an endothelial-to-mesenchymal transition-like process 
mediated by TGFβ-RI (164). Thus, BM-EPCs, which may harbor more stem cell-like 
properties and more easily trans-differentiate into SMPCs, are marked by the waning of 
endothelial markers and functionality. Whereas, PB-EPCs are likely to be in a more 
committed stage in their differentiation process, and do not give rise to smooth muscle 
progeny spontaneously.   
Supporting our study, Fedrovich et al. observed early BM-EPCs (i.e., BM-EPCs 
cultured for approximately 1 week in endothelial growth media) to express CD31 only 
transiently, and lose CD31 expression as culture time increased (43). BM-EPCs also 
displayed transient endothelial cell phenotype, including isolectin B4 binding and 
acetylated LDL-incorporation. Also, it is important to note that in other previous studies 
that report their isolated BM-EPCs to be CD31 positive, they may have studied their BM-
EPCs at this early stage. Also, many other studies have not specified whether their BM-
EPCs express CD31, they only provide their isolation protocol.  
These putative BM-EPC may possibly be more appropriately referred to as 
smooth-muscle like progenitor cells; however, although not a superior endothelial 
progenitor cell source, this population may still serve as an important option for enhanced 
vascularization and/or bone formation in engineered bone tissue.  Firstly, there is an 
established cooperation between endothelial cells and perivascular cells (i.e., smooth 
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muscle cells located at the periphery of capillaries) that is fundamental for vascular 
maturation (35).   Also, perivascular cells have been shown to differentiate into 
osteoblasts, and contribute to bone formation in vivo (165). Lastly, bone tissue 
engineering studies have reported positive results when implanting not only PB-EPCs, 
but also BM-EPCs, at a bone defect site, for enhanced vascularization and bone 
formation in vivo.   Thus, given these established relationships between EPCs, 
perivascular cells and MSC derived-osteoblasts, future studies should upgrade co-culture 
systems, and perhaps explore tri-cultures involving these three cell types (i.e., PB-EPCs, 
putative BM-EPCs and MSC derived-osteoblasts) for further enhancement of bone 
formation and vascular networks in vivo. 
 
4.5. Conclusions 
 
For tissue engineering applications, effective bone regeneration requires rapid 
neo-vascularization of implanted grafts to ensure the survival of cells in the early post-
implantation phase.  Incorporation of autologous endothelial progenitor cells (EPCs) for 
the promotion of primitive vascular network formation ex vivo has offered great promise 
for improved graft survival, enhanced rate of vascularization and bone regeneration in 
vivo.  For clinical usage, identification of an optimal EPC isolation source from the 
patient is critical. We have, for the first time, characterized and directly compared EPCs 
from rabbit peripheral blood and bone marrow (PB-EPCs and BM-EPCs, respectively).  
PB-EPCs outperformed BM-EPCs on all measures.  PB-EPCs displayed typical 
endothelial cell markers, such as CD31, as well as high angiogenic potential in three-
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dimensional extracellular matrix in vitro.  Furthermore, PB-EPCs cultured 
simultaneously with mesenchymal stem cells, displayed significantly enhanced 
expression levels of key osteogenic and vascular markers, including alkaline phosphatase, 
bone morphogenetic protein 2, and vascular endothelial growth factor.  On the contrary, 
putative BM-EPCs did not express CD31, and instead, expressed key smooth muscle 
markers.  BM-EPCs further failed to display vasculogenic activity.  Hence, the highly 
angiogenic peripheral blood derived-EPCs may serve as an ideal cell population for 
enhanced vascularization and success of engineered bone tissue. 
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5. EVALUATION OF PRE-VASCULARIZED 
OPTIMALLY-POROUS SCAFFOLDS FOR ENHANCED 
NEO-VASCULARIZATION AND BONE FORMATION IN 
VIVO 
 
5.1. Introduction 
Many cellular-based bone tissue engineering approaches involve the utilization of 
bone marrow derived mesenchymal stem cells (MSCs) as osteo-progenitor cells to 
promote and accelerate bone regeneration.  In this approach, MSCs are seeded on 
scaffolds for colonization and implantation at a defect site.  However, upon implantation, 
colonized cells in the interior regions of scaffolds with depth dimensions greater than 
one-millimeter experience limited oxygen and nutrient availability, since they are 
dependent on post-implantation vascularization that may occur on the order of days to 
weeks.  Due to limited nutrient delivery and waste products removal via diffusion and 
proper functional vascularization, cell viability, and in turn, bone regeneration and host 
integration is severely hindered. 
Efficient methods to establish near-immediate neovascularization in bone tissue 
engineered constructs are essential.  In vitro pre-vascularization of bone tissue 
engineering constructs with endothelial progenitor cells (EPCs) have gained significant 
attention in this respect (48).   EPCs, which may be easily isolated from the patient’s 
peripheral blood, demonstrate high proliferative potential for ex vivo expansion, as well 
as the ability to enhance and accelerate neovascularization in vivo (166).  Moreover, 
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when co-implanted with MSCs at a bone defect site enhanced neovascularization and 
bone formation is observed.     This enhancement is a result of synergistic communication 
(i.e., “cross-talk”) between MSCs and EPCs (167, 168), where MSCs have been shown to 
release angiogenic factor VEGF (169, 170), and EPCs have been shown to release 
osteogenic factor, such as BMP-2 and BMP-4 (171, 172).   Although this pre-
vascularization approach with EPCs and MSCs has been examined and proven effective, 
the ideal cell ratio that would potentially yield functional bone grafts has not yet been 
investigated.   
In this study, we investigated a two-pronged approach for enhanced neo-
vascularization and bone formation in vivo.  We utilized our optimally-porous scaffolds 
with tunable, increased porosity, especially in the range of 300-400 um, which has been 
cited as the critical pore size range for neo-vascularization (16).  These scaffolds 
demonstrate enhanced performance, specifically in respect to increased oxygen tension 
levels, near-normal pH levels, and increased cell viability in the interior regions of the 
constructs after long-term in vitro culture with MSCs.  Moreover, we investigated the 
effectiveness of various co-culture ratios of MSCs and EPCs on these scaffolds in 
promoting neo-vascularization and bone formation in vivo. 
 
5.2. Materials and Methods  
 
5.2.1. In Vitro Culture of Cell-Seeded Optimally-Porous 
Scaffolds 
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Optimally porous scaffolds (20% NaCl/80% PLGA scaffolds; 10 mm diameter, 2 
mm height) were seeded with a total of 250,000 cells/scaffold and cultured in a 1-to-1 
mix of endothelial and osteogenic media for 2 days 37oC and 5% CO2. Prior to culture on 
scaffolds, MSCs were cultured in osteogenic media (DMEM, 10% FBS, 10 nM 
dexamethasone, 50 µg/ml ascorbic acid, 5 mM β-glycerophosphate) on tissue culture 
plate (TCP) for 7 days.   Various cell conditions seeded on scaffolds were examined: (1) 
MSC-derived osteoblasts, (2) EPCs, (3) co-culture of 4 parts MSC-derived osteoblasts to 
1 part EPC (4:1), (4) co-culture of 1 part MSC-derived osteoblasts to 1 part EPC (1:1), 
and (5) co-culture of 1 part MSC-derived osteoblasts to 4 parts EPC (1:4).   
 
5.2.2.   In Vitro Performance Evaluation of Cell-Seeded 
Optimally-Porous Scaffolds 
 
Expression of other osteogenic markers, RunX2 and Collagen Type I, and 
vasculogenic markers, CD31 and vWF, was analyzed by immuofluorescence.  After 2 
days in vitro, cell-seeded constructs were fixed in 10% formalin for 1 hour at room 
temperature, rinsed with PBS, and permeabilized with 0.25% Triton X-100 for 10 
minutes.  Constructs were rinsed with PBS, blocked in 10% normal goat serum for 1 
hour, and then incubated with the following primary antibodies for 1 hour: anti-RunX2 
antibody (Abcam, ab76956, 1:50), anti-Collagen I antibody (Abcam, ab34710, 1:100), 
anti-CD31 antibody (Abcam, ab28364, 1:50), anti-Von Willebrand Factor antibody 
(Abcam, ab6994, 1:1000), Anti-β-Tubulin (Millipore 05-661, 1:200).  Samples were then 
washed and labeled with the corresponding secondary antibody: anti-mouse IgG 
secondary antibody-FITC (sc-2099, Santa Cruz) or anti-rabbit IgG secondary antibody-
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FITC (sc-53805, Santa Cruz) diluted 1:100 in 1% BSA/PBS for 40 min at room 
temperature. Finally, cell nuclei were counterstained using propidium iodide (81845, 
Sigma, St. Louis, MO).  Stained constructs were examined via confocal microscopy 
(Zeiss LSM Confocor 2). 
 
5.2.3. In Vivo Performance Evaluation of Cell-Seeded 
Optimally-Porous Scaffolds 
First, to evaluate the most effect ratio of mesenchymal stem cells (MSCs) and 
peripheral-blood derived endothelial progenitor cells (PB-EPCs) seeded on our 
optimally-porous scaffolds for the promotion of vascularization in vivo, we utilized a 
SCID mouse subcutaneous implant model.  Second, we evaluated the performance in 
respect to vascularization and bone regeneration potential of our optimally-porous 
scaffolds seeded with the most appropriate cell progenitor ratio and implanted in a rabbit 
ulnar bone defect model (Figure 5-1).  
 
Figure 5-1.   Study plan for evaluating the vascular and bone regeneration potential 
of optimally-porous scaffolds seeded with clinically-relevant progenitor cells in vivo. 
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5.2.3.1. SCID Mouse Subcutaneous Implant Model 
5.2.3.1.1. Construct Implantation 
 
To evaluate the in vivo performance of various combination of peripheral blood 
(PB)-derived EPCs (PB-EPCs) and MSC-derived osteoblasts, we implanted the 5 
construct conditions described in Section 5.2.1 after 2 days in vitro to ensure proper cell 
adherence (Figure 5-2).  As a negative controls, we used an acellular optimally-porous 
scaffolds. Male Fox Chase (CB17) SCID (severe combined immunodeficiency) (Charles 
River Laboratories, Wilmington, MA, USA) mice were anaesthetized with isoflurane in 
the induction chamber at a range of 3-5%.  The animals were maintained on 2-4% 
isoflurane with the nose cone between placement of implants in separate subcutaneous 
dorsal pockets (2 implants/ animal; 3 animals/condition).  The animals were post-
operatively treated with the analgesic buprenorphine (0.05mg/kg, subcutaneous).   All 
animal experiments were approved by the University of Connecticut Health Center 
Animal Care and Use Committee (protocol 2009-593). 
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Figure 5-2.  Implantation of constructs in a dorsal subcutaneous SCID mouse 
model.  (A, B)  An incision with approximately the same length as the construct’s 
diameter is created in the dorsum of the mouse, (C) the construct is implanted 
subcutaneously, and (D) the skin at the implantation site is stapled closed. 
 
5.2.3.1.2. Histological Staining and Analysis 
 
The implanted constructs were retrieved 8 weeks after implantation to analyze the 
blood vessel formation and bone formation. Samples were fixed overnight in 10% 
formalin and processed for paraffin sections. Histological staining was performed with 
Masson’s Trichrome Staining (Sigma, HT15) on 5 µm thick paraffin sections according 
to the manufacturer’s protocol.  Stained sections were analyzed under the light 
microscope Olympus BX50 with Olympus DP70 camera.   For collagen quantification, 
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we utilized the RBG plug-in in ImageJ (National Institutes of Health), and specifically, 
collagen, which stains blue via Masson’s Trichrom Staining, was quantified.   Ten 
random images under 40X magnification were analyzed per sample (3 samples/group; 
thirty total images per group) in ImageJ using the RBG Measure Plug-in 
(http://rsb.info.nih.gov/ij/plugins/color-histogram.html) to measure the Collagen stained 
blue with Trichrome Stain.  Images were opened in Image J and converted to RBG Color 
(Image > Type > RBG Color), then the background was subtracted (Process > Subtract 
Background > Light Background), the RBG was measured on the selected region of 
interest (ROI).    For vessel quantification, we analyzed and counted vascular structures 
in ten random images taken under 20X magnification for each group. 
 
5.2.3.1.3. Immunohistochemical Analysis 
 
To confirm vascularization and bone formation, we performed 
immunohistochemical analysis for endothelial markers CD31 and vWF, and bone 
markers RunX2 and Collagen Type I, respectively.  We immune-stained sections of the 
group containing the scaffold seeded with 1 part MSC-derived osteoblasts and 1 part EPC 
(1:1).  We used paraffin-embedded mouse limbs (post-natal day 1) as a positive control.  
Briefly, rehydrated sections were exposed to heat-mediated antigen target retrieval 
(Target Retrieval Solution, Dako S1700) for 5 minutes at 98oC, then blocked in 10% 
normal goat serum in PBS for 1 hour at room temperature.  Sections were then incubated 
with the following primary antibodies overnight at 4oC: anti-RunX2 antibody (Abcam, 
ab76956, 1:50), anti-Collagen I antibody (Abcam, ab34710, 1:100), anti-CD31 antibody 
(Abcam, ab28364, 1:50), anti-Von Willebrand Factor antibody (Abcam, ab6994, 1:1000), 
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Anti-β-Tubulin (Millipore 05-661, 1:200).  Samples were then washed and labeled with 
the corresponding secondary antibody: anti-mouse IgG secondary antibody-FITC (sc-
2099, Santa Cruz) or anti-rabbit IgG secondary antibody-FITC (sc-53805, Santa Cruz) 
diluted 1:100 in 1% BSA/PBS for 40 min at room temperature. Finally, sections were 
mounted with Propidium Iodide/Anti-fade Solution (S7112, Millipore), and examined via 
confocal microscopy (Zeiss LSM ConfoCor2, 20X magnification). 
 
5.2.3.2. Rabbit Ulnar Defect Model 
 
5.2.3.2.1. Construct Implantation 
 
 
Optimally porous scaffolds (20% NaCl/80% PLGA scaffolds; 15 mm height, 5 
mm diameter) were seeded with a total of 500,000 cells/scaffold and cultured in a 1-to-1 
mix of endothelial and osteogenic media for 2 days 37oC and 5% CO2. Prior to culture on 
scaffolds, MSCs were cultured in osteogenic media (DMEM, 10% FBS, 10 nM 
dexamethasone, 50 µg/ml ascorbic acid, 5 mM β-glycerophosphate) on tissue culture 
plate (TCP) for 7 days.   Various cell conditions seeded on scaffolds were examined: (1) 
MSC-derived osteoblasts, (2) EPCs, (3) co-culture of 1 part MSC-derived osteoblasts to 1 
part EPC (1:1), (4) acellular (i.e., scaffold alone).   
New Zealand white rabbits (4-5 kg weight) were anesthetized via an 
intramuscular injection of a mixture of ketamine (50mg/kg), xylazine (6mg/kg), and 
acepromazine (1mg/kg) (Figure 5-3). The right forelimb of the rabbit were shaved, and 
prepped with betadine and 70% ethanol. A longitudinal incision was made to expose the 
mid-diaphysis of ulna. A segment of the ulna measuring 15 millimeters in length was 
 removed using a bone saw. 
wound was closed by suturing
post-implantation, animals were
formalin for 24 hours, and then
 
 
Figure 5-3.  Preparation for
utilized during implantation of constructs in a critical
rabbit.  The rabbit is prepared pre
up to a heart monitor, and (D) closely monitored during the operation.  (F)  The 
rabbit’s right arm is prepared, cleansed
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 Figure 5-4.  Steps involved in implantation of a construct into a rabbit ulnar b
defect model.  (A) An incision is made in the right arm of the rabbit, (B, C) the 
surrounding muscle is dissected to expose the u
the first cut into the bone.  (E)  The length of the construct is marked off on the b
of a sterile wooden stick, and (F, G) is used to measure the length of the bone defect.  
(H) A second cut is made in the bone, and the 15 millimeter bone piece is removed.  
(I) The bone and construct are equivalent in length.  (J)  The construct is sec
the defect, and (K) the surrounding muscle layer is sutured, and (L) then the 
surrounding skin is sutured.
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Measurements include volumetric basis, but accurate measures are based on mass, which 
captures all mineral including what is not taken into account in volume measurements of 
repairing bone with low density regions.  Mass is calibrated to a stepped hydroxyapatite 
phantom, units of mg of HA per cubic cm (mg HA/cm3).  Since the bone remodeling is 
significant, such that formation/resorption/remodeling are not distinguishable and 
includes regions of high and low density, to measure all formation, the total mass of all 
bone (radius, callus, everything) was measured within the set length.  We also measured 
and subtracted off the mass of the radius in the intact limb within the matching region of 
each experimental limb.   
 
5.2.3.2.4. Histological Staining and Analysis 
 
 Limbs were embedded in methyl methacrylate using a slow methylmethacrylate 
(sMMA) processing, infiltration and embedding techniques as described by Kecena et al., 
and then sectioned at 7 µm thickness with a Reichert Jung Polycut E microtome and a 
Tungsten carbide D profile knife (Dornt Hart), and mounted onto glass slides. These 
sections were then be stained with hematoxylin and eosin to evaluate cellular events, von 
Kossa to evaluate all the mineralized tissue at the site, and with Goldner’s Trichrome to 
evaluate the osteoid, or new unmineralized bone being deposited at bone forming sites.   
All staining was performed according to protocols described by Kecena et al.  (173). 
 
5.2.4. Statistical Analysis  
 
For vascular and bone quantification analysis (i.e., histology and MicroCT), a 
two-way analysis of variance (ANOVA) was preformed to compare data.  Error is 
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reported in figures as the standard deviation (SD) and significance was determined using 
a probability value of p < 0.05. 
 
5.3. Results 
5.3.1. Cell-Seeded Constructs In Vitro Evaluation 
Cell-seeded macro-porous scaffolds were evaluated after 2 days in culture (i.e., 
pre-implantation stage) (Figure 5-6).  Each macro-porous scaffolds was seeded with a 
total of 250,000 cells, and the following cellular conditions were examined in vitro to 
confirm cell performance, phenotype and survival at the pre-implantation stage: (1) 
MSC-derived osteoblasts, (2) EPCs-, and (3) co-culture of MSC-derived osteoblasts and 
EPCs at a 1:1 ratio.  As seen in Figure 3, MSC-derived osteoblasts maintained their 
differentiation as demonstrated by positive immune-staining of bone markers collagen 
type 1 (Col1) and RunX2, which was observed in MSC-derived osteoblast – seeded 
constructs, as well as co-culture seeded constructs.  Furthermore, EPCs maintained the 
endothelial cell phenotype as demonstrated by the positive immune-staining of vascular 
endothelial markers CD31 and von Willebrand Factor (vWF), which was observed in 
EPC – seeded constructs, as well as co-culture seeded constructs. 
    
 Figure 5-6.  Immunofluorescence staining of endothelial markers CD31 and vWF, 
osteogenic markers RunX2 and Collagen type I, and tubulin on MSC, EPC and co
culture of MSC:EPC (1:1) constructs pre
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constructs after 8 weeks in vivo.   However, in comparison to collagen formation in 
constructs seeded with MSC-derived osteoblasts, only constructs seeded with co-cultured 
MSC-derived osteoblasts and EPCs at ratios of 4:1 and 1:1 demonstrated significant 
collagen formation.  On the other hand, subcutaneous implantation of acellular and EPC-
seeded constructs resulted significant adipose tissue formation, instead of collagen 
formation.   
Vascular formation analysis throughout the constructs was also performed on the 
Trichrome-stained sections.  Implantation of EPCs significantly enhanced vascularization 
throughout the constructs.  As seen in Figure 5-8, constructs seeded with EPCs 
demonstrated significantly more vascularization than constructs that were initially 
implanted without cells.  However, constructs co-seeded with MSC-derived osteoblasts 
and EPCs at ratio of 1:1 (1 OB: 1 EPC) demonstrated the highest level of vascularization.  
Implantation of constructs co-seeded with MSC-derived osteoblasts and EPCs at ratio of 
1:4 did result in significant vascularization compared to acellular constructs, however 
lower than that of EPC-seeded and 1:1 (1 OB: 1 EPC) –seeded constructs.  It is important 
to note that significant adipose tissue formation was observed in implanted acellular 
constructs and constructs seeded with EPCs or higher level of EPCs in co-culture (1 OB: 
4 EPC).   Qualitative assessment of vascular, collagen and adipose tissue formation is 
shown in Figure 8.  Thus, 1 OB: 1 EPC constructs showed the highest level of 
vascularization and collagen formation.  Vessel formation was confirmed via CD31 and 
von Willabrand Factor (vWF)  immunostaining, and bone formation was confirmed via 
Collagen type 1 (Col1) and RunX2 immunostaining (Figure 5-9).  
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Figure 5-8.  (A)  Quantification of In Vivo Vascularization.  (** Significance 
compared to Negative (p < 0.05), # Significance compared to EPC (p < 0.05)).  (B) 
Quantification of collagen staining.  (** Significance compared to Negative (p < 
0.05); # Significance compared to MSC (p < 0.05)). 
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RunX2 and Collagen type I on (A) construct pre-seeded with MSC:EPC (1:1), and 
(B) mouse limb post-natal day 1 (positive control). 
 
 
5.3.2.2. Rabbit Ulnar Critical Size Bone Defect 
Implantation 
 
A 15 millimeter bone defect was created in the ulnar bone of New Zealand White 
rabbits (4-5 kilograms), and an optimally-porous construct (cylinder of 5 millimeter 
diameter, and 15 millimeter height) was inserted into the bone defect.  The construct was 
previously seeded with 250,000 mesenchymal stem cells (MSCs), endothelial progenitor 
cells (EPCs), or a 1-to-1 ratio of MSCs and EPCs (125,000 MSCs and 125,000 EPCs), or 
no cells (i.e., acellular construct to serve as a negative control), and cultured for 2 day in 
a 1-to-1 mix of osteogenic and endothelial growth media.  We examined 6 rabbits for 
each group (i.e., 4 groups; acellular, MSC, EPC, 1 MSC:1 EPC).  As seen in Figure 5-10, 
x-ray analysis was utilized immediately post-operation to confirm a bone defect of 15 
millimeters was created.    
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Figure 5-10.  Radiograph of rabbit (A) sham (i.e., no defect) arm, and (B) right arm 
(with defect) immediately post-implantation. 
 
Rabbits were monitored closely for their recovery and performance.  Several days 
to one week post operation, all rabbits were sitting up, walking, eating, drinking, and 
performing as expected for post-operation.  Rabbits were fully functioning in their 
movements (i.e., walking, running, jumping), and applying weight on their forearms 
(including their arm that operated on) at 6 and 12 weeks post-operation.  After 12 weeks, 
all rabbits were sacrificed for analysis and evaluation of bone and vascular regeneration 
at the bone defect.   
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Figure 5-11.  Representative cross-section MicroCT image of remodeled bone in the 
middle of the rabbit ulnar bone defect.  U = ulnar bone, R = radius bone.  Scale bar 
= 5 mm. 
 
 
MicroCT analysis was utilized to evaluate bone regeneration at the defect site.     
As seen in Figure 5-11, significant remodeling and callus formation was observed in 
most bone specimens, such that formation, resorption, and/or remodeling are not 
distinguishable, and includes regions of high and low density.  Therefore, in order 
to measure all bone formation, the total mass of all bone (i.e., ulnar, radius, callus) 
within the set length was measured.  In addition, the mass of the radius in the 
intact limb also measured.  To quantify the mass and bone volume within the ulnar 
defect, the mass of the intact radius was subtracted off the mass of the matching 
region of each experimental limb.   
 
Limited bone regeneration was observed in the acellular group, which confirmed 
this model as a critical-sized bone defect (Figure 5-12).   The MSC and EPC group 
displayed higher levels of bone regeneration than the acellular group (Figure 5-13).  
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However, the rabbit group that received constructs seeded with 1-to-1 ratio of MSCs and 
EPCs displayed significantly higher levels of bone regeneration than that of the acellular 
group.  As seen by the longitudinal sections in Figure 5-12, the 1 MSC: 1 EPC group 
displayed complete bone bridging throughout the thickness of the defect, whereas the 
other groups did not.    Furthermore, as seen in Figure 5-14, the highest amount of 
regenerated bone volume and mass was observed in the 1:1 MSC:EPC group.   
 
 
Figure 5-12.  MicroCT analysis of ulnar bone defect 12 weeks post-implantation.  
Representative scout view images (i.e., radiographs), three-dimensional 
reconstructed images, and longitudinal section images are shown for each group 
(i.e., Acellular, MSC-seeded, EPC-seeded, and a 1:1 ratio of MSC:EPC seeded 
construct). Scout views were utilized to determine the region of interest (ROI) for 
bone mass and volume quantification.  Scale bar = 5 millimeters.  
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Figure 5-13.  (A) Bone Volume and (B) Mass with the ulnar bone defect.  * indicates 
p < 0.05. 
 
 
Figure 5-14.  Representative histological images of Von Kossa –stained cross-
sections (top two rows) and longitudinal sections (bottom two rows).  Images were 
taken under low magnification to view the entire defect area in the section.  Images 
displayed under 4X represent regions of interest (highlighted in red box) under low 
magnification. Scale bar (low magnification) = 2 millimeters.  Scale bar (4X 
magnification) = 500 µm.  
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Histological analysis of Von Kossa stained sections confirmed the findings from 
MicroCT analysis (Figure 5-14).  The acellular group displayed a lack of mineralized 
tissue within the defect, whereas the cell-seeded groups with MSCs and EPCs showed 
increased bone mineralization located at the bony edges of the bone defect.  Moreover, 
the 1:1 MSC:EPC –seeded construct group displayed the highest amount of the bone 
mineralization not just localized to the bony edge of the defect, and instead there are 
signs of attempted bony bridging.   Quantative analysis of the Von Kossa stained sections 
demonstrated a significant increase in mineralized bone area in MSC- and EPC- seeded 
groups compared to acellular constructs, however their levels are not significantly 
different from each other.  The co-culture 1:1 MSC:EPC- seeded group displayed the 
most significant increase in mineralized bone area compared to the acellular group 
(Figure 5-14, Figure 5-15).   
 
 Figure 5-15.  Quantification of mineralized bone area formed within the rabbit 
ulnar defect.  Three regions
samples in each group under low magnification with a thresholding analysis tool 
from ImageJ software.  ** indicates p < 0.05,  ## indicates p < 0.001
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the MSC- and EPC- seeded groups also displaying increased vascularization compared to 
the acellular group (Figure 5-19). 
 
 
Figure 5-16.  Representative histological images of Goldner’s Trichrome –stained 
longitudinal sections imaged under low, 4X, 10X, 20X and 40X magnification. 
Images shown for 4X magnification were taken from the region of interest 
highlighted in the low magnification image.  Images shown for 10X, 20X, and 40X 
magnification are representative images of each group.  Scale bar for low 
magnification images = 5 mm; Scale bar for 4X magnification images = 500 µm;  
Scale bar for 10X images = 500 µm; Scale bar for 20X images = 250 µm; 40X images 
= 100 µm. 
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Figure 5-17.  Labeled Goldner’s Trichrome stained sections imaged under (A) 20X 
(scale bar = 250 µm),  and (B) 40X (scale bar = 100 µm).  M = microsphere scaffold, 
 C = unmineralized collagen, BV = blood vessel, O = osteoblast, Os = osteoid, B = 
mineralized bone.   
 
 
 
Figure 5-18.  Quantification of collagen formation within the rabbit ulnar defect.  
Ten regions on Trichrome stained sections were analyzed for the intensity of 
collagen (green color) from 3 samples in each group under 20X magnification with a 
color (RBG) histogram anal
255, with 255 representing the highest green intensity).  
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ysis tool from ImageJ software (arbitrary scale of 0 to 
 
 
 Figure 5-19.  Quantification of vessels within the rabbit ulnar defect.  Vessels were 
counted in five regions on Trichrome stained sections under 10X magnification for 3 
samples in each group. 
 
 
 
5.4. Discussion
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microsphere scaffolds that demonstrate tunable oxygen tension and pH levels in the 
scaffold’s interior regions after long term in vitro cell culture.   Specifically, by adding 
NaCl crystals to a mixture of PLGA microspheres, and leaching out the NaCl via soaking 
in water after thermal sintering the molded mixture, we developed biodegradable 
scaffolds with increased pore sizes and accessible pore volume, while retaining 
mechanical strength in the range of human cancellous bone.  
 With our newly-designed oxygen tension controlled matrices, we set forward to 
investigate the most effective cell ratio of MSC-derived osteoblasts and EPCs for in vitro 
pre-vascularization, and subsequent neo-vascularization and bone formation in vivo.   We 
investigated the following MSC-derived osteoblasts/EPC ratios: 1 part MSC-derived 
osteoblasts to 4 parts EPC (1:4), 1 part MSC-derived osteoblasts to 1 part EPC (1:1), and 
4 parts MSC-derived osteoblasts to 1 part EPC (4:1).   We confirmed the maintenance of 
endothelial cell markers (i.e., CD31 and von Willabrand Factor (vWF)) by EPCs, and 
osteogenic cell markers (i.e., collagen type 1 and RunX2) by MSCs, cultured alone and in 
co-culture via immunofluoresence.  After 2 days in vitro, the constructs of the various 
cells ratios, as well as the cell types alone, were implanted subcutaneously in SCID mice.  
Constructs seeded with MSC-derived osteoblasts and EPCs at a ratio of 1:1 demonstrated 
not only the highest level of vascularization throughout the implant construct, but also 
collagen formation after 8 weeks in vivo.  Though constructs seeded with EPCs alone, as 
well as in co-culture with MSC-derived osteoblasts (ratio of 1:4) also demonstrated 
significant vascular formation throughout the construct compared to acellular constructs, 
it was significantly less than that of constructs seeded with the cells at a 1:1 ratio.  In 
addition, significant collagen formation was observed throughout all the constructs that 
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were seeded with both cells types at all ratios (1:4, 1:1, 4:1), as well as constructs seeded 
with MSC-derived osteoblasts.  However, again, constructs seeded with MSC-derived 
osteoblasts and EPCs at a ratio of 1:1 resulted in the highest levels of collagen formation.  
Vascular and bone formation in vivo was confirmed through immunostaining of 
endothelial markers CD31 and vWF, as well as osteogenic markers collagen type 1 and 
RunX2, respectively.   Implanted acellular constructs demonstrated significant adipose 
tissue formation, as well as constructs seeded with only one cell type (i.e., EPCs-alone, 
MSC-derived osteoblasts- alone), as well co-culture ratio 1:4.   
  With this, we selected the ratio of 1:1 MSC:EPC as the most effective progenitor 
cell ratio, and pursued a load-bearing bone defect model.  We evaluated the performance 
of 4 different groups, acellular scaffold constructs (i.e., negative control), MSC-seeded 
scaffold constructs, EPC-seeded scaffold constructs, and a co-culture of MSCs and EPCs 
at a ratio of 1:1.  The co-culture group outperformed, and displayed the most significant 
increase in bone formation and vascularization with the bone defect as confirmed by 
MicroCT, and histological analysis.  Furthermore, this group displayed the least amount 
of adipose and fibrous tissue formation, as compared to the acellular group, and MSC- 
and EPC- seeded group.  
 
5.5. Conclusions 
The fundamental implications of this study are apparent, and will lay the 
groundwork for future bone tissue engineering studies.  We have developed oxygen 
tension-controlled matrices allowing for enhanced in vitro cell viability, as well the 
identified of the most effective cell ratio of MSC-derived osteoblasts to EPCs, two easily 
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accessible autologous cell sources.  Though many studies have investigated co-
implantation of MSC-derived osteoblasts and EPCs for effective neo-vascularization and 
bone formation, we were the first to examine the proper ratio of these two cell types.  
Further, we utilized both, optimally-porous oxygen tension-controlled matrices and the 
optimal ratio of effective progenitor cells for the enhanced repair and regeneration of a 
critically-sized load-bearing bone defect in rabbits.   
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6. CONCLUSIONS AND FUTURE DIRECTIONS 
Large area or critically-sized bone defects represents a major clinical problem in 
orthopaedic and cranio-/maxillo- facial surgery (127).  Large area bone defects may 
result from trauma, tumor resection, revision surgery and developmental deformities, and 
are unable to heal spontaneously (4).  Repair of large defects require bone grafts/graft 
substitutes that can physically support bone regeneration, while providing surface area for 
cell attachment and tissue growth. Current treatment options for large area bone defects 
include bone grafts, distraction osteogenesis, demineralized bone matrix, and porous 
hydroxyapatite; all of which have been associated with significant challenges and 
complications (5-10).   Thus, there is a warranted search for better bone replacement 
methods to overcome the drawbacks of the currently used bone graft materials.  
Bone tissue engineering research has revealed tremendous potential for the 
treatment of bone defects.  The bone tissue engineering paradigm classically involves the 
combination of one or more of the following components: a mechanically-compatible 
scaffold, effective cell populations and/or growth factors.   However, central necrosis or 
lack of bone tissue formation due to the lack of or insufficient vascularization of bone 
constructs is a well-recognized obstacle to the success of complete bone regeneration and 
host integration in bone tissue engineering (35).  
In the present study, we have demonstrated a two-pronged approach involving the 
development of optimally-porous constructs that allow for enhanced cell viability, as well 
as the identification of effective clinically-relevant cells for enhanced bone formation and 
vascularization.   Again, in the first component of our approach, we developed a novel 
optimally-porous biodegradable scaffold for bone regeneration and vascularization.  We 
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fabricated poly(D,L-85 lactide-co-15 glycolide) (PLGA) microsphere scaffolds with 
increased porosity via the combination of thermal sintering and porogen (i.e., NaCl 
particles) leaching.  Specifically, we combined PLGA microspheres with NaCl, thermally 
sintered, and then leached out the NaCl by soaking the constructs in water. Through this 
method, scaffold porosity and mechanical properties may be tuned according to the 
clinical requirement by controlling the size and amount of the porogen added during the 
fabrication process. 
Through this method, we have improved PLGA microsphere scaffold 
performance and its ability to support osteoblast cell survival, proliferation and 
mineralization throughout the construct, and yet retained mechanical compatibility for 
effective bone regeneration.  We determined PLGA microsphere scaffolds fabricated 
with 20% NaCl to be optimally-porous.    Although optimally-porous scaffolds displayed 
decreased mechanical strength as compared to the control scaffolds (i.e., fabricated 
without porogen), the mechanical strength of these scaffolds remained within the 
mechanical constraints of human cancellous bone.  However, unlike control scaffolds 
with limited pore sizes and accessible pore volume, optimally-porous scaffolds displayed 
significantly more pores sizes in the range of 200-400 µm, which has been previously 
cited as a critical pore size range for vascularization in bone tissue engineering 
constructs.   Optimally-porous scaffolds also displayed increased oxygen levels and near-
normal pH levels.  These scaffolds proved to be fully osteoconductive as they supported 
pre-osteoblast cell infiltration, proliferation, and survival throughout the entire scaffold in 
vitro.  Furthermore, optimally-porous PLGA microsphere scaffolds displayed enhanced 
and homogenous mineralization in vitro.   
 161
In addition, we demonstrated the ability to modulate scaffold porosity and in turn, 
develop oxygen tension controlled matrices that may be effective for large area bone 
regeneration.  Specifically, increasing the concentration of porogen during scaffold 
fabrication resulted in a systematic increase in not only porosity, but also available 
oxygen tension throughout the matrix.  The enhanced survival, proliferation, 
differentiation and mineralization of pre-osteoblasts may be attributed to the increase in 
available oxygen tension. Thus, the proposed optimally-porous scaffolds with improved 
oxygen availability and bone compatible mechanical properties are desirable for large 
area bone regeneration. Oxygen tension control via scaffold porosity optimization may 
provide opportunities in designing next generation scaffold systems most effective for 
large area/ critical sized bone defect repair. 
As for the second component of our two-pronged approach, we aimed to identify 
effective clinically relevant cell populations for enhanced bone formation and 
vascularization.  We examined endothelial progenitor cells (EPCs) as an effective 
endothelial population since they have been previously proven to promote vascularization 
and in turn, promote successful bone formation at the graft site.  Additionally, EPCs 
display high angiogenic, proliferative and survival potential in situ.   
We have, for the first time, sought to identify the ideal isolation source for EPCs, 
either bone marrow or peripheral blood (BM-EPCs or PB-EPCs), that would yield the 
most effective EPC cell population for enhanced vascularization and bone formation.  
PB-EPCs outperformed BM-EPCs on all measures.  PB-EPCs displayed typical 
endothelial cell markers, such as CD31, as well as high angiogenic potential in three-
dimensional extracellular matrix in vitro.  Furthermore, PB-EPCs cultured 
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simultaneously with mesenchymal stem cells (MSCs), displayed significantly enhanced 
expression levels of key osteogenic and vascular markers, including alkaline phosphatase, 
bone morphogenetic protein 2, and vascular endothelial growth factor.  On the contrary, 
BM-EPCs did not express CD31, and instead, expressed key smooth muscle markers.  
BM-EPCs further failed to display vasculogenic activity.  Therefore, we identified the 
highly angiogenic peripheral blood derived-EPCs (PB-EPC) as an ideal autologous cell 
population since their isolation does not risk donor site morbidity, and importantly, they 
effectively result in enhanced vascularization and success of engineered bone tissue 
regeneration. 
 With the fabrication of newly-designed optimally-porous scaffolds and 
identification of effective progenitor cells, we set forward to investigate the most 
effective cell ratio of MSC-derived osteoblasts and EPCs for in vitro pre-vascularization, 
and subsequent neo-vascularization and bone formation in vivo.   We determined that 
constructs seeded with MSC-derived osteoblasts and EPCs at a ratio of 1:1 demonstrated 
not only the highest level of vascularization throughout the implant construct, but also 
collagen formation 8 weeks post-implantation in a mouse subcutaneous model.  Vascular 
and bone formation in vivo was confirmed through immunostaining of endothelial 
markers CD31 and vWF, as well as osteogenic markers collagen type 1 and RunX2, 
respectively.  With this, we selected the ratio of 1:1 MSC:EPC as the most effective 
progenitor cell ratio, and pursued a load-bearing, critical-sized bone defect model.  We 
evaluated the performance of 4 different groups, acellular scaffold constructs (i.e., 
negative control), MSC-seeded scaffold constructs, EPC-seeded scaffold constructs, and 
a co-culture of MSCs and EPCs at a ratio of 1:1.  The co-culture group outperformed, and 
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displayed the most significant increase in bone formation and vascularization with the 
bone defect as confirmed by MicroCT, and histological analysis.  Furthermore, this group 
displayed the least amount of adipose and fibrous tissue formation, as compared to the 
acellular group, and MSC- and EPC- seeded group.  
As a whole, this investigation presents a landmark study, and may lay the 
groundwork for future bone tissue engineering studies to make steps even closer to 
achieving clinical success in bone regeneration and repair. We have developed optimally-
porous and oxygen tension-controlled scaffolds allowing for enhanced in vitro cell 
viability, as well the identified of the most effective cell ratio of MSC-derived osteoblasts 
to EPCs, two easily accessible autologous cell sources. Further, we utilized both, 
optimally-porous oxygen tension-controlled matrices and the optimal ratio of effective 
progenitor cells for the enhanced repair and regeneration of a critically-sized load-bearing 
bone defect in rabbits.  Future studies should focus on adopting the fundamental concepts 
presented in this investigation (i.e., scaffold and autologous cell population) into a even 
more clinically-tailored concept.  For example, more effective cell isolation, seeding and 
culturing methods need to be used in order to streamline the engineering process, and 
decrease the safety risks associated with the handling the constructs during the pre-
implantation period.  Bioreactors that can combine all three steps may be used for this 
purpose, and may drive the way for safer and more effective bone tissue engineering. In 
addition, the incorporation of immunomodulatory strategies may be used to modulate the 
host’s foreign-body response (i.e., fibrous tissue encapsulation), an event that is often 
observed to be an inhibitory factor for optimal tissue regeneration and integration.   
In conclusion, bone tissue engineering research has recently gained significant 
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momentum and revealed tremendous potential for the treatment of bone defects, and 
prospects for achieving clinically successful bone regeneration are extremely optimistic.  
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7. APPENDIX 1 – Protocols  
 
7.1. Fabrication of PLGA Microspheres 
7.1.1. Materials 
• Poly(D,L-85 Lactide-co-15 glycolide) (PLGA) (Lakeshore 
Biomaterials; Birmingham, AL) 
• Poly (vinyl alcohol) (PVA) (Sigma) 
• Methylene chloride (CH2Cl2) (Sigma)  
7.1.2. Protocol 
85:15 PLGA polymer was dissolved in organic solvent, Methylene Chloride at 
4:1 ratio and vortexed until it dissolved. The mixture was then slowly added to 
a 1% poly (vinyl alcohol) solution while stirring at 250 rpm and left stirring 
over night at 300 rpm. The microspheres were then vacuum dried for 24 hours 
then sieved to obtain 425-600 µm size range and kept in desiccator until 
needed.  
 
7.2. Fabrication of Optimally-Porous PLGA 
Microsphere Scaffold  
7.2.1. Materials 
• PLGA microspheres (425-600 µm diameter) 
• Porogen, NaCl crystals (200-300 µm diameter)  
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• Steel mold to fabricate disc-shaped (10 mm diameter, 2 mm 
height) or cylinder-shaped (5 mm diameter, 15 mm or 10 mm 
height) scaffolds 
• Oven set to 100oC 
 
7.2.2. Protocol 
Control scaffolds were fabricated by packing approximately 0.15 g of PLGA 
microspheres (425-600 µm diameter) into each compartment within the steel 
mold.  Scaffolds with increased porosity were fabricated by mixing PLGA 
microspheres (425-600 µm diameter) and NaCl crystals (200-300 µm diameter) at 
specific weight ratios (i.e., PLGA:NaCl ratios include 90:10, 80:20, 70:30, 60:40, 
50:50), which was then packed in the the steel mold in a similar manner as 
described with the control scaffolds.  The mold was then subjected to heat 
treatment of 100°C for 1 hour to form three-dimensional scaffolds. The mold was 
then allowed to cool to room temperature before the scaffolds were removed from 
the mold.  Scaffolds were then soaked in water for 2 hours in order to leach out 
the NaCl.   Scaffolds were then stored in a desiccator until further use. 
 
7.3. Mechanical Testing 
7.3.1. Materials 
• Pre-fabricated PLGA microsphere scaffolds (10 mm height x 5 
mm diameter) 
• Instron model 5544 
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• Computer with installed Merlin data analysis software 
 
7.3.2. Protocol 
Cylindrical scaffolds (n = 6) with 2:1 aspect ratio (10 mm length and 5 mm 
diameter) were used for mechanical characterization. Compressive testing will 
carry out using an Instron model 5544 with a cross head speed of 2 mm/min 
maintained until the sample failed.  We followed the standard protocol of 
ASTM 1621.37. The compressive modulus and maximum compressive 
strength of scaffolds were determined using the Merlin data analysis software. 
Compressive strength was defined as the maximum stress magnitude. 
Apparent modulus was measured as the tangential slope of the linear region of 
the effective stress–strain curve at 50% of compressive strength magnitude. 
 
7.4. MicroCT Analysis 
7.4.1. Materials 
• Pre-fabricated PLGA microsphere scaffolds (2 mm height x 10 
mm diameter) 
• Cone-beam micro- focus X-ray computed tomography 
(mCT40; Scanco Medical AG) 
 
a. PROTOCOL 
Scaffold specimens were imaged using cone-beam micro- focus X-ray 
computed tomography (CT) to render three- dimensional (3D) models for 
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direct quantitation of porosity (mCT40; Scanco Medical AG). Serial 
tomographic images were acquired at 45kV and 177mA, collecting 2000 
projections per rotation at 300 millisecond integration time. Three- 
dimensional 16-bit grayscale images were reconstructed using standard 
convolution back-projection algorithms with Shepp and Logan filtering, and 
rendered within a 12.3-mm field of view at a discrete density of 4,629,630 
voxels/mm3 (isometric 6 mm voxels). Segmentation of solid scaffold from 
open porosity was performed in conjunction with a con- strained Gaussian 
filter to reduce noise, applying a threshold of - 220 Hounsfield units (water = 
0, air = - 1000). Direct measurements of internal porosity included volume 
fraction, size, connectivity, accessible internal pore volume, and accessible 
solid surface area of the scaffold (as a function of pore dimension). The 
accessible volume and surface parameters provide direct measurements of the 
pore volume and the surface available to cell infiltration as a function of 
minimum pore dimension, using a distance transformation algorithm similar 
to that used by Moore et al.   
 
7.5. Scanning Electron Microscopy (SEM) Using the 
FEI Strata 400s Dual Beam FIB 
7.5.1. Materials 
• PLGA microsphere scaffolds 
• Gold/palladium 
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7.5.2. Protocol 
The morphology of the PLGA microsphere scaffolds was analyzed using the 
FEI Strata 400s Dual Beam FIB. The surface characterization of both 
microspheres and scaffolds was done in the SEM mode (2KeV). Samples 
were prepared by coating with gold/palladium (1-2 minutes) and examined 
under SEM. 
 
7.6. Scaffold Sterilization 
7.6.1. Materials  
• 70% ethanol 
• PBS 
• UV radiation 
 
7.6.2. Protocol 
Scaffolds were sterilized by immersing in 70% ethanol for 30 minutes. 
Scaffolds were then washed three times in sterile PBS before exposing 
them to UV radiation, 30 minutes each side of scaffold. Scaffolds were 
then placed in 24 well plates and let to dry for few minutes.  
 
7.7. Cell Culture 
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7.7.1. Cell Types 
7.7.1.1. MC3T3 Pre-Osteoblast Cells 
Pre-osteoblastic MC3T3-E1 cells were obtained from American 
Type Culture Collection (ATCC, Manassas, VA).  Cells from 
Passage 18-23 were used for experiments.  
 
7.7.1.2. Rabbit Mesenchymal Stem Cells (MSCs) 
7.7.1.2.1. Materials 
• Betadine Solution 
• 100% Ethanol 
• Phosphate Buffered Saline (PBS) Solution  
• Isolation Medium (a-MEM + 10% Fetal Bovine Serum 
+ 1% Pen/Strep) 
• Growth Medium (a-MEM + 15% Fetal Bovine Serum + 
1% Pen/Strep) 
• Lymphoprep (1.077 g/mL) 
• Sterile Drapes and Sponges  
• Scalpel 
• Sterile Petri Dishes (100 x 15 mm) 
• Sterile Disposable Syringes with Luer Lock Sterile 
Needles (16-, 18- and 21-G) 
• Sterile glass beaker (100 mL) 
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7.7.1.2.2. Protocol 
The isolated long bones of New Zealand white rabbits were 
placed in a beaker containing 100% EtOH for 5 minutes, and 
then in individual 50 mL centrifuge tubes containing isolation 
media.  The bones were kept on ice until ready for marrow 
isolation. The long bones were removed from media and place 
into a 100 mm sterile Petri dish in a sterile cell culture hood. 
The bones were rinsed with PBS, and any adherent muscle or 
soft tissues were removed from the long bones using scalpel 
and scissors.  The long bones were rinsed again with PBS and 
transferred to a clean 100 mm sterile Petri dish.  The 
metaphyses (flared ends of long bone) of each bone were 
removed using a bone cutter to expose the marrow cavity.  The 
long bone pieces were placed into individual sterile 50 mL 
polystyrene test tubes, and 5 milliliters of isolation medium 
(containing 1250 U heparin) was used to flush the marrow 
contents repeatedly using a 5 mL syringe containing a 21gauge 
needle.  The marrow contents were centrifuged at 1000 x g 
(2400 rpm) for 5-10 minutes at 4°C.  The supernatant 
(containing mainly bone marrow fat and isolation medium) was 
removed, and the cell pellet was re-suspended in 5 mL of 
isolation medium, and then 5 ml of Lymphoprep was added to 
a new 15 milliliter sterile centrifuge tube, and the cell 
suspension was layered onto the Lymphoprep layer and 
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centrifuged at 400 x g (1500 rpm) for 30-40 min at 18-20°C. 
Centrifugation resulted in 4 different layers: (i) the bottom is 
predominately red blood cells/granulocytes, (ii) above is a clear 
Ficoll layer, (iii) above this is a slightly pink hazy layer 
containing the majority of the mononuclear cells, and (iv) the 
uppermost is predominantly plasma, platelets and PBS. The 
uppermost layer was aspirated taking care to avoid disturbing 
the mononuclear layer. The mononuclear layer and two-thirds 
of the Ficoll layer was transferred to new 50-ml tubes, and 
centrifuged at 600-750 rpm for 10 minutes at 18-20°C. The 
supernatant was aspirated and the pellet was washed twice with 
PBS, and then centrifuged at 500 g for 5 minutes. The cells 
were resuspended in growth medium, and then plated at an 
appropriate seeding density on TCPS culture flasks, and 
cultured at 37°C in 5% CO2. Non-adherent cells were removed 
after 24 hours by washing with PBS.   The basal media was 
changed subsequently every 4 days, until culture reached 90% 
confluency (2 weeks).  MSCs were recovered using 0.25% 
Trypsin-EDTA and re-plated at a density of 5,000-6,000 cells 
per cm2 of surface area as passage 1 (P1) cells. 
 
7.7.1.3. Rabbit Bone Marrow-Derived Endothelial 
Progenitor Cells (BM-EPCs) 
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7.7.1.3.1. Materials 
• Betadine Solution 
• 100% Ethanol 
• Phosphate Buffered Saline (PBS) Solution 
• Sterile Drapes and Sponges  
• Scalpel 
• Sterile Petri Dishes (100 x 15 mm) 
• Sterile Disposable Syringes with Luer Lock 
• Sterile Needles (16-, 18- and 21-G) 
• Sterile glass beaker (100 mL) 
• Lymphoprep (1.077 g/mL) 
• Endothelial Growth Media-2 (EGM-2, Lonza) 
• 150 mm plates coated with Rabbit Type 1 Collagen (1 
µg/cm2)  
• 1 plate / 50 ml of collected blood 
• 0.25% Trypsin/EDTA 
 
7.7.1.3.2. Protocol 
Bone marrow from the long bones of New Zealand White 
Rabbits (4-5 kg) were be isolated, mixed with an equal volume 
of PBS and centrifuged on a Lymphoprep (1.077 g/ml) gradient 
for 400 x g (1500 rpm) for 30-40 min at 18-20°C.  The 
mononuclear fraction was isolated, and then washed three 
times with PBS.  The mononuclear fraction was cultured on 
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150 mm culture dishes coated with 1 µg/cm2of rabbit type I 
collagen in EGM-2 Endothelial Medium (EGM-2) at 37oC and 
5% CO2. After 4 days of culture, non-adherent cells were 
removed by washing with PBS, and a fresh medium was 
applied.  When cells reached about 90% confluency, cells were 
trypsinized, and passaged. The cells at passage 2-4 were used 
for cell characterization and construct engineered bone. 
 
7.7.1.4. Rabbit Peripheral Blood-Derived Endothelial 
Progenitor Cells (PB-EPCs) 
7.7.1.4.1. Materials 
• Anesthesia (ketamine (90-120 mg/kg body wt) and 
xylazine (5-10 mg/kg body wt) given via intramuscular 
injection) 
• BD Vacutainer Chemistry Tubes - 10 mL  Plasma Tubes 
with Spray-Coated Sodium Heparin (BD, #02-689-6) 
• BD Vacutainer Tube Holder (BD, #22-289-953) 
• BD Vacutainer Blood Collection Needles  21 x 1-1/2 in. 
(BD, #266521) 
• 70% ethanol  
• Lymphoprep 
• Phosphate Buffered Saline (PBS) Solution (1x) 
• Endothelial Growth Media-2 (EGM-2, Lonza) 
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• 150 mm plates coated with Rabbit Type 1 Collagen (1 
µg/cm2)  
• 1 plate / 50 ml of collected blood 
• 0.25% Trypsin/EDTA 
 
7.7.1.4.2. Protocol 
Peripheral blood was obtained via terminal exsanguination of a 
New Zealand White rabbit (4-5 kg).   The rabbits were 
anesthetized with intramuscular ketamine (90-120 mg/kg body 
wt) and xylazine (5-10 mg/kg body wt). The rabbit was 
positioned in dorsal recumbency, and chest area was wiped 
with 70% ethanol.  An incision overlying the thoracic cavity 
was made to expose the heart.  Blood collection was performed 
by puncturing the heart with a 21 guage needle connected to a 
Vacutainer blood collection system.  Once blood withdrawal 
was complete, sodium pentobarbital is injected intracardiac at 
100 mg/kg to ensure death.   
Rabbit peripheral blood mononuclear cells (PBMNCs) was 
isolated from ~200 ml of peripheral blood by density gradient 
centrifugation with Lymphoprep separation solution (d=1.077 
g/ml).  Specifically, 15 milliliters of Lymphoprep was added to 
each 50-ml centrifuge tube.  Then, an equal amount of PBS 
was added to the peripheral blood, and 35 milliliters of 
blood/PBS solution was slowly pipetted into each 50-ml 
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centrifuge tube containing Lymphoprep, and then centrifuged 
at 400 g or 20 min at room temperature.  This resulted in four 
visible layers after centrifugation: (i) the bottom is 
predominately red blood cells, (ii) above is a clear Lymphoprep 
layer, (iii) above this is a slightly pink and hazy layer 
containing the majority of the mononuclear cells, and (iv) the 
uppermost is predominately PBS. The uppermost layer was 
aspirated taking care to avoid disturbing the mononuclear 
layer.  The mononuclear layer and two-thirds of the Ficoll layer 
was transferred to new 50-ml tubes, and PBS was added to fill 
each tube and spin at 1500 g for 5 min to pellet cells. The pellet 
was washed once with PBS, resuspend in EGM-2 media, and 
then plated mononuclear cells from each 50 ml collected blood 
onto one 100 mm collagen-coated plate.  The cells were 
cultured at 37oC and 5% CO2  for 4 days, and then non-
adherent cells removed by washing with PBS two times. The 
culture was maintained for another 4–5 weeks, and media was 
be changed every 3 days. After reaching about 80% 
confluence, cells were trypsinized and seeded into 150 mm 
culture plate coated with rabbit Type I collagen for expansion.  
EPCs from passage 2– 4 were used for experiments.  
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7.7.1.5. Rabbit Vascular Smooth Muscle Cells (SMCs) 
7.7.1.5.1. Materials  
• Betadine Solution 
• Isopropyl Alcohol 
• 100% Ethanol 
• Phosphate Buffered Saline (PBS) Solution 
• Sterile Drapes and Sponges  
• Scalpel, forceps 
• Sterile Petri Dishes (100 x 15 mm) 
• Sterile glass beaker (100 mL) 
• DMEM + 3X Penicillin/Streptomycin 
• 0.25% Trypsin/EDTA 
• 7 milliliters of digesting solution (10mL of 
DMEM+PenStrep containing 15 U/mL Elastase 
(Worthington), 200 U/mL collagenase Type 2 
(Worthington), and 1.7 mg/mL of bovine serum 
albumin (BSA))  
• 0.22-um low-protein retention filter (Millipore, 
Billerica, MA))  
 
7.7.1.5.2. Protocol   
In a New Zealand white rabbit, the thoracic aorta was isolated 
from its origin just above the heart to the iliac bifurcation, and 
then transferred to a 50 ml test tube containing DMEM + 3x 
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penicillin/ streptomycin 37 °C.   The vessels were rinsed three 
times with DMEM + 3X Pen/Strep at 37°C, and then the 
connective tissues and adventitia was gently removed from the 
aorta using forceps.  The aorta was washed in DMEM with 3X 
Pen/Strep at 37°C by repeatedly pipetting out with a wide-
mouthed, glass pipet to ensure the removal of blood within the 
aorta.  The aorta was chopped into small pieces, and then was 
added to 7mL of digesting solution (10mL of 
DMEM+PenStrep containing 15 U/mL Elastase 
(Worthington), 200 U/mL collagenase Type 2 (Worthington), 
and 1.7 mg/mL of bovine serum albumin (BSA).  This 
solution was filtered through a 0.22-um low-protein retention 
filter (Millipore, Billerica, MA)) and incubated at 37 °C for 
about 60–75 min with gentle shaking.  The completion of 
digestion is indicated by homogenization of the aorta in the 
digestion media. The solution was then spun at 1000 g for 5 
min, and then the supernatant was gently discarded.  The 
pellet was washed by swirling gently (slight dissociation) with 
5 milliliter glass pipette three times with DMEM/PenStrep (5 
milliliters). The supernatant containing single cells was spun 
at 100 g for 30 seconds, and then the cells were plated on 
culture dishes containing cell culture media, and culture at 5% 
CO2 and 95% air.  
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7.7.1.6. Human Umbilical Vein Endothelial Cells 
(HUVECs)  
HUVECs were obtained from American Type Culture Collection 
(#RL-2873, ATCC, Manassas, VA).  Cells from Passage 4-6 were 
used for experiments.  
 
7.7.2. Cell Culture Mediums 
7.7.2.1. Basal Growth Medium 
Basal growth medium for MC3T3 cells, MSCs and SMCs is 
DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin.  
 
7.7.2.2. Osteogenic Medium 
7.7.2.2.1. MC3T3 Cells 
Cells were cultured in DMEM supplemented with 10% FBS, 
1% penicillin-streptomycin, 3mM β-glycerophosphate and 10 
µg/ml ascorbic acid. 
 
7.7.2.2.2. Mesenchymal Stem Cells 
For osteogenic differentiation, the culture medium (DMEM, 
10% FBS, 1% Penicillin/Streptomycin) was supplemented with 
10-8 M dexamethasone, 10mM β-glycerophosphate, and 50 
µg/ml ascorbic acid. 
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7.7.2.3. Endothelial Growth Medium 
BM-EPCs, PB-EPCs and HUVECs were cultured in EGM-2 media 
(CC-3162, Lonza).  EGM-2 includes endothelial basal medium 
(EBM2) supplemented with 10% FBS, 1% 
Penicillin/Streptomycin, and EGM2 Singlequots (hEGF,VEGF, 
hFGF-B, R3-IGF-1, ascorbic acid, heparin, gentamicin–
amphotericin-B.    
 
7.7.2.4. 1-to-1 Mix of Osteogenic And Endothelial 
Medium 
7.7.2.4.1. Co-Culture of Mesenchymal Stem Cells and Endothelial 
Progenitor Cells 
Co-cultures of MSCs and EPCs were cultured in a 1-to-1 mix 
of osteogenic and endothelial medium (i.e., 1 part osteogenic 
media (DMEM, 10% FBS, 1% Penicillin/Streptomycin, 10-8 M 
dexamethasone, 10 mM β-glycerophosphate, and 50 ug/ml 
ascorbic acid) and 1 part endothelial media (EGM-2 media, 
10% FBS, 1% Penicillin/Streptomycin, EGM2 Singlequots)). 
 
7.7.3. Cryopreservation Of Cells 
7.7.3.1. Materials 
• Dimethyl sulfoxide (DMSO, Sigma-Aldrich, D4540) 
• Cryogenic vials 
• 0.25% Trypsin-EDTA (Sigma-Aldrich, T4049) 
• 15ml centrifuge tube  
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• 70% isopropyl alcohol (inside the cryogenic storage 
container) 
• PBS Phosphate-Buffered Saline (Gibco) 
• Cryogenic storage container 
7.7.3.2. Protocol 
To cryopreserve cells for later use, the cells were trypsinized and 
transferred to a 15 milliliter centrifuge tube, and centrifuged at 500 
rpm for 10 minutes. The cells were resuspended in 5 milliliters of 
media, and counted using trypan blue and a hemacytometer for a 
viable cell count. In each cryopreservation 1.5 milliliter tube, 0.4 ml 
FBS, 0.1 ml DMSO, and 1x106 cells/0.5 ml media was added to create 
a cell suspension of 1x106 cells per milliliter. The cells were then 
immediately transferred to cyrogenic storage container at -80°C 
overnight, before permanent storage in liquid nitrogen.  
 
7.8. Cell Seeding on Scaffolds and Culture 
Conditions 
After cell trypsinization, a cell suspension was uniformly seeded onto the 
scaffolds. The disc-shaped scaffolds were placed flat on the culture plate, and a 20 µL 
cell suspension was uniformly added to the top of the scaffold. The cylindrical 
scaffolds were placed along the length of the scaffold on the culture plate, and a 40 
µL cell suspension was added to the lengthwise surface as the scaffold was slowly 
rotated (i.e., along the long axis of the scaffold) to maintain uniform cell seeding. The 
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cell-seeded scaffolds were incubated for 2 hour at 37°C to allow for cell adhesion 
onto the scaffolds before 1 milliliter of media was added.  Cell culture was 
maintained for pre-determined time-points in an incubator at 37°C, 5% CO2, and 95% 
humidified air.  
 
7.9. Cell Seeding Efficiency 
7.9.1. Materials 
• Cell suspension 
• Hemocytometer 
• Trypan blue  
• Light microscope 
7.9.2. Protocol 
After 6 hours of cell seeding, scaffolds were transferred to new wells. Cells at 
the bottom of the original wells were trypsinized, resuspended, and counted 
with a hemocytometer. The cell-seeding efficiency (i.e., the number of cells 
that adhered to the scaffolds) was determined by the difference between the 
number of cells initially seeded and the number of cells that were counted at 
the bottom of the well.  
 
7.10. Cell Proliferation (PicoGreen Analysis) 
7.10.1. Materials 
• DNA solution in 1% Triton X100 solution 
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• Quant-iTTM PicoGreen® dsDNA Assay Kit (Molecular 
Probes, #P7589) 
• PicoGreen dsDNA quantitation reagent (Component A) 
• Buffer, 20X TE (Component B) 
• Lambda DNA standard (Component C) 
• Sterile, distilled, DNase-free water 
 
7.10.2. Protocol 
To quantitate dsDNA (double stranded DNA), we utilized the Quant-iTTM 
PicoGreen® dsDNA Assay Kit.   PicoGreen dsDNA quantitation reagent is an 
ultrasensitive fluorescent nucleic acid stain for quantitating dsDNA in 
solution.  To prepare sample, the experimental DNA solution was diluted in 
TE to a final volume of 1.0 milliter in test tubes. 1.0 mL of the aqueous 
working solution of the Quant-iTTM PicoGreen® reagent was added to each 
sample, and then incubated for 2-5 minutes at room temperature in the dark.   
The standards were prepared as indicated below. The fluorescence of the 
unknown samples and standards were measured using the TECAN at a 
wavelength of 523 nm.  The fluorescence value of the reagent blank was 
subtracted from that of each of the samples.  The DNA concentration of the 
sample was determined from the standard curve generated in DNA Standard 
Curve.  
 
High Range Standard curve for λDNA: 
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Volume (µL) 
of 2µg/µL 
λDNA 
Volume (µL) 
of 1X TE 
(diluted B) 
Volume 
(µL) of 
diluted A 
Final concentration 
of λDNA 
0 1000 1000 0ng/uL (blank) 
1 999 1000 1 ng/µL 
10 990 1000 10 ng/µL 
25 975 1000 25 ng/µL 
50 950 1000 50 ng/µL 
100 900 1000 100 ng/µL 
250 750 1000 250 ng/µL 
500 500 1000 500 ng/µL 
1000 0 1000 1000 ng/µL 
 
7.11. Alkaline Phosphatase Assay 
7.11.1. Materials 
• Sample in 1% Triton X100 
• BioRad Alkaline Phosphatase Substrate Kit (Bio-Rad 
Laboratories, Inc) 
• Diethanolamine Buffer (5X) (make 1X soln from 5X soln: 1ml 
5X soln: 4ml H2O=1X) 
• Note: to make 0.4 N sodium hydroxide solution (dissolve 2.0g 
sodium hydroxide in 125 ml of DDI water) 
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• p-Nitrophenylphosphate, 5mg each, tablets 
• For every 5 ml of the 1X solution, add 1 tablet to be completely 
dissolved 
b. PROTOCOL 
Alkaline phosphatase activity of cells cultured on microsphere scaffolds were 
measured as an early marker for osteogenic phenotype using an alkaline 
phosphatase (ALP) substrate kit (Bio-Rad, Hercules, CA). In this assay, the 
early phenotypic marker ALP, from osteoblasts in culture, converts p-
nitrophenyl phosphate (p-NPP) into p-nitrophenol (p- NP). The rate of p-NP 
formation is directly proportional to the ALP activity and can be measured 
colorimetrically. At pre-determined timepoints, the cell-scaffold constructs 
were washed twice with PBS to remove any unattached cells. These scaffolds 
were then frozen in a −70°C with 1 mL of 1% Triton X100. At the end of the 
cell study, samples from all time points were subjected to three freeze−thaw 
cycles and collected the cell lysate for ALP assay. For a volume of 100 µL of 
cell lysate, a 400 µL of p-NPP substrate solution and buffer mixture was 
added and incubated at 37 °C for 30 min. The reaction was stopped by adding 
500 µL of 0.4 N NaOH. Subsequently, the ALP induced p-NP production can 
be estimated by measuring the absorption at 405 nm the TECAN. The results 
of ALP activity will be normalized by the total protein or DNA (i.e., BCA 
assay or DNA Picogreen Assay) from each individual sample.  
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7.12. Bicinchoninic Acid (BCA) Total Protein Assay 
7.12.1. Materials 
• BCA Protein Assay Reagent (Bicinchoninic Acid)  (Peirce, # 
23225) 
o Kit Contents: BCA Reagent A, 2 x 500 mL; BCA 
Reagent B, 25 mL; Albumin Standard Ampules, 
2mg/mL, 10 x 1mL 
• 1% Triton X100 (Sigma-Aldrich, # X100-100ML) 
7.12.2. Protocols 
In order to normalize specific protein levels of cells cultured on scaffolds, we 
determined total protein levels via the Bicinchoninic Acid Assay (BCA) total 
protein assay.  At each time point, the media was aspirated off, and the 
scaffolds were washed once with PBS.  The cells were lysed with 1% Triton 
X100 (1 milliliter/sample), and two freeze-thaw cycles.  The working reagent 
was prepared by mixing 50 parts of BCA reagent A with 1 part of BCA 
reagent B.  In a 48 well plate, 100 µl of each unknown sample or standard 
(i.e., diluted with 1% Triton X100 solution) was pipetted, and then 800 µl of 
the working reagent was added to each well, and mixed thoroughly.  The plate 
was covered and incubated  at 37oC for 30 minutes, and then the absorbance 
was measured at 550 nm on Tecan.  
 
Diluted albumin (BSA) standards: 
Vial Volume of Volume & Source Final BSA 
 187
diluent  (µl) of BSA concentration 
A 450 150 µl of stock 500 µg /ml 
B 300 300 µl of A 250 µg /ml 
C 300 300 µl of B 125 µg /ml 
D 360 240 µl of C 50 µg /ml 
E 300 300 µl of D 25 µg /ml 
F 320 80 µl of E 5 µg /ml 
G 400 0 0 = blank 
 
 
7.13. Alizarin Red Mineralization Assay 
7.13.1. Materials 
• 4 M Alizarin Red, pH 4.23: add 1.369g of powder dye to 100 
ml of DDI water, use 1N NaOH to adjust pH. 
• 10% (w/v) Cetylpyridinium Chloride (CPC), pH 7.0: add 10g 
to 100ml of 10mM Sodium Phosphate Na2PO4.  Use 1N HCl to 
adjust pH 
• 10 mM Na2PO4: dissolve 0.142 in 100 mL 
• 70% Ethanol 
• PBS w/o Ca or Mg 
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7.13.2. Protocol 
Mineralized matrix synthesis was evaluated using Alizarin Red staining 
method for calcium deposition. This colorimetric analysis is based on 
solubility of the red matrix precipitate with cetylpyridinium chloride (CPC) to 
yield a purple solution. At predetermined time points, cell-scaffold constructs 
were rinsed free of media with DDI water and fixed for 1 hour with 70% 
ethanol at 4°C. Ethanol was removed and constructs were air-dried for 5 –10 
minutes.  The samples were washed one time with DDI water, and then 
covered with 500 µL alizarin red dye for 10 minutes at room temperature. 
Samples were then washed with DDI water 5 or more times until no color can 
be washed out. Next, 1 milliliter of 10% CPC was added on cellularized 
scaffolds and incubated at room temperature for 30 minutes at which point the 
color will be stable. The absorbance was read on a plate reader at 562 nm 
using TECAN. Samples can be diluted 1:10 in additional CPC if necessary (if 
the machine reads “OVER” you can dilute).  
 
7.14. Histology 
 
7.14.1. Paraffin-Embedding & Sectioning 
7.14.1.1. Materials 
• Formalin-fixed samples 
• Ethanol (70%, 95%, 100%) 
• Histoclear (National Diagnostics, #HS-200) 
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• Paraplast (Fisher, #23-021-401) 
7.14.1.2. Protocol 
After 24 hours of formalin fixation, samples were processed 
through the following steps for paraffin-embedding:  
Solution Time (min) 
70% ethanol 20 min 
95% ethanol 20 min 
95% ethanol 20 min 
100% ethanol 20 min 
100% ethanol 20 min 
100% ethanol 20 min 
Histoclear 30 min 
Histoclear 30 min 
Paraffin 30 min 
Paraffin 30 min, 65OC 
 
7.14.2. Poly(Methylmetharylate) (PMMA) Slow Embedding 
& Sectioning 
7.14.2.1. Materials 
• Formalin-fixed samples 
• Ethanol (70%, 95%, 100%) 
• Toluene 
• Methylmethacrylate (MMA)  
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• Dibutyl phthalate (DP) containing increasing 
concentrations of the catalyst benzoyl peroxide (BP) 
• Tungsten carbide knife 
• Chromalum-gel coated slides 
 
7.14.2.2. Protocol 
The formalin-fixed bones were stripped of soft tissue and placed 
directly in 70% ethanol at 4°C for at least 24 hours.  (Bones can be 
stored for up to one month at 4°C in 70% ethanol).  After 24 hours, 
bones were processed in a tissue processor and dehydrated and 
cleared according to the following schedule:  
Solution Time(hr) 
70% ethanol 1.5 
95% ethanol 1.5 
95% ethanol 2.0 
100% ethanol 3.0 
100% ethanol 4.0 
100% ethanol 4.0 
100% ethanol:toluene (50:50) 4.0 
Toluene 3.5 
Toluene 2.0 
Toluene 2.0 
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Bones were subjected to alternating cycles of pressure and 
vacuum on the tissue processor in each solution above.  Following 
dehydration and clearing, bones were infiltrated with a mixture of 
85% methylmethacrylate (MMA) and 15% dibutyl phthalate (DP) 
containing increasing concentrations of the catalyst benzoyl 
peroxide (BP) as follows:  MMA I (3 days): 85% MMA, 15%DP;  
MMA II (3 days): 85% MMA, 15% DP, 1% BP;  MMA III (3 
days): 85% MMA, 15% DP, 2.5% BP.  Each MMA solution was 
stirred at least two hours prior to use.  All infiltration was carried 
out at 4°C.   
Bases for embedding were prepared in 20 ml scintillation 
vials containing 3 ml of MMA III polymerized in a 37°C radiant 
heat oven.  Once infiltration was complete, bones were placed on a 
pre-polymerized base of MMA III, covered with freshly made 
MMA III, capped tightly and allowed to sit at room temperature 
overnight.  The next day, the bones were placed in a 37°C radiant 
heat oven for four days.  Once polymerization was completed, 
glass vials were removed from the oven, incubated at -20°C for 
one hour and glass was removed by breaking.   
Specimen blocks were then trimmed and sanded on a 
Buehler Mataserve Grinder-Polisher (Buehler, Lake Bluff, IL) with 
60 or 240 grit grinding paper (Carobinmet Special Silicon Carbide 
Grinding Paper, Buehler) for course grinding and polishing, 
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respectively.  Prepared bone blocks were clamped directly into 
Reichert-Jung Polycut E Microtome block holder, and trimmed 
using a tungsten-carbide knife, D-profile (Delaware Diamond 
Knives, Wilmington, DE).  The block face and knife were 
moistened with 40% EtOH to facilitate sectioning.  Once the area 
of the ulnar bone was reached, 7 µm sections were carefully 
removed from the knife blade with fine foreceps.  Sections were 
placed on a 95% ethanol that was on chrome-alum-gel coated 
slides, and teased and flattened using a very fine paintbrush.  
Sections were covered with a strip of clear plastic and remaining 
wrinkles and excess ethanol were removed by rolling over the 
plastic with a small roller.  Slides were stacked and pressure was 
applied using a paper clamp.  Sections mounted on chrome-alum-
gel coated slides were incubated overnight at 37oC to adhere 
sections to slide.  The sections for VonKossa staining were 
mounted on the Silane-Plus coated slides, and sections for 
Trichrome and H&E staining were mounted on charged slides.  
Sections were adhered to the slides by overnight incubation at 
60°C.  
 
7.14.3. Histological Staining 
7.14.3.1. Hematoxylin & Eosin Stain 
7.14.3.1.1. Materials 
• For paraffin-embedded sections: Xylene/Histoclear 
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• For sMMA-embedded sections: Cellsolve (ethylene glycol 
monomethyl ether acetate, Fisher Scientific) 
• Ethanol (100% and 95%) 
• dH2O 
• Hematoxylin (Fisher, #67-650-09) 
• Bluing Solution (Fisher, #67-690-02) 
• Eosin (Fisher, #23-245-658) 
• Mounting Media (Thermo Scientific, #22-110-610) 
 
7.14.3.1.2. Protocol 
Solution Time 
Xylene/Histoclear/Cellsolve 25 min 
Xylene/Histoclear/Cellsolve 25 min 
100% ethanol 5 min 
100% ethanol 3 min 
95% ethanol 5 min 
95% ethanol 3 min 
 dH2O 2 min 
Hematoxylin 1 min 
Running tap H2O Until clear 
Bluing Solution 1 min 
Running tap H2O Till clear 
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 dH2O 2 min 
95% Ethanol 2 min 
Eosin 30 sec 
 dH2O 2 min 
95% ethanol 3 min 
95% ethanol 5 min 
100% ethanol 3 min 
100% ethanol 5 min 
Xylene/Histoclear 3 min 
Xylene/Histoclear 5 min 
Mounting Media Coverslip 
 
7.14.3.1.3. Results 
• Nuclei -------------------------------- blue 
• Cytoplasm --------------------------- pink 
7.14.3.2. Masson’s Tri-Chrome Stain 
7.14.3.2.1. Materials 
• For paraffin-embedded sections: Xylene/Histoclear 
• For sMMA-embedded sections: Cellsolve (ethylene glycol 
monomethyl ether acetate, Fisher Scientific) 
• Ethanol (100% and 95%) 
• dH2O 
• Masson’s Trichrome Staining Kit (Sigma-Aldrich #HT15) 
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o Biebrich Scarlet-Acid Fuchsin Solution (0.9%) 
o Phosphotungstic Acid Solution (10%) 
o Phosphomolybdic Acid Solution (10%) 
 Prepare Working Phosphotungstic/ 
Phosphomolybdic Acid Solution by mixing 
1 volume of Phosphotungstic Acid Solution, 
and 1 volume Phosphomolybdic Acid 
Solution, with 2 volumes of deionized water. 
Discard after one use. 
o Aniline Blue Solution (2%) 
• Bouin’s Solution (Sigma-Aldrich, # HT10-1-32) 
• Weigert’s Iron Hematoxylin solution 
• 1% Acetic Acid 
• Mounting Media (Thermo Scientific, #22-110-610) 
7.14.3.2.2. Protocol 
Solutions Time 
Xylene/Histoclear/Cellsolve 25 min 
Xylene/Histoclear/Cellsolve 25 min 
100% ethanol 5 min 
100% ethanol 3 min 
95% ethanol 5 min 
95% ethanol 3 min 
 dH2O 2 min 
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Bouin’s Solution 15 min, 56oC 
Running tap H2O Until clear 
Weigert’s Iron Hematoxylin 
Solution 
5 min 
Running tap H2O Till clear 
 dH2O 2 min 
Biebrich Scarlet-Acid Fucshin 5 min 
 dH2O 2 min 
Phosphotungstic/Phosphomolybdic 
Acid Solution 
5 min 
 Aniline Blue Solution 5 min 
Acetic Acid 2 min 
 dH2O 2 min 
95% ethanol 3 min 
95% ethanol 5 min 
100% ethanol 3 min 
100% ethanol 5 min 
Xylene/Histoclear 3 min 
Xylene/Histoclear 5 min 
Mounting Media Coverslip 
 
* Unless indicated otherwise, the step was performed at 
room temperature. 
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7.14.3.2.3. Results 
• Collagen fibers---------------------------- blue 
• Nuclei-------------------------------------- black 
• Cytoplasm, fibrin, erythrocytes ----------- red 
 
7.14.3.3. Von Kossa Stain 
7.14.3.3.1. Materials 
• For paraffin-embedded sections: Xylene/Histoclear 
• For sMMA-embedded sections: Cellsolve (ethylene glycol 
monomethyl ether acetate, Fisher Scientific) 
• 1% Aqueous Silver Nitrate Solution 
• 5% Sodium Carbonate-Formaldehyde 
• 0.1% Nuclear Fast Red Solution 
• Ethanol (100% and 95%) 
• dH2O 
• Mounting Media (Thermo Scientific, #22-110-610) 
 
7.14.3.3.2. Protocol 
Solution Time 
Xylene/Histoclear/Cellsolve 25 min 
Xylene/Histoclear/Cellsolve 25 min 
100% ethanol 5 min 
100% ethanol 3 min 
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95% ethanol 5 min 
95% ethanol 3 min 
 dH2O 2 min 
1% silver nitrate solution 30 min; dark 
Running tap H2O Until clear 
5% sodium carbonate-
formaldehyde 
2 min 
Running tap H2O Till clear 
 dH2O 2 min 
Methyl green pyronin 20 min 
 dH2O 2 min 
95% ethanol 3 min 
95% ethanol 5 min 
100% ethanol 3 min 
100% ethanol 5 min 
Xylene/Histoclear 3 min 
Xylene/Histoclear 5 min 
Mounting Media Coverslip 
 
7.14.3.3.3. Results 
• Calcium salts ---------- black or brown-black 
• Osteoid ----------------------red or light pink 
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7.15. Immunohistochemistry  
7.15.1. Materials 
• Histoclear or Xylene 
• Ethanol (100%, 95%) 
• Distilled water 
• Dako Target retrevial (S1700, Dako) 
• Hydrogen Peroxide (216763, Sigma-Aldrich) 
• Phosphate buffered saline 1X (Sigma) 
• Bovine Serum Albumin (BSA) (A9418-5G, Sigma-
Aldrich) 
• Primary Antibody 
• Secondary Antibody (HRP-conjugated or fluorescent) 
• Normal Goat Serum (NGS) (S-1000, Vector 
Laboratories) 
• Blocking Solution (10 mL PBS, 0.05 g BSA) 
• Primary/Secondary Antibody Solution (10 mL PBS, 
0.05 g BSA, 300 ul Normal Goat Serum, and 1o 
Antibody) 
• TBS plus 0.025% Triton X-100 
• DAB Substrate Kit, 3,3’-diaminobenzidine (SK-4100, 
Vector)  
• PAP pen (#ab2601, Abcam) 
• Mounting Media (Thermo Scientific, #22-110-610) 
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• Coverslips 
7.15.2. Protocol 
Immunohistochemistry is the localization of antigens or proteins in tissue 
sections by the use of labeled antibodies as specific reagents through antigen-
antibody interactions that are visualized by a marker such as fluorescent dye 
or enzyme.  Before proceeding with the staining protocol, the slides were 
deparaffinized and rehydrated, since incomplete removal of paraffin can cause 
poor staining of the section. The slides were placed in Histoclear for 5 
minutes, and this was repeated two times.  The slides then underwent serial 
dehydration.  The slides were placed in 100% ethanol for 10 minutes (2 
times), and then 95% ethanol for 10 minutes (2 times).  The slides were 
transferred to distilled water for 5 minutes (2 times), and then antigen retrevial 
(Dako Target retrevial) was performed for 5 minutes at 98oC.  This step serves 
to break the methylene bridges and expose the antigenic sites in order to allow 
the antibodies to bind. The slides were then washed 2 times for 5 minutes each 
in TBS and 0.025% Triton X-100 with gentle agitation.  The slides were 
blocked in 10% normal serum with 1% BSA in TBS for 2 hours at room 
temperature.  The slides were then drained for a few seconds (do not rinse) 
and then wiped around the sections with tissue paper.  The primary antibody 
diluted in TBS with 1% BSA was applied, and incubated overnight at 4°C. 
The slides were rinsed 2 times for 5 minutes each in TBS and 0.025% Triton 
with gentle agitation.  If an HRP conjugate was used for detection, the slides 
were incubated in 0.3% H2O2 in TBS for 15 minutes.  For enzymatic detection 
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(HRP conjugates), HRP-conjugated secondary antibody was applied to the 
slide diluted to the concentration recommended by the manufacturer in TBS 
with 1% BSA, and incubated for 1 hour at room temperature. For fluorescent 
detection, fluorophore-conjugated secondary antibody was applied to the slide 
diluted to the concentration recommended by the manufacturer in TBS with 
1% BSA, and incubated for 1 hour at room temperature.  The slides were 
rinsed 3 times for 5 minutes each with TBS.  If using fluorescent detection, 
the procedure ended at this step and the slides were coversliped with mounting 
medium. If visualizing the protein with a chromogen, the slides were 
developed with a chromogen (i.e., 3,3'- Diaminobenzidine (DAB)) for 10 
minutes at room temperature.  The slides were rinsed in running tap water for 
5 minutes, and then counterstained with hematoxylin. The slides were then 
dehydrated, cleared and mounted with coverslips.  
 
7.16. Immunocytochemistry 
7.16.1. Materials 
7.16.2. Histoclear or Xylene 
• Ethanol (100%, 95%) 
• Distilled water 
• Dako Target retrevial (S1700, Dako) 
• Hydrogen Peroxide (216763, Sigma) 
• Phosphate buffered saline 1X (Sigma) 
• Bovine Serum Albumin (BSA) (A9418-5G, Sigma) 
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• Primary Antibody 
• Secondary Antibody (HRP-conjugated or fluorescent) 
• Normal Goat Serum (S-1000, Vector Laboratories) 
• Blocking Solution (10 mL PBS, 0.05 g BSA) 
• Primary/Secondary Antibody Solution (10 mL PBS, 
0.05 g BSA, 300 ul Normal Goat Serum, and 1o 
Antibody) 
• TBS plus 0.025% Triton X-100 
• DAB Substrate Kit, 3,3’-diaminobenzidine (SK-4100, 
Vector)  
• PAP pen (#ab2601, Abcam) 
• Mounting Media (Thermo Scientific, #22-110-610) 
• Coverslips 
7.16.3. Protocol 
To examine cell expression of specific proteins, we performed 
immunocytochemistry.  First, cells were removed from cell culture, washed 
briefly with PBS, and then covered to a depth of 2-3 mm with 2-4% 
formaldehyde in PBS for 15 minutes at room temperature.  The fixative was 
aspirated, and then the cells were rinsed three times in PBS for 5 minutes 
each.  To permeabilize the cells, the cells were covered with ice-cold 100% 
methanol, and incubated in methanol for 10 minutes at –20°C. The specimens 
were then incubated with 10% normal blocking serum in PBS for 20 minutes 
to suppress non-specific binding of IgG. Blocking serum ideally should be 
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derived from the same species in which the secondary antibody is raised. The 
specimens were then incubated with primary antibody for 60 minutes. 
Optimal antibody concentration should be determined by titration; 
recommended range is 0.5–5.0 µg/ml in PBS with 1.5% normal blocking 
serum. The specimens were then washed with three changes of PBS for 5 
minutes each, and then incubated for 45 minutes with fluorochrome-
conjugated secondary antibody diluted to 1–5 µg/ml in PBS with 1.5%–3% 
normal blocking serum. The specimens were then washed with three changes 
of PBS, and incubated with DAPI to stain the nuclei.   The cells were then 
covered in multi-well plate with aqueous mounting medium, and viewed 
under a fluorescence microscope. 
 
7.17. Live/Dead Cell Viability Analysis 
7.17.1. Materials 
• Phosphate buffered saline 1X (Sigma) 
• Live/Dead® Viability/Cytotoxicity Kit (#L3224, 
Invitrogen)  
• Glass Bottom Dishes, 35 mm uncoated (P35G-1.0-14-
C, MatTek) 
7.17.2. Protocol 
To examine cell viability, we utilized the Live/Dead Viability Kit, which 
contains calcein AM and ethidium homodimer-1. Membrane-permeant calcein 
AM is cleaved by esterases in live cells to yield cytoplasmic green 
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fluorescence, and membrane-impermeant ethidium homodimer-1 labels 
nucleic acids of membrane-compromised cells with red fluorescence.  The 
sample was rinsed with PBS two times, and incubated with Live/Dead 
solution (10 milliliters PBS, 4 µl ethidium bromide, 1.25 µl calcien AM) for 1 
hour.  The samples were rinsed with once with PBS, and viewed under 
fluorescent microscope or confocal microscope (requires sample to be on 
Glass Bottom Dishes). 
 
7.18. Gene Expression Analysis 
7.18.1. RNA Extraction 
7.18.1.1. Materials  
• Qiagen RNeasy Mini Kit 
o RNeasy Mini Spin Columns (pink)  
o Collection Tubes (1.5 ml)  
o Collection Tubes (2 ml) 
o Buffer RLT  (Add 10 µl β-ME per 1 ml Buffer 
RLT) 
o Buffer RW1 
o Buffer RPE (concentrate; add 4 volumes of 
ethanol (96–100%) as indicated on the bottle to 
obtain a working solution.)  
o RNase-Free Water  
• QIAshredder Spin Columns 
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• 14.3 M β-mercaptoethanol (β-ME)   
• Sterile, RNase-free pipette tips  
• 96–100% ethanol 
7.18.1.2. Protocol 
We used Qiagen RNeasy Mini Kit to extract and purify RNA from 
cells cultured on scaffolds.  First, to directly lyse cells, 0.5 milliliters 
of Buffer RLT was added, and then pipetted the lysate directly into a 
QIAshredder spin column placed in a 2 ml collection tube, and 
centrifuged for 2 min at full speed. 1 volume of 70% ethanol was 
added to the homogenized lysate, mixed well by pipetting, transferred 
to an RNeasy spin column placed in a 2 ml collection tube, and 
centrifuged for 15 seconds at ≥8000 x g (≥10000 RPM). The flow-
through was discarded. If the sample volume exceeded 700 µl, 
successive aliquots was centrifuged in the same RNeasy spin column. 
The flow-through was discarded after each centrifugation, and 700 µl 
Buffer RW1 was added to the RNeasy spin column and then 
centrifuged for 15 seconds at ≥8000 x g (≥10000 rpm RPM to wash 
the spin column membrane. The flow-through was discarded, and 500 
µl Buffer RPE was added to the RNeasy spin column, and then 
centrifuged for 15 seconds at ≥8000 x g (≥10000 RPM) to wash the 
spin column membrane.  The flow-through was discarded, and 500 µl 
Buffer RPE was added to the RNeasy spin column, and centrifuged for 
2 minutes at ≥8000 x g (≥10000 RPM) to wash the spin column 
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membrane.  The RNeasy spin column was placed in a new 2 ml 
collection tube, and centrifuged at full speed for 1 minute.  The 
RNeasy spin column was placed in a new 1.5 ml collection tube, and 
30–50 µl RNase-free water was added directly to the spin column 
membrane, and centrifuged for 1 minute at ≥8000 x g (≥10000 RPM) 
to elute the RNA.  We used the NanoDrop machine to measure the 
RNA concentration in each sample.  3 µg of RNA per sample was used 
to carry out gene quantification analysis. 
 
7.19. Quantitative Polymerase Chain Reaction (Q-
PCR) 
7.19.1. Materials 
• Clontech Sprint RT Complete cDNA synthesis kit 
(Clontech; Mountain View, CA) 
• BioRad MyiQ2 Two-Color Real-Time PCR Detection 
System 
• 2x iQ real-time PCR Supermix (BioRad; Hercules, CA) 
• TaqMan® Gene Expression Assay Probes (Applied 
Biosystems; Carlsbad, CA)  
• Microseal 96-Well PCR Plates (BioRad; Hercules, CA) 
• iQ real-time PCR Supermix 
• TaqMan® Gene Expression Assay probe (Applied 
Biosystems) 
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7.19.2. Protocol 
For cDNA synthesis, 2 µg total RNA was used as a template for 
Clontech Sprint RT Complete cDNA synthesis kit (Clontech; 
Mountain View, CA) in a total volume of 20 µl. For quantitative real 
time PCR, BioRad MyiQ2 Two-Color Real-Time PCR Detection 
System, 2x iQ real-time PCR Supermix (BioRad; Hercules, CA), 
TaqMan® Gene Expression Assay Probes (Applied Biosystems; 
Carlsbad, CA) were loaded in Microseal 96-Well PCR Plates (BioRad; 
Hercules, CA).   Each well contained 10 µl of iQ real-time PCR 
Supermix, 1 ul of TaqMan® Gene Expression Assay probe and 9 µl of 
diluted cDNA.  Threshold cycle values of target genes was 
standardized against GAPDH expression and normalized to the 
expression in the control culture. The –fold change in expression was 
calculated using the ∆∆Ct comparative threshold cycle method. 
 
7.20. Angiogenic Potential Assays 
7.20.1. 2D Matrigel Assay 
7.20.1.1. Materials 
• BD Matrigel Basement Membrane Matrix High 
Concentration (354248, BD Biosciences) 
• Serum-free DMEM 
• Endothelial Growth Media-2 (EGM-2) (Lonza) 
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• Glass Bottom Dishes, 35 mm uncoated (P35G-1.0-14-
C, MatTek) 
• Live/Dead® Viability/Cytotoxicity Kit (#L3224, 
Invitrogen)  
• Phosphate buffered saline 1X (Sigma) 
 
7.20.1.2. Protocol 
To evaluate the angiogenic potential of endothelial cells, we cultured 
the cells on Matrigel, a solid gel of basement proteins prepared from 
the Engelbreth Holm-Swarm (EHS) mouse tumor.  Cells with high 
angiogenic potential will rapidly align and form hollow tube-like 
structures.  For this, we diluted the Matrigel (stock concentration 20 
mg/ml) to 10 mg/ml with serum-free DMEM, and evenly coated glass 
bottom 35 mm cell culture dishes with 75 µl of diluted Matrigel, and 
incubate for 30 minutes at 37oC. 300 µl cell suspension containing 
80,000 cells was plated, and incubated for 5-6 hours.  The cells were 
stained with Live/Dead staining, and imaged via confocal 
microscropy.  The following criteria were quantified: pattern 
recognition, branch point counting, average and total capillary tube 
length.  For pattern recognition quantification, we assigned numerical 
values for specific visual patterns (see below) (adapted from Millipore, 
In Vitro Angiogenesis Assay Kit).   
Pattern  Value 
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7.20.2. 3D Matrigel Assay 
7.20.2.1. Materials 
• BD Matrigel Basement Membrane Matrix High 
Concentration (354248, BD Biosciences) 
• 48 well cell culture plate 
• Cell culture media 
7.20.2.2. Protocol 
Matrigel was thawed overnight at 4oC on ice.  Matrigel was handled 
with pre-cooled pipettes, tips, and tubes when preparing for useage, 
since Matrigel will gel rapidly at 22oC to 35oC.  Cells were 
encapsulated in Matrigel (106 cells/mL Matrigel) by mixing a 1x106 
cell suspension in chilled media (750 µl) with 750 µl of Matrigel (20 
mg/ml), to make a final concentration of 10 mg/ml of Matrigel.  500 µl 
of this Matrigel/cell suspension mixture was seeded into each well in a 
48-well plate.  3 samples per group were seeded, and cultured in a 1-
Individual cells, well separated  0  
Cells begin to migrate and align themselves 1  
Capillary tubes visible. No sprouting.  2  
Sprouting of new capillary tubes visible.  3  
Closed polygons begin to form.  4  
Complex mesh like structures develop  5  
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to-1 mixture of osteogenic and angiogenic medium for 7 days in 48 
well cell culture plates.  The following twelve sample groups were 
studied: PB-EPCs alone; BM-EPCs alone; MSCs:PB-EPCs co-culture 
ratios of 1:4, 1:2, 1:1, 2:1, and 4:1; and MSCs:BM-EPCs co-culture 
ratios of 1:4, 1:2, 1:1, 2:1, and 4:1. Three-dimensional samples (10 
mm diameter, 2 mm height) were paraffin-embedded, sectioned and 
then stained with hematoxylin and eosin.  Four samples per group 
were embedded, and three sections per sample were stained (one from 
top, middle and bottom; approximately 200 µm apart from each other).   
Stained sections were analyzed under the light microscope Olympus 
BX50 with Olympus DP70 camera.  Twelve images viewed under 10X 
magnification, and the number of branches were counted for each 
sample. 
 
 
7.21. Flow Cytometry 
7.21.1. Materials 
• 1x106 cell suspension (for each marker of interest)  
• BD Cytofix/Cytoperm™ BD Cytofix/Cytoperm™ 
Fixation/Permeabilization Solution Kit (#554714, BD 
Bioscience) 
• BD Pharmingen™ Stain Buffer (FBS) (#554656, BD 
Bioscience) 
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• BD Perm/WashTM buffer (#554723, BD Bioscience) 
• Live/Dead Fixable Stain in Far Red (#L10120, 
Invitrogen) 
• Primary antibody 
• Fluorochrome-conjugated secondary antibody 
7.21.2. Protocol 
Flow cytometry (FCM) is a technique that may be used for counting and 
examining surface and intracellular proteins on cells. 
7.21.2.1. Surface Staining Cells 
To examine one cell surface marker, a sample of cells in suspension 
containing at least 1 × 106 cells was centrifuged.  The supernatant was 
discarded, and the cells were washed once with 1 milliliter of Staining 
Buffer, and the resuspended in 1 milliliter of Staining Buffer 
containing 1 µL of the reconstituted fluorescent reactive dye.  The 
suspension was incubated at room temperature or on ice for 30 
minutes, protected from light, and then washed with 1 milliliter of 
Staining Buffer and resuspended in 50 µl of Staining Buffer.  The cell 
suspension of ~106 cells in 50 µl of Staining Buffer was then stained 
with the appropriate amount of a primary antibody specific for 30 
minutes at 4°C.  The excess antibody was washed off following 
staining, and 1.5-2 milliliters of Staining buffer was added to each 
tube, and centrifuged 5 minutes at 2000 RPM.  The supernatant was 
aspirated, and 100 µl of staining buffer was added to each tube, and 
then 0.5-1 µg of the fluorochrome-conjugated secondary antibody. The 
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sample was vortexed and incubated for 15-30 minutes in a covered ice 
bucket.  To wash off excess antibody following staining, 1.5-2 
milliliters of staining buffer was added to each tube and then 
centrifuged in tabletop microfuge for 5 minutes at 2000 RPM.  The 
supernatant was aspirated off, and the cells were resuspended in 250 µl 
for tubes of Fixation/Permeabilization solution for 20 min. at 4°C. 
(Note: Cell aggregation is avoided by vortexing prior to the addition of 
the Fixation/Permeabilization solution.)  The cells were washed two 
times in 1× BD Perm/WashTM buffer (e.g., 1 milliliters /wash for 
staining in tubes) and pellet.  (NOTE: BD Perm/WashTM buffer must 
be maintained in washing steps to keep cells permeabilized.)  
Resuspend in Staining Buffer prior to flow cytometric analysis. 
 
7.21.2.2. Intracellular Staining Cells 
A sample of cells in suspension (> 1 × 106 cells) was centrifuged, and 
the supernatant was discarded.  The cells were washed once with 1 
milliliter of Staining Buffer. The cells were resuspended in 1 milliliters 
of Staining Buffer containing1 µL of the reconstituted fluorescent 
reactive dye, and then incubated at room temperature or on ice for 30 
minutes, protected from light.  The cells were washed with 1 milliliters 
of Staining Buffer, and then resuspended in 250 µl 
Fixation/Permeabilization solution for 20 minutes at 4°C. The cells 
were washed two times in 1× BD Perm/WashTM buffer (e.g., 1 
milliliters/wash for staining in tubes) and pellet.  (NOTE: BD 
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Perm/WashTM buffer must be maintained in washing steps to keep 
cells permeabilized.)  The cells were resuspended in 50 µl of BD 
Perm/WashTM Buffer, and then stained the ~106 cells in 50 µl of BD 
Perm/WashTM buffer with the appropriate amount of a primary 
antibody specific for 30 min at 4°C.  To wash off excess antibody 
following staining, 1.5-2 milliliters of BD Perm/WashTM buffer was 
added to each tube, and then centrifuged for 5 minutes at 3000-4000 
RPM for intracellular staining.  The supernatant was aspirated off, and 
100 µl of BD Perm/WashTM buffer was added to each tube with 0.5-1 
µg fluorochrome-conjugated secondary antibody. The sample was 
vortexed and incubated for 15-30 minutes in a covered ice bucket.  To 
wash off excess antibody following staining, 1.5-2 milliliters of BD 
Perm/WashTM buffer was added to each tube, and centrifuged in a 
tabletop microfuge for 5 minutes at 2000 RPM (or 3000-4000 RPM 
for intracellular staining).  The sample was then resuspended in 400 µl 
Staining Buffer prior to flow cytometric analysis. 
 
7.22. Western Blot Analysis 
7.22.1. Materials 
• CellLytic M buffer and Protease Inhibitor (Sigma)  
• 4-15% Tris-HCl Ready Gels 
• Laemmli Sample Buffer 
• Mini-PROTEAN Tetra System 
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• 10x Tris/Glycine/SDS Buffer 
• Precision Plus Protein Dual Color Standard 
• 10x Tris/Glycine Buffer 
• Mini Trans-Blot Electrophoresis Transfer Cell 
• Blot Papers  
• 0.2 µm Nitrocellulose Membrane 
• TBS-T solution (10x Tris-Buffered Saline, 0.1% 
Tween-20) 
• 10% milk/TBS-T solution 
• Primary and secondary antibodies 
• Super Signal West Pico Chemiluminescent Substrate  
• CL-XPosure Film  
 
7.22.2. Protocol 
CellLytic M buffer and Protease Inhibitor (Sigma; St. Louis, MO) were 
added to cells and then incubated at 4°C for 30 minutes.  Cells were removed 
by mechanical scrapping and spun down at 10,000 rpm for 5 minutes.  Protein 
concentrations were measured using BCA Protein Assay Kit and the 
absorbance of the samples were measured at 562 nm after 30 minute 
incubation at 37°C.  Each sample was prepared with Laemmli Sample Buffer 
and samples were boiled for 5 minutes.  25 µg of each sample were run on 4-
15% Tris-HCl Ready Gels for western blot protein electrophoresis.   Mini-
PROTEAN Tetra System, 10x Tris/Glycine/SDS Buffer, Precision Plus 
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Protein Dual Color Standard were used and gels were run at a constant 100 
volts.  Gels were transferred at a constant 100 Volts for 2 hours using 10x 
Tris/Glycine Buffer, Mini Trans-Blot Electrophoresis Transfer Cell, Blot 
Papers and 0.2 µm Nitrocellulose Membrane.  Membranes were blocked for 2 
hours at 4°C in 10% milk/TBS-T solution (10x Tris-Buffered Saline, 0.1% 
Tween-20).  Membranes were washed with TBS-T solution after each 
incubation.  Membranes were incubated overnight with primary antibodies 
diluted in 5% milk/TBS-T solution at 4°C. Membranes were incubated for 45 
minutes with secondary antibody diluted in 5%milk/TBS-T solution at 4°C 
and then washed three times with TBS-T. Super Signal West Pico 
Chemiluminescent Substrate was used for detection, and CL-XPosure Film 
was used for exposure of the membranes.  All reagents and materials for 
western blot analysis were purchased from BioRad (Hercules, CA) unless 
otherwise indicated. 
 
7.23. Animal Models 
7.23.1. SCID Mouse Subcutaneous Implant Model 
Fox Chase CB17 SCID® (Severe Combined Immunodeficiency) male 
mice (Charles River Laboratories, Cambridge, MA), ages 50–56 days were 
used for the mouse subcutaneous implant model.  Prior to surgery, animals 
were given 0.05-0.1 mg/kg Buprenorphine subcutaneous for pre-operative 
analgesia.  Animals were anesthetized with an intraperitonial injection of a 
mixture of ketamine (90-120 mg/kg body wt) and xylazine (5-10 mg/kg body 
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wt) given IP. After the animals were fully anesthetized, the surgical site on 
animals (dorsum) was shaved and cleaned with 70% ethanol, betadine and 
again with 70% ethanol. Two subcutaneous pouches were created bilaterally 
of the dorsal side (i.e., both the sides of the spine) by making incisions 
approximately 2.5 cm long using blunt dissection techniques, and a sterile 
polymer scaffold will be inserted into each pouch.  
Post-surgery, animals were kept in recovery cages placed on heating pads 
and under warm light to maintain body temperature, which was monitored 
with a rectal thermometer every 15-20 minutes until recovery. The animals 
were administered Buprenorphine (0.05-0.1 mg/kg SQ) twice per day 8-10 
hours apart for up to 48 hours and then as needed to minimize pain post 
surgery. The following signs of pain were monitored: lack of grooming, 
sitting haunched up in a corner of the cage, rapid and shallow breathing, 
reaching less frequently for food and water. Furthermore, the surgical wounds 
were evaluated daily during the first postoperative week for the presence of 
infection or dehiscence.  At pre-determined time-points, animals were 
sacrificed by CO2 narcosis followed by cervical dislocation. 
 
7.23.2. New Zealand White Rabbit Ulnar Critical-Size Bone 
defect Model 
New Zealand White male rabbits (4-5 kg) from Millbrook Breeding Labs  
(Amherst, MA, USA) were used to perform the rabbit ulnar critical-size bone 
defect model. Animals were housed with ad libitum access to food and water 
prior to surgery. A dose of 0.01-0.05 mg/kg buprenorphine was given IM 
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approximately 1 hour prior to,  5-10 mg/kg Xylazine given IM 10 min prior 
to, and 33 – 35 mg/kg Ketamine IM. Sedation was confirmed through ear/toe 
pinch. Sedation was maintained during surgery with 0.5-2% isoflurane.  
Sterile surgical technique and sterile fields was maintained at all times 
prior to and during surgery. Briefly, protective lubricant was applied to eyes 
of the rabbit, and an ear catheter was placed for administration of IV fluids 
(i.e., Normosol R, Lactated Ringers) during anesthesia at approximately 
10ml/kg/hr. Rabbits were then intubated. Once intubated, isoflurane 0.5-2% 
was initiated and maintained through the surgical procedure. The surgical site 
on the animal was shaved, cleaned with 70% ethanol, betadine, and 70% 
ethanol again, and then placed on a sterile drape and the area around the 
surgical site covered with sterile drapes. The surgeon wore a sterile gown, and 
gloves and will wear a face mask, eye shield, and cap. The instruments were 
autoclaved at 121oC for 15 minutes to ensure sterility. Instruments were 
opened within the sterile field. Between surgeries on different animals, 
unused, sterile instruments were used. A surgical hypothermia unit that uses 
circulating warm water was placed under the rabbit during surgery.  
Under sterile conditions, a lateral incision approximately 2.5 centimeters 
long was made and the tissue overlying the ulna was dissected. A 1.5 cm 
segmental osteoperiosteal defect was created in the middle of the ulna using 
an oscillating saw. The defect was filled with the construct, and the soft 
tissues was closed in layers, using resorbable sutures to close muscle tissue. 
The skin was approximated and closed using 3-0 absorbable sutures. 
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Subcuticular suturing with buried knots will be employed to minimize or 
prevent chewing of the surgical area, along with surgical glue. The overlying 
skin was also be closed with non-degradable sutures.  
After the surgical procedure was complete, animals were kept in the 
recovery room. Pain will be will be monitored through frequent observations: 
grinding of teeth, lack of grooming, sitting hunched up in a corner of the cage, 
rapid and shallow breathing, reaching less frequently for food and water. 
When the animal was ready to be extubated, a 25mcg fentanyl patch was 
applied to a shaved area over the dorsal neck/interscapular region. The patch 
was maintained at therapeutic levels for 72 hours, at which time it was either 
be removed or replaced. If there was an unexpected time lapse, then another 
dose of buprenex was administered to fill the gap until patch fentanyl is 
absorbed (which may take up to 8 hours). All animals were weighed once per 
week. Animals were housed with access to food and water ad libitum. Post op 
analgesia was considered for up to 5-6 days if needed. Animals were given 
hay cubes, bunny blocks, and fresh produce to stimulate appetite or for 
environmental enrichment.  
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